|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of A2M mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ABCA1 mRNA; Glucose results in decreased expression of ABCA1 protein morroniside inhibits the reaction [Glucose results in decreased expression of ABCA1 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of ABCA1 protein] |
CTD |
PMID:34485530 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO |
Glucose results in decreased expression of ABCB1 protein |
CTD |
PMID:22363694 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ABCB4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb7 |
ATP binding cassette subfamily B member 7 |
decreases expression |
ISO |
Glucose results in decreased expression of ABCB7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:69,295,598...69,436,775
Ensembl chr X:69,295,552...69,436,858
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]]; Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]] |
CTD |
PMID:10856430 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Benzbromarone results in decreased activity of ABCC2 protein] inhibits the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione]; [Furosemide results in increased activity of ABCC2 protein] promotes the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione]; [sulfanitran results in increased activity of ABCC2 protein] promotes the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione] |
CTD |
PMID:19782883 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ABCD2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ABCG1 mRNA; Glucose results in decreased expression of ABCG1 protein morroniside inhibits the reaction [Glucose results in decreased expression of ABCG1 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of ABCG1 protein] |
CTD |
PMID:34485530 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions decreases expression increases expression decreases phosphorylation |
ISO EXP |
[INS protein co-treated with Glucose] results in increased expression of ACACA mRNA; [Pyruvic Acid co-treated with Glucose] results in increased phosphorylation of ACACA protein; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]]; SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of ACACA mRNA] Glucose results in decreased expression of ACACA protein modified form Glucose results in increased expression of ACACA mRNA |
CTD |
PMID:15066988 PMID:18482975 PMID:19071085 PMID:19724016 PMID:24349266 PMID:33838154 More...
|
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions decreases phosphorylation |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]]; ACACB protein affects the reaction [Glucose results in decreased expression of NPHS1 protein]; ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]; ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]; ACACB protein affects the reaction [Glucose results in decreased expression of SLC2A4 protein]; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of IRS1 protein] Glucose results in decreased phosphorylation of ACACB protein |
CTD |
PMID:33957017 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression multiple interactions decreases expression |
ISO EXP |
Glucose results in increased expression of ACE protein Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein] Glucose results in decreased expression of ACE mRNA CEBPB protein inhibits the reaction [Glucose results in increased expression of ACE protein] Glucose results in increased expression of ACE mRNA NFE2L2 protein affects the reaction [Glucose results in increased expression of ACE mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA] |
CTD |
PMID:16452552 PMID:29211853 PMID:29266779 PMID:31655124 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions decreases expression |
EXP ISO |
NFE2L2 protein affects the reaction [Glucose results in decreased expression of ACE2 mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA] CEBPB protein inhibits the reaction [Glucose results in decreased expression of ACE2 protein]; Glucose inhibits the reaction [CEBPB protein binds to ACE2 promoter]; Valsartan inhibits the reaction [Glucose results in decreased expression of ACE2 protein] |
CTD |
PMID:29211853 PMID:29266779 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
Ascorbic Acid inhibits the reaction [Glucose results in decreased activity of ACHE protein] |
CTD |
PMID:26163454 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
EXP ISO |
Glucose results in increased expression of ACLY mRNA Glucose deficiency results in increased expression of ACLY mRNA; Glucose deficiency results in increased expression of ACLY protein |
CTD |
PMID:24349266 PMID:26811028 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein] |
CTD |
PMID:16135072 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions |
EXP |
[Glucose co-treated with Oxygen] affects the activity of ACO2 protein; Glucose results in decreased expression of and results in decreased activity of ACO2 protein; LONP1 protein affects the reaction [SRT1720 inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of ACO2 protein]]; manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin inhibits the reaction [[Glucose co-treated with Oxygen] affects the activity of ACO2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Glucose co-treated with Oxygen] affects the activity of ACO2 protein]; SRT1720 inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of ACO2 protein] |
CTD |
PMID:11520895 PMID:31639451 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ACOT1 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression |
ISO |
Glucose results in increased expression of ACOX1 mRNA |
CTD |
PMID:36156098 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucose results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ACSBG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Acsm2 |
acyl-CoA synthetase medium-chain family member 2 |
increases expression |
ISO |
Glucose results in increased expression of ACSM2 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
increases expression |
ISO |
Glucose results in increased expression of ACSS1 mRNA |
CTD |
PMID:36156098 |
|
NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucose results in increased expression of ACSS2 mRNA |
CTD |
PMID:36156098 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
increases expression multiple interactions decreases expression |
EXP ISO |
Glucose results in increased expression of ACTA1 mRNA HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]]; Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ACTA1 mRNA; fucoxanthin inhibits the reaction [Glucose results in decreased expression of ACTA1 mRNA] |
CTD |
PMID:24810525 PMID:33448797 PMID:37567420 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions increases expression |
ISO EXP |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in increased expression of ACTA2 protein]; [Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [Glucose results in increased expression of ACTA2 protein] Glucose results in increased expression of ACTA2 mRNA; Glucose results in increased expression of ACTA2 protein cinnamaldehyde inhibits the reaction [Glucose results in increased expression of ACTA2 protein] |
CTD |
PMID:20060012 PMID:21829520 PMID:26045780 PMID:29163160 PMID:35961541 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of ACTB protein |
CTD |
PMID:22314686 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actg1 |
actin, gamma 1 |
multiple interactions |
EXP |
ACTG1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232 Ensembl chr 3:105,619,737...105,624,232
|
|
G |
Actr2 |
actin related protein 2 |
multiple interactions decreases expression |
ISO |
Eucalyptol inhibits the reaction [Glucose results in decreased expression of ACTR2 protein] |
CTD |
PMID:31483951 |
|
NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases expression |
ISO |
Glucose results in decreased expression of ADAM17 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ADAM19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adam32 |
ADAM metallopeptidase domain 32 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ADAM32 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:67,102,384...67,212,163
Ensembl chr16:67,102,320...67,212,161
|
|
G |
Adam7 |
ADAM metallopeptidase domain 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of ADAM7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:42,833,796...42,882,201
Ensembl chr15:42,833,796...42,882,201
|
|
G |
Adam8 |
ADAM metallopeptidase domain 8 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ADAM8 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADAM8 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression |
ISO |
Glucose results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases methylation multiple interactions increases expression |
ISO |
Glucose results in decreased methylation of ADCY7 gene fucoxanthin inhibits the reaction [Glucose results in decreased methylation of ADCY7 gene]; fucoxanthin inhibits the reaction [Glucose results in increased expression of ADCY7 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adgra1 |
adhesion G protein-coupled receptor A1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRA1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:194,629,744...194,673,254
Ensembl chr 1:194,629,726...194,672,550
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRB1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Adgre4 |
adhesion G protein-coupled receptor E4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRE4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760
|
|
G |
Adgrf4 |
adhesion G protein-coupled receptor F4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ADGRF4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:18,272,050...18,303,219
Ensembl chr 9:18,272,050...18,303,217
|
|
G |
Adgrg4 |
adhesion G protein-coupled receptor G4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ADGRG4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:134,734,610...134,864,449
Ensembl chr X:134,854,736...134,864,449
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
decreases expression |
ISO |
Glucose results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression increases expression multiple interactions increases secretion |
EXP ISO |
Glucose results in decreased expression of ADIPOQ protein Glucose results in increased expression of ADIPOQ protein [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; tributyltin promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] Glucose deficiency results in increased secretion of ADIPOQ protein ADIPOQ protein inhibits the reaction [Glucose results in decreased expression of ADIPOR2 protein]; argan oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein]; Corn Oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein] |
CTD |
PMID:21912612 PMID:24802182 PMID:29165388 PMID:32407875 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions decreases expression |
EXP |
FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]; FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]; FOXO1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]]; FOXO1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]; Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein] Glucose results in decreased expression of ADIPOR1 mRNA; Glucose results in decreased expression of ADIPOR1 protein |
CTD |
PMID:24413998 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions decreases expression |
EXP |
ADIPOQ protein inhibits the reaction [Glucose results in decreased expression of ADIPOR2 protein] |
CTD |
PMID:21912612 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; [cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased transport of Glucose; Prazosin inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose] |
CTD |
PMID:15550506 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose; [Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose] |
CTD |
PMID:18552870 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in decreased abundance of Glucose; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADRB3 mRNA |
CTD |
PMID:20930473 PMID:37567420 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucose results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agbl4 |
AGBL carboxypeptidase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AGBL4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions increases expression |
ISO EXP |
GLO1 inhibits the reaction [Glucose promotes the reaction [RELA protein binds to AGER promoter]]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER protein]; Glucose promotes the reaction [RELA protein binds to AGER promoter]; Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; RELA promotes the reaction [Glucose results in increased expression of AGER mRNA]; Rutin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER protein]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER protein] [Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]] Glucose results in increased expression of AGER mRNA; Glucose results in increased expression of AGER protein AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]] |
CTD |
PMID:19557821 PMID:19759273 PMID:19833897 PMID:22467055 PMID:30101366 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
increases uptake |
ISO |
AGL protein results in increased uptake of Glucose |
CTD |
PMID:24700805 |
|
NCBI chr 2:204,705,053...204,760,966
Ensembl chr 2:204,705,053...204,760,828
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases expression affects metabolic processing |
ISO EXP |
(3,4-dihydroxyphenylamino)-2-imidazoline inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; acetovanillone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]; Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of FOSL1 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]; Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]; Rotenone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]] 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose results in increased expression of AGT mRNA]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose results in increased expression of AGT protein]; alpha-cyano-4-hydroxycinnamate inhibits the reaction [Glucose results in increased expression of AGT mRNA]; alpha-cyano-4-hydroxycinnamate inhibits the reaction [Glucose results in increased expression of AGT protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT protein]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT mRNA]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT protein]; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of AGT mRNA]; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of AGT protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of AGT mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of AGT protein]; NFE2L2 protein affects the reaction [Glucose results in increased expression of AGT mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; Rotenone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Rotenone inhibits the reaction [Glucose results in increased expression of AGT protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT protein]; Taurine inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Taurine inhibits the reaction [Glucose results in increased expression of AGT protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of AGT protein]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Valsartan promotes the reaction [Glucose results in increased expression of AGT protein] AGT protein affects the metabolism of Glucose Glucose results in increased expression of AGT mRNA; Glucose results in increased expression of AGT protein |
CTD |
PMID:11115780 PMID:12130563 PMID:15677497 PMID:16452552 PMID:19225232 PMID:19861503 PMID:29211853 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of AGTR1 mRNA; Glucose results in increased expression of AGTR1 protein Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein] CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR1 protein] |
CTD |
PMID:16452552 PMID:29266779 PMID:31655124 PMID:34464088 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions increases expression |
ISO |
CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR2 protein] |
CTD |
PMID:29266779 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases response to substance |
ISO |
4,7-phenanthroline inhibits the reaction [AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]]; AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]; alpha-naphthoflavone inhibits the reaction [AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]] AHR protein promotes the reaction [Tetrachlorodibenzodioxin affects the susceptibility to Glucose] AHR results in increased susceptibility to Glucose |
CTD |
PMID:8738555 PMID:19623578 PMID:21849270 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of AIF1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization multiple interactions |
EXP |
Glucose affects the localization of AIFM1 protein Quercetin affects the reaction [Glucose affects the localization of AIFM1 protein]; sesamin affects the reaction [Glucose affects the localization of AIFM1 protein] |
CTD |
PMID:19146853 PMID:22524206 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Ak8 |
adenylate kinase 8 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of AK8 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of AK8 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 3:12,028,895...12,144,468
Ensembl chr 3:12,028,954...12,144,465
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
increases expression |
ISO |
Glucose results in increased expression of AKAP5 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions decreases expression |
ISO |
fidarestat inhibits the reaction [Glucose results in decreased expression of AKR1A1 mRNA] |
CTD |
PMID:16805838 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions increases expression |
ISO |
AKR1B1 protein promotes the reaction [Glucose results in increased abundance of Sorbitol] Glucose results in increased expression of AKR1B1 mRNA; Glucose results in increased expression of AKR1B1 protein |
CTD |
PMID:16805838 PMID:25451566 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of AKR1C6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of AKR1C18 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions increases response to substance decreases expression decreases phosphorylation |
ISO EXP |
Glucose results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [Glucose affects the susceptibility to INS protein] which affects the phosphorylation of AKT1 protein; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Fluorometholone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] AKT1 protein mutant form results in increased susceptibility to Glucose deficiency 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency] which results in increased phosphorylation of EIF4EBP1 protein; [Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; AKT1 protein modified form inhibits the reaction [arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein modified form inhibits the reaction [monomethylarsonous acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein promotes the reaction [Glucose affects the phosphorylation of and affects the activity of FOXO3 protein]; Bezafibrate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; Glucose affects the phosphorylation of and affects the activity of AKT1 protein; methyl pyruvate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Glucose results in decreased expression of AKT1 protein modified form 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; [3,4-Dihydroxyphenylacetic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Catechin co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein; Acetylcysteine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form] |
CTD |
PMID:15806154 PMID:16385087 PMID:17520061 PMID:18004065 PMID:20370652 PMID:21031461 PMID:21333731 PMID:21803128 PMID:23159718 PMID:23453443 PMID:23954465 PMID:24946264 PMID:24971582 PMID:25471227 PMID:26054749 PMID:27049278 PMID:29981789 PMID:30914352 PMID:32602595 PMID:33270355 PMID:33450223 PMID:33957017 PMID:35264022 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
affects response to substance |
ISO |
AKT2 protein affects the susceptibility to Glucose |
CTD |
PMID:21964073 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions increases metabolic processing decreases uptake |
ISO EXP |
[Fructose co-treated with Glucose] results in increased glycation of ALB protein; [Peroxynitrous Acid co-treated with Glucose] results in increased glycation of ALB protein; Phlorhizin inhibits the reaction [Glucose results in decreased uptake of ALB protein]; pimagedine inhibits the reaction [[Fructose co-treated with Glucose] results in increased glycation of ALB protein]; pimagedine inhibits the reaction [[Peroxynitrous Acid co-treated with Glucose] results in increased glycation of ALB protein]; ursonic acid inhibits the reaction [[Fructose co-treated with Glucose] results in increased glycation of ALB protein] Glucose results in increased metabolism of ALB protein [Glucose deficiency co-treated with ALB protein] results in decreased expression of FABP4 mRNA; [Glucose deficiency co-treated with ALB protein] results in decreased expression of PCK1 mRNA ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]]; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:8536680 PMID:12196478 PMID:12434198 PMID:16313995 PMID:27415824 PMID:36933777 More...
|
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of ALCAM mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
increases expression |
ISO |
Glucose deficiency results in increased expression of ALDH1B1 protein |
CTD |
PMID:22314686 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of ALDH2 protein N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ALDH2 protein] |
CTD |
PMID:29128638 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3b3 |
aldehyde dehydrogenase 3 family, member B3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ALDH3B3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
Glucose results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ALDOA mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucose results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alk |
ALK receptor tyrosine kinase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ALK mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Glucose results in increased expression of ALOX12 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
EXP ISO |
[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein; caffeic acid inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; Edaravone inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; SB 203580 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein] Glucose results in increased expression of ALOX5 mRNA |
CTD |
PMID:18951527 PMID:31655124 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpk3 |
alpha-kinase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ALPK3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:135,014,455...135,062,294
Ensembl chr 1:135,014,499...135,062,302
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression multiple interactions |
ISO EXP |
Glucose results in decreased expression of ALPL mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL protein]]; Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]] morroniside inhibits the reaction [Glucose results in decreased expression of ALPL mRNA] |
CTD |
PMID:32643284 PMID:33450223 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amer2 |
APC membrane recruitment protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AMER2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455
|
|
G |
Amot |
angiomotin |
decreases expression |
ISO |
Glucose results in decreased expression of AMOT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Glucose results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:16805838 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd61 |
ankyrin repeat domain 61 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ANKRD61 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of ANKRD61 mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr12:10,718,908...10,723,267
Ensembl chr12:10,718,908...10,723,265
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Glucose results in decreased expression of ANXA5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of AOC1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AOC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
EXP |
Glucose results in decreased expression of APC mRNA |
CTD |
PMID:21818840 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcs |
amyloid P component, serum |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of APCS mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression decreases expression |
EXP |
Glucose results in increased expression of APOA1 mRNA; Glucose results in increased expression of APOA1 protein Glucose results in decreased expression of APOA1 mRNA |
CTD |
PMID:9322794 PMID:9668074 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
Glucose promotes the reaction [Copper Sulfate results in increased cleavage of APOB protein] |
CTD |
PMID:19489629 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
affects secretion multiple interactions decreases expression |
ISO |
Glucose deficiency affects the secretion of APOE protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of APOE mRNA; morroniside inhibits the reaction [Glucose results in decreased expression of APOE mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of APOE protein] Glucose results in decreased expression of APOE mRNA; Glucose results in decreased expression of APOE protein |
CTD |
PMID:24802182 PMID:34485530 PMID:37567420 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apol9a |
apolipoprotein L 9a |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of APOL9A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of AQP1 mRNA benazepril inhibits the reaction [Glucose results in increased expression of AQP1 mRNA]; valsartan inhibits the reaction [Glucose results in increased expression of AQP1 mRNA] |
CTD |
PMID:11510275 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions increases expression |
ISO |
Glucose promotes the reaction [AQP3 protein results in increased transport of Glycerol] Glucose results in increased expression of AQP3 mRNA; Glucose results in increased expression of AQP3 protein |
CTD |
PMID:12234316 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions increases expression |
EXP |
benazepril inhibits the reaction [Glucose results in increased expression of AQP4 mRNA]; valsartan inhibits the reaction [Glucose results in increased expression of AQP4 mRNA] |
CTD |
PMID:11510275 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of AQP5 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AQP5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Aqp8 |
aquaporin 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AQP8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AREG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Glucose results in increased expression of ARG2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap6 |
Rho GTPase activating protein 6 |
increases expression |
ISO |
Glucose results in increased expression of ARHGAP6 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ARHGDIB mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of ARHGDIB mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arl4d |
ADP-ribosylation factor like GTPase 4D |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of ARL4D mRNA; ARL4D protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
|
|
G |
Arl5b |
ADP-ribosylation factor like GTPase 5B |
increases expression |
ISO |
Glucose results in increased expression of ARL5B mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:77,955,864...77,979,895
Ensembl chr17:77,955,818...77,979,854
|
|
G |
Arl5c |
ADP-ribosylation factor like GTPase 5C |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ARL5C mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:82,985,213...82,993,425
Ensembl chr10:82,985,216...82,992,002
|
|
G |
Armcx6 |
armadillo repeat containing, X-linked 6 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of ARMCX6 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr X:97,929,032...97,932,031
Ensembl chr X:97,929,041...97,931,977
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions increases activity |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Glucose promotes the reaction [[ARNT protein binds to G6PC1 promoter] which results in increased expression of G6PC1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA] [Glucose co-treated with Oxygen deficiency] inhibits the reaction [ARNT protein binds to HIF1A protein] Glucose results in increased activity of ARNT protein |
CTD |
PMID:15767253 PMID:18227068 PMID:33962019 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arsj |
arylsulfatase family, member J |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of ARSJ mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ASCL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
affects expression |
ISO |
Glucose affects the expression of ASNS mRNA |
CTD |
PMID:17409444 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Aspg |
asparaginase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ASPG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Aspn |
asporin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ASPN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041
|
|
G |
Atad1 |
ATPase family, AAA domain containing 1 |
multiple interactions |
EXP |
ATAD1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 1:230,544,227...230,610,524
Ensembl chr 1:230,544,047...230,596,548
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ATF3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression increases response to substance multiple interactions |
ISO EXP |
Glucose deficiency results in increased expression of ATF4 mRNA ATF4 protein results in increased susceptibility to Glucose Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF4 protein] Glucose deficiency results in increased expression of ATF4 protein 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]; [Galactose co-treated with Glucose deficiency] promotes the reaction [Leflunomide results in increased expression of ATF4 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]] |
CTD |
PMID:27226639 PMID:27278863 PMID:29427785 PMID:31022492 PMID:34801538 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression multiple interactions |
ISO EXP |
Glucose deficiency results in increased expression of ATF6 protein Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF6 protein]; Glucose results in increased expression of and affects the localization of ATF6 protein; Metformin inhibits the reaction [Glucose results in increased expression of and affects the localization of ATF6 protein] 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF6 protein]; ATF6 protein modified form promotes the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]] |
CTD |
PMID:31022492 PMID:34801538 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg10 |
autophagy related 10 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ATG10 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of ATG10 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions decreases expression |
EXP |
3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]; N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]; ULK1 protein affects the reaction [Glucose results in decreased expression of ATG5 protein]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions decreases expression |
EXP |
Inositol inhibits the reaction [Glucose results in decreased expression of ATG7 protein] |
CTD |
PMID:35243728 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atl1 |
atlastin GTPase 1 |
multiple interactions |
EXP |
ATL1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
increases expression |
ISO |
Glucose results in increased expression of ATOX1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO EXP |
Glucose results in decreased expression of and results in decreased activity of ATP1A1 protein; INS protein inhibits the reaction [Glucose results in decreased expression of ATP1A1 protein] [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of and affects the localization of ATP1A1 protein; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of and affects the localization of ATP1A1 protein] |
CTD |
PMID:22162761 PMID:29702141 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ATP2A1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of ATP2A1 mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein |
CTD |
PMID:25997894 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]; Y 27632 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of ATP6AP2 mRNA; Glucose results in increased expression of ATP6AP2 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 protein] |
CTD |
PMID:19861503 |
|
NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
Glucose results in increased expression of AURKA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
affects secretion |
ISO |
Glucose deficiency affects the secretion of AZGP1 protein |
CTD |
PMID:24802182 |
|
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
|
|
G |
B2m |
beta-2 microglobulin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of B2M mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of B3GAT3 mRNA [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]; IL1B protein inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
B3gnt6 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of B3GNT6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:152,484,572...152,496,226
Ensembl chr 1:152,486,343...152,492,150
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of B4GALNT4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of BAD protein]; Glucose results in decreased phosphorylation of and results in decreased activity of BAD protein |
CTD |
PMID:20370652 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
EXP ISO |
[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of BAK1 mRNA [Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA] |
CTD |
PMID:29122578 PMID:33962019 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of BAMBI mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Barx2 |
BARX homeobox 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of BARX2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013
|
|
G |
Batf2 |
basic leucine zipper ATF-like transcription factor 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BATF2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:203,467,291...203,479,428
Ensembl chr 1:203,468,097...203,475,889
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions affects expression |
ISO EXP |
Glucose results in increased expression of BAX mRNA; Glucose results in increased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA]; Carnosine inhibits the reaction [Glucose results in increased expression of BAX mRNA]; diallyl trisulfide inhibits the reaction [Glucose results in increased expression of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MitoTEMPO inhibits the reaction [Glucose results in increased expression of BAX protein]; NDRG2 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]; salvianolic acid inhibits the reaction [Glucose results in increased expression of BAX protein]; spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein] 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein modified form; CEBPB protein inhibits the reaction [Glucose results in increased expression of BAX protein]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; Valsartan inhibits the reaction [Glucose results in increased expression of BAX protein] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in increased expression of BAX protein]; [Dithionite co-treated with Glucose deficiency] results in increased expression of BAX protein; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of BAX protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]]; cinnamic acid inhibits the reaction [Glucose results in increased expression of BAX protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of BAX protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]]; Metformin inhibits the reaction [Glucose results in increased expression of BAX protein]; morroniside inhibits the reaction [Glucose results in increased expression of BAX protein]; naringenin inhibits the reaction [Glucose results in increased expression of BAX mRNA]; naringenin inhibits the reaction [Glucose results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; Quercetin affects the reaction [Glucose affects the expression of BAX protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]; sesamin affects the reaction [Glucose affects the expression of BAX protein]; STIM1 protein affects the reaction [Glucose results in increased expression of BAX protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein] |
CTD |
PMID:21803128 PMID:22524206 PMID:23192364 PMID:23451161 PMID:24218232 PMID:24682241 PMID:25238743 PMID:25305180 PMID:26054749 PMID:27234048 PMID:28106847 PMID:28675767 PMID:28713934 PMID:29266779 PMID:30144576 PMID:30431688 PMID:30802477 PMID:31115753 PMID:31323227 PMID:31672611 PMID:31935362 PMID:32602595 PMID:33759271 PMID:33962019 PMID:36462176 PMID:37417536 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; [Palmitic Acid co-treated with Glucose] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]; SIRT1 protein mutant form inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased expression of BBC3 mRNA] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BBC3 protein modified form; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BBC3 protein] |
CTD |
PMID:24451382 PMID:28675767 PMID:33962019 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of BCHE mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl11a |
BCL11 transcription factor A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of BCL11A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression affects expression multiple interactions |
ISO EXP |
Glucose results in decreased expression of BCL2 mRNA; Glucose results in decreased expression of BCL2 protein Glucose affects the expression of BCL2 mRNA; Glucose affects the expression of BCL2 protein 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; [Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] affects the expression of BCL2 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; cinnamic acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Diosgenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; Metformin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; morroniside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; Quercetin affects the reaction [Glucose affects the expression of BCL2 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; sesamin affects the reaction [Glucose affects the expression of BCL2 protein]; STIM1 protein affects the reaction [Glucose results in decreased expression of BCL2 protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; [Resveratrol co-treated with Glucose] results in increased expression of BCL2 protein; asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; diallyl trisulfide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]; Glucose results in increased degradation of and results in decreased expression of BCL2 protein; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MitoTEMPO inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Quercetin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; Rutin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; salvianolic acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Tamoxifen inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]] 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein; [Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR210 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein] |
CTD |
PMID:18088078 PMID:19557821 PMID:21413024 PMID:21803128 PMID:21818840 PMID:22467055 PMID:22524206 PMID:23108914 PMID:23192364 PMID:23637816 PMID:23954465 PMID:24218232 PMID:24349266 PMID:24682241 PMID:25305180 PMID:26054749 PMID:27234048 PMID:27481074 PMID:28106847 PMID:28713934 PMID:30144576 PMID:30431688 PMID:30802477 PMID:31115753 PMID:31323227 PMID:31672611 PMID:31935362 PMID:32602595 PMID:33759271 PMID:33962019 PMID:34801538 PMID:36462176 PMID:37417536 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
BCL2L1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]]; resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] |
CTD |
PMID:25471227 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l15 |
Bcl2-like 15 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078
|
|
G |
Bco1 |
beta-carotene oxygenase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of BCO1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of BDKRB1 protein argan oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein]; Corn Oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein] |
CTD |
PMID:29165388 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression increases expression |
EXP ISO |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein]; [Resveratrol co-treated with Glucose] results in increased expression of BECN1 protein; Inositol inhibits the reaction [Glucose results in decreased expression of BECN1 protein] Glucose results in increased expression of BECN1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]]; Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]]; HU 308 inhibits the reaction [Glucose results in decreased expression of BECN1 protein] |
CTD |
PMID:25997894 PMID:28713934 PMID:30459625 PMID:33450223 PMID:35243728 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Begain |
brain-enriched guanylate kinase-associated |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of BEGAIN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:127,943,651...127,979,876
Ensembl chr 6:127,943,651...127,979,841
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP protein]]; Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]] morroniside inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of BGLAP protein] Glucose results in decreased expression of BGLAP mRNA; Glucose results in decreased expression of BGLAP protein |
CTD |
PMID:32643284 PMID:33450223 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of BHMT mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
decreases expression multiple interactions |
ISO EXP |
Glucose results in decreased expression of BMP2 mRNA cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of BMP2 mRNA]; tin mesoporphyrin promotes the reaction [Glucose results in decreased expression of BMP2 mRNA] morroniside inhibits the reaction [Glucose results in decreased expression of BMP2 mRNA] |
CTD |
PMID:19924377 PMID:32643284 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmper |
BMP-binding endothelial regulator |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BMPER mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
multiple interactions decreases expression |
ISO EXP |
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA] Glucose results in decreased expression of BNIP3L protein Inositol inhibits the reaction [Glucose results in decreased expression of BNIP3L protein] |
CTD |
PMID:33962019 PMID:35243728 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BST2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
Btbd17 |
BTB domain containing 17 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of BTBD17 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:99,826,132...99,832,624
Ensembl chr10:99,826,132...99,832,624
|
|
G |
C1qtnf3 |
C1q and TNF related 3 |
decreases expression |
ISO |
Glucose results in decreased expression of C1QTNF3 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433
|
|
G |
C1r |
complement C1r |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of C1R protein |
CTD |
PMID:24802182 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C1s |
complement C1s |
affects secretion |
ISO |
Glucose deficiency affects the secretion of C1S protein |
CTD |
PMID:24802182 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of C3 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of C3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of C3 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of C3 mRNA |
CTD |
PMID:17178593 PMID:23199288 PMID:37567420 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C4b |
complement C4B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of C4B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of HC mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HC mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of C5AR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cabp4 |
calcium binding protein 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CABP4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:201,428,671...201,442,950
Ensembl chr 1:201,428,672...201,433,172
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CACNA1S mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CALCA mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CALCA mRNA |
CTD |
PMID:31655124 PMID:37567420 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm2 |
calmodulin 2 |
multiple interactions |
EXP |
CALM2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucose results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of CALU protein |
CTD |
PMID:24802182 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
multiple interactions |
EXP |
CALY protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551
|
|
G |
Canx |
calnexin |
decreases expression multiple interactions increases expression |
ISO EXP |
Glucose results in decreased expression of CANX mRNA Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CANX protein] |
CTD |
PMID:17178593 PMID:34801538 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Capn1 |
calpain 1 |
multiple interactions increases expression |
EXP ISO |
2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside inhibits the reaction [[Oxygen co-treated with Glucose deficiency] results in increased expression of CAPN1 protein]; [Oxygen co-treated with Glucose deficiency] results in increased expression of CAPN1 protein Glucose results in increased expression of CAPN1 protein Furans analog inhibits the reaction [Glucose results in increased expression of CAPN1 protein] |
CTD |
PMID:24726522 PMID:28911973 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CAR3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases activity increases expression increases cleavage |
ISO EXP |
Acetylcysteine inhibits the reaction [Glucose results in increased cleavage of CASP1 protein]; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP1 protein]; Glucose results in increased cleavage of and results in increased activity of CASP1 protein; Glucose results in increased expression of and results in increased cleavage of CASP1 protein Glucose results in increased activity of CASP1 mRNA; Glucose results in increased activity of CASP1 protein Glucose results in increased expression of CASP1 mRNA; Glucose results in increased expression of CASP1 protein [Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein; Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein]; L 709049 analog inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of CASP1 protein]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Glucose results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]]; swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form; Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form]; L 709049 analog inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Suramin inhibits the reaction [Glucose results in increased activity of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein] |
CTD |
PMID:20370652 PMID:21832250 PMID:23647015 PMID:27783111 PMID:29031534 PMID:34212273 PMID:35191607 PMID:35607288 PMID:35961541 PMID:36066211 PMID:37473909 More...
|
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
multiple interactions increases expression increases cleavage |
ISO EXP |
TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP12 protein]; waixenicin A inhibits the reaction [Glucose results in increased cleavage of CASP12 protein] Glucose results in increased expression of CASP12 protein Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CASP12 protein] |
CTD |
PMID:30076216 PMID:34801538 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression increases cleavage decreases expression |
ISO EXP |
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; [Glucose deficiency co-treated with Acetylcysteine] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; [Palmitic Acid co-treated with Glucose] results in increased cleavage of CASP3 protein; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Carnosine inhibits the reaction [Glucose results in increased activity of CASP3 protein]; diallyl trisulfide inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Fluorometholone inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Gliclazide inhibits the reaction [Glucose results in increased expression of CASP3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MitoTEMPO inhibits the reaction [Glucose results in increased activity of CASP3 protein]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Rosiglitazone inhibits the reaction [Glucose results in increased activity of CASP3 protein]; rutecarpine inhibits the reaction [Glucose results in increased activity of CASP3 protein]; salvianolic acid inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased cleavage of CASP3 protein] [Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein; [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP3 protein]; Glucose deficiency inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein modified form]; Glucose results in increased cleavage of and results in increased activity of CASP3 protein; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; INO 1001 inhibits the reaction [Glucose results in increased activity of CASP3 protein]; MIR144 mRNA promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR322 affects the reaction [Glucose results in increased cleavage of CASP3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; TRAF3 affects the reaction [Glucose results in increased cleavage of CASP3 protein]; TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein]; VDAC1 protein inhibits the reaction [Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; VDAC1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; waixenicin A inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein] Glucose results in increased activity of CASP3; Glucose results in increased activity of CASP3 protein 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; [Dithionite co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] affects the expression of and affects the activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP3]; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; cinnamic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; diallyl trisulfide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; Glucose results in increased expression of and results in increased activity of CASP3 protein; Glucose results in increased expression of and results in increased cleavage of CASP3 protein; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; HMOX1 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein modified form]; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; Metformin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Metformin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; morroniside inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; NFE2L2 mutant form inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; NFE2L2 protein mutant form affects the reaction [plumbagin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; NFE2L2 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; plumbagin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP3 protein modified form]; sesamin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; STIM1 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; WDR35 protein affects the reaction [Glucose results in increased activity of CASP3 protein]; Y 27632 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein] Glucose results in increased expression of CASP3 mRNA; Glucose results in increased expression of CASP3 protein; Glucose results in increased expression of CASP3 protein modified form Glucose results in decreased expression of CASP3 mRNA |
CTD |
PMID:15322300 PMID:16135072 PMID:17065336 PMID:17309078 PMID:17928392 PMID:18004065 PMID:18088078 PMID:18791325 PMID:18973755 PMID:19767878 PMID:19892008 PMID:20028456 PMID:20224876 PMID:20370652 PMID:21803128 PMID:22524206 PMID:23192364 PMID:23453443 PMID:23637816 PMID:23758074 PMID:23770986 PMID:24349266 PMID:24451382 PMID:24682241 PMID:24720662 PMID:24810525 PMID:25238743 PMID:25305180 PMID:25488258 PMID:25516495 PMID:25896937 PMID:25997894 PMID:27234048 PMID:28106847 PMID:28675767 PMID:29095437 PMID:29457851 PMID:29702141 PMID:29719095 PMID:30076216 PMID:30144576 PMID:30431688 PMID:30802477 PMID:31115753 PMID:31655124 PMID:31935362 PMID:33759271 PMID:33962019 PMID:34212273 PMID:34801538 PMID:35191607 PMID:35264022 PMID:36462176 PMID:36928891 PMID:37417536 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO EXP |
Glucose results in increased activity of CASP8 protein [Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA] Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP8] |
CTD |
PMID:18791325 PMID:18973755 PMID:33962019 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases expression increases activity |
ISO EXP |
[Glucose deficiency co-treated with Acetylcysteine] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP9 protein; salvianolic acid inhibits the reaction [Glucose results in increased cleavage of CASP9 protein] Glucose results in increased expression of CASP9 mRNA [Glucose co-treated with IGF2R protein modified form] results in increased expression of CASP9 protein; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP9]; Glucose results in increased expression of and results in increased cleavage of CASP9 protein; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP9 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP9 mRNA] |
CTD |
PMID:17309078 PMID:18791325 PMID:23192364 PMID:25997894 PMID:30431688 PMID:36462176 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casz1 |
castor zinc finger 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CASZ1 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of CASZ1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 5:159,243,965...159,393,935
Ensembl chr 5:159,243,995...159,393,400
|
|
G |
Cat |
catalase |
multiple interactions decreases expression increases expression decreases activity increases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]]; [Glucose deficiency co-treated with CAT] affects the localization of ENDOG protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with CAT] results in increased cleavage of PARP1 protein; CAT inhibits the reaction [Glucose deficiency affects the folding of SOD2 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK1 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK14 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK3 protein]; CAT inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; CAT protein inhibits the reaction [Glucose promotes the reaction [EDN1 protein results in increased chemical synthesis of Inositol 1,4,5-Trisphosphate]]; cyclopamine inhibits the reaction [SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; Furans analog inhibits the reaction [Glucose results in decreased activity of CAT protein]; SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of CAT protein]; solanesol inhibits the reaction [Glucose results in decreased activity of CAT protein]; spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein] Glucose results in decreased expression of CAT mRNA [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in decreased activity of CAT protein; CAT protein inhibits the reaction [Glucose results in increased expression of AGT mRNA]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNA11 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNAQ protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB1 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB2 protein]; naringenin inhibits the reaction [Glucose results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Glucose results in decreased activity of CAT protein] Glucose deficiency results in increased expression of CAT protein; Glucose results in increased expression of CAT protein [Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein; cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; cyclopamine promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] |
CTD |
PMID:12130563 PMID:17309078 PMID:20691780 PMID:21818840 PMID:23192364 PMID:23421680 PMID:23494737 PMID:26054749 PMID:27481074 PMID:28027979 PMID:28911973 PMID:32602595 PMID:37586544 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of CAV1 mRNA; Glucose results in decreased expression of CAV1 protein EGF protein inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]; Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA] |
CTD |
PMID:19816600 PMID:31655124 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucose results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cbs |
cystathionine beta synthase |
increases expression decreases expression |
ISO EXP |
Glucose results in increased expression of CBS mRNA Glucose deficiency results in decreased expression of CBS mRNA |
CTD |
PMID:17178593 PMID:35577173 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccdc116 |
coiled-coil domain containing 116 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of CCDC116 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr11:83,842,707...83,850,607
Ensembl chr11:83,845,557...83,850,607
|
|
G |
Ccdc169 |
coiled-coil domain containing 169 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CCDC169 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:139,321,644...139,351,161
Ensembl chr 2:139,321,670...139,351,161
|
|
G |
Ccdc190 |
coiled-coil domain containing 190 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CCDC190 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:82,147,161...82,154,863
Ensembl chr13:82,147,176...82,154,863
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions increases secretion |
ISO EXP |
Glucose results in increased expression of CCL2 mRNA; Glucose results in increased expression of CCL2 protein (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCL2 protein]; [Glucose co-treated with fatostatin] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 protein]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Aspirin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Aspirin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Aspirin inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; CCL2 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; chromic chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; chromium nicotinic acid complex inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Clofibrate inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Clofibrate inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Clofibrate inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; diphenyleneiodonium inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Fenofibrate inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Glucose inhibits the reaction [Fructose results in increased secretion of CCL2 protein]; Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]; HTS 466284 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; isoangustone A inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; manganese chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; nothofagin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; nothofagin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; picolinic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; psicose inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; psicose inhibits the reaction [Glucose results in increased expression of CCL2 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of MCP1 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Selenium inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]] Glucose results in increased expression of CCL2 mRNA; Glucose results in increased expression of CCL2 protein; Glucose results in increased expression of MCP1 mRNA duanbanhuain A inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; duanbanhuain B inhibits the reaction [Glucose results in increased secretion of CCL2 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCL2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CCL2 mRNA; manganese chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]; SNHG1 affects the reaction [Glucose results in increased expression of CCL2 mRNA]; SNHG1 affects the reaction [Glucose results in increased expression of CCL2 protein]; SNHG1 affects the reaction [MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]] |
CTD |
PMID:16143069 PMID:16600694 PMID:17178593 PMID:17607302 PMID:17655880 PMID:17665966 PMID:19132243 PMID:19158351 PMID:19225232 PMID:20542118 PMID:21367880 PMID:22036992 PMID:23329836 PMID:24436987 PMID:24513509 PMID:25338943 PMID:29420703 PMID:32613381 PMID:36243327 PMID:37567420 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CCL28 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions decreases expression |
ISO |
Glucose results in increased expression of CCL5 mRNA [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL5 mRNA Glucose results in decreased expression of CCL5 mRNA |
CTD |
PMID:17178593 PMID:31655124 PMID:32613381 PMID:32942007 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CCL7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
Glucose results in increased expression of CCN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCN2 protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]; Cadmium inhibits the reaction [Glucose results in increased expression of CCN2 protein]; CCL2 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein]; Zinc inhibits the reaction [Glucose results in increased expression of CCN2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of CCN2 mRNA] Aspirin inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]; CCN2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; fatostatin inhibits the reaction [Glucose results in increased expression of CCN2 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of CCN2 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]] Glucose results in increased expression of CCN2 mRNA; Glucose results in increased expression of CCN2 protein |
CTD |
PMID:10026205 PMID:14586741 PMID:19369054 PMID:21124846 PMID:21367880 PMID:22031849 PMID:26891083 PMID:33270355 More...
|
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCNB1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of CCND1; Glucose results in increased expression of CCND1 mRNA [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA] resveratrol inhibits the reaction [Glucose results in increased expression of CCND1 protein] [Glucose co-treated with resveratrol] results in decreased expression of CCND1 mRNA; resveratrol inhibits the reaction [Glucose results in increased expression of CCND1 mRNA] |
CTD |
PMID:23690508 PMID:24064760 PMID:24971582 PMID:27049278 PMID:27481074 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of CCNE1 protein resveratrol inhibits the reaction [Glucose results in increased expression of CCNE1 protein] |
CTD |
PMID:24971582 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
ISO |
Glucose results in increased expression of CCNL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Ccr10 |
C-C motif chemokine receptor 10 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CCR10 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr10:86,108,551...86,110,988
Ensembl chr10:86,108,551...86,110,988
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CCR6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCR7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
CD14 protein affects the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Curcumin inhibits the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]]; Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein] |
CTD |
PMID:18180316 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
multiple interactions |
EXP |
CD151 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd160 |
CD160 molecule |
decreases expression |
ISO |
Glucose results in decreased expression of CD160 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:184,340,820...184,383,421
Ensembl chr 2:184,340,599...184,375,834
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD163 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd19 |
CD19 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CD19 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975
|
|
G |
Cd1d1 |
CD1d1 molecule |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CD1D1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089
|
|
G |
Cd226 |
CD226 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD226 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:82,449,924...82,545,107
Ensembl chr18:82,450,568...82,543,051
|
|
G |
Cd247 |
Cd247 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD247 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263
|
|
G |
Cd300a |
Cd300a molecule |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CD300A mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD300A mRNA |
CTD |
PMID:31525975 PMID:37567420 |
|
NCBI chr10:99,929,801...99,942,674
Ensembl chr10:99,929,801...99,942,674
|
|
G |
Cd300lb |
CD300 molecule-like family member b |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD300LB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:99,964,801...99,974,790
Ensembl chr10:99,964,801...99,974,790
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
ISO |
(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA] Glucose results in increased expression of CD36 mRNA |
CTD |
PMID:32613381 PMID:36156098 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD3E mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CD40LG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CD44 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD44 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd48 |
Cd48 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD48 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cd5 |
Cd5 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CD5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd52 |
CD52 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD52 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd6 |
Cd6 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd74 |
CD74 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD74 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd8b |
CD8 subunit beta |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD8B1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:103,312,578...103,328,553
|
|
G |
Cd96 |
CD96 molecule |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD96 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:54,702,290...54,776,618
Ensembl chr11:54,702,290...54,776,621
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CDC42 mRNA; Glucose results in increased expression of CDC42 protein Eucalyptol inhibits the reaction [Glucose results in increased expression of CDC42 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of CDC42 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CDC42 protein] |
CTD |
PMID:24659233 PMID:31483951 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in decreased expression of CDH1 protein]; [Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein]; DKK1 protein inhibits the reaction [Glucose results in decreased expression of CDH1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in decreased expression of CDH1 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of CDH1 protein] Glucose results in decreased expression of CDH1 mRNA; Glucose results in decreased expression of CDH1 protein |
CTD |
PMID:21829520 PMID:26045780 PMID:29163160 PMID:33992720 PMID:35445903 PMID:35961541 More...
|
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh5 |
cadherin 5 |
decreases expression |
ISO |
Glucose results in decreased expression of CDH5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CDK1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CDK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Glucose results in increased phosphorylation of CDK9 protein 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased phosphorylation of CDK9 protein]; CDK9 protein affects the reaction [Glucose results in increased expression of COL4A4 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of IL1B mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of IL6 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of NOS2 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of TGFB1 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of TNF mRNA]; CDK9 protein affects the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; CDK9 protein affects the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; CDK9 protein affects the reaction [Glucose results in increased secretion of IL6 protein]; CDK9 protein affects the reaction [Glucose results in increased secretion of TNF protein] |
CTD |
PMID:33631230 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of CDKN1A mRNA Glucose results in decreased expression of CDKN1A protein Glucose promotes the reaction [SETD7 protein binds to CDKN1A promoter]; NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; TGFB1 protein promotes the reaction [Glucose promotes the reaction [SETD7 protein binds to CDKN1A promoter]]; TGFB1 protein promotes the reaction [Glucose results in increased expression of CDKN1A mRNA] Glucose results in increased expression of CDKN1A mRNA; Glucose results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased expression of CDKN1A mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA; [Palmitic Acid co-treated with Glucose] results in increased expression of CDKN1A mRNA; Fluorometholone inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; Melatonin inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Phytic Acid inhibits the reaction [Glucose results in increased expression of CDKN1A mRNA]; Phytic Acid inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1A mRNA]; SIRT1 protein mutant form inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased expression of CDKN1A mRNA]; TAS1R1 protein affects the reaction [Glucose results in decreased expression of CDKN1A protein] |
CTD |
PMID:17178593 PMID:22561310 PMID:24451382 PMID:27049278 PMID:27652271 PMID:33962019 PMID:33992720 PMID:35264022 PMID:38000455 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of CDKN1B protein [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA] NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] |
CTD |
PMID:22561310 PMID:33962019 PMID:33992720 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CDKN2A protein alternative form SIRT3 protein inhibits the reaction [Glucose results in increased expression of CDKN2A protein alternative form] |
CTD |
PMID:23494737 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions decreases expression decreases secretion |
ISO |
cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of CEACAM1 mRNA]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased secretion of CEACAM1 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CEACAM3 mRNA |
CTD |
PMID:19924377 PMID:37567420 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Ceacam19 |
CEA cell adhesion molecule 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CEACAM19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:79,542,107...79,550,927
Ensembl chr 1:79,542,107...79,550,927
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
CEBPA protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPA protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; Glucose promotes the reaction [CEBPA protein binds to EDN1 promoter]; Glucose results in increased localization of and results in increased activity of CEBPA protein; pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein]; SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein]; U 0126 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein] |
CTD |
PMID:24376792 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions decreases expression |
ISO |
CEBPB protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPB protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; Glucose promotes the reaction [CEBPB protein binds to EDN1 promoter]; Glucose results in increased localization of and results in increased activity of CEBPB protein; pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein]; SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein]; U 0126 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein] CEBPB protein inhibits the reaction [Glucose results in decreased expression of ACE2 protein]; CEBPB protein inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of MMP2 protein]; CEBPB protein inhibits the reaction [Glucose results in decreased expression of MAS1 protein]; CEBPB protein inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of ACE protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR1 protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR2 protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of BAX protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of COL3A1 protein]; CEBPB protein inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; Glucose inhibits the reaction [CEBPB protein binds to ACE2 promoter] Glucose results in decreased expression of CEBPB protein |
CTD |
PMID:24376792 PMID:28482072 PMID:29266779 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
CEBPD protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPD protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; Glucose promotes the reaction [CEBPD protein binds to EDN1 promoter]; Glucose results in increased localization of and results in increased activity of CEBPD protein; pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein]; SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein]; U 0126 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein] |
CTD |
PMID:24376792 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celf3 |
CUGBP, Elav-like family member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CELF3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:182,116,034...182,130,163
Ensembl chr 2:182,116,073...182,130,163
|
|
G |
Celf4 |
CUGBP, Elav-like family member 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CELF4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:16,786,578...17,065,045
Ensembl chr18:16,786,867...17,064,786
|
|
G |
Celsr1 |
cadherin, EGF LAG seven-pass G-type receptor 1 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CELSR1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 7:116,987,616...117,125,035
Ensembl chr 7:116,987,605...117,125,164
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of CELSR3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CELSR3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CEMIP mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CENPF mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cert1 |
ceramide transporter 1 |
multiple interactions increases expression |
EXP |
rhodioloside inhibits the reaction [Glucose results in increased expression of CERT1 mRNA]; TXNIP protein affects the reaction [Glucose results in increased expression of CERT1 mRNA] |
CTD |
PMID:29031534 |
|
NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074
|
|
G |
Ces2f |
carboxylesterase 2F |
increases expression |
ISO |
Glucose results in increased expression of CES2F mRNA |
CTD |
PMID:31525975 |
|
NCBI chr19:7,527...14,898
Ensembl chr19:7,527...14,898
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CES2H mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfap45 |
cilia and flagella associated protein 45 |
increases expression |
ISO |
Glucose results in increased expression of CFAP45 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878
|
|
G |
Cfap74 |
cilia and flagella associated protein 74 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CFAP74 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:165,970,611...166,046,068
Ensembl chr 5:165,979,805...166,046,071
|
|
G |
Cfap97d1 |
CFAP97 domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CFAP97D1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:86,933,585...86,944,566
Ensembl chr10:86,933,808...86,938,244
|
|
G |
Cfd |
complement factor D |
decreases expression multiple interactions |
EXP ISO |
Glucose results in decreased expression of CFD mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CFD mRNA |
CTD |
PMID:3299706 PMID:37567420 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cfl1 |
cofilin 1 |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of CFL1 protein |
CTD |
PMID:24802182 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cfp |
complement factor properdin |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of CFP mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of CFP mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
multiple interactions |
EXP |
CHAC1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
multiple interactions |
ISO |
Glucose promotes the reaction [TCF19 protein binds to CHD2 protein] |
CTD |
PMID:29042441 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CHGB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Chkb |
choline kinase beta |
multiple interactions |
EXP |
CHKB protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 7:120,500,960...120,504,359
Ensembl chr 7:120,500,984...120,504,461
|
|
G |
Chrdl2 |
chordin-like 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CHRDL2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CHRDL2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
increases expression |
EXP |
Glucose results in increased expression of CHRM2 mRNA |
CTD |
PMID:18715473 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Cimap1c |
ciliary microtubule associated protein 1C |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of CIMAP1C mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:57,248,746...57,281,084
Ensembl chr 8:57,248,746...57,281,004
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CKAP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Ckb |
creatine kinase B |
multiple interactions increases activity |
ISO |
Glucose inhibits the reaction [daidzein results in increased activity of CKB protein]; Glucose inhibits the reaction [Dihydrotestosterone results in increased activity of CKB protein]; Glucose inhibits the reaction [Estradiol results in increased activity of CKB protein]; Glucose inhibits the reaction [Genistein results in increased activity of CKB protein] Glucose results in increased activity of CKB protein |
CTD |
PMID:16621514 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
increases expression |
ISO |
Glucose results in increased expression of CKS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clec4a |
C-type lectin domain family 4, member A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CLEC4N mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:156,340,439...156,434,212
Ensembl chr 4:156,414,688...156,432,402
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CLEC4E mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Clhc1 |
clathrin heavy chain linker domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CLHC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:103,288,116...103,328,725
Ensembl chr14:103,288,134...103,328,715
|
|
G |
Clic6 |
chloride intracellular channel 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CLIC6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:31,737,813...31,780,360
Ensembl chr11:31,737,813...31,780,061
|
|
G |
Clspn |
claspin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CLSPN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CLSTN3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CMA1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Cnih2 |
cornichon family AMPA receptor auxiliary protein 2 |
increases expression |
ISO |
Glucose results in increased expression of CNIH2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089
|
|
G |
Cnn1 |
calponin 1 |
increases methylation decreases expression multiple interactions |
ISO |
Glucose results in increased methylation of CNN1 gene Glucose results in decreased expression of CNN1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of CNN1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression multiple interactions increases expression |
EXP |
Glucose results in decreased expression of CNR1 mRNA MIR29A mRNA inhibits the reaction [Glucose results in increased expression of CNR1 mRNA]; MIR29A mRNA inhibits the reaction [Glucose results in increased expression of CNR1 protein] Glucose results in increased expression of CNR1 mRNA; Glucose results in increased expression of CNR1 protein |
CTD |
PMID:19501110 PMID:30642005 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cntn4 |
contactin 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CNTN4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:138,624,584...139,622,499
Ensembl chr 4:139,099,152...139,621,090
|
|
G |
Cntnap2 |
contactin associated protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CNTNAP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:74,109,455...76,366,434
Ensembl chr 4:74,109,472...76,362,027
|
|
G |
Cntnap5b |
contactin associated protein family member 5B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CNTNAP5A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:17,863,367...18,766,983
Ensembl chr13:18,093,420...18,761,014
|
|
G |
Col19a1 |
collagen type XIX alpha 1 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of COL19A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:26,673,916...27,022,139
Ensembl chr 9:26,675,391...27,022,106
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
affects secretion decreases expression increases expression multiple interactions |
ISO EXP |
Glucose deficiency affects the secretion of COL1A1 protein Glucose results in decreased expression of COL1A1 mRNA Glucose results in increased expression of COL1A1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in decreased expression of COL1A1 mRNA]]; DKK1 protein inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA]; Melatonin inhibits the reaction [Glucose results in decreased expression of COL1A1 mRNA]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of COL1A1 mRNA] Curcumin analog inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA] |
CTD |
PMID:24802182 PMID:28700904 PMID:29163160 PMID:38000455 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions increases secretion increases expression |
ISO |
troglitazone inhibits the reaction [Glucose results in increased expression of COL1A2 mRNA] Glucose deficiency results in increased secretion of COL1A2 protein |
CTD |
PMID:17199790 PMID:24802182 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col27a1 |
collagen type XXVII alpha 1 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of COL27A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:76,647,302...76,765,989
Ensembl chr 5:76,647,429...76,765,174
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
affects secretion increases expression multiple interactions |
ISO |
Glucose deficiency affects the secretion of COL3A1 protein Glucose results in increased expression of COL3A1 protein CEBPB protein inhibits the reaction [Glucose results in increased expression of COL3A1 protein]; Valsartan inhibits the reaction [Glucose results in increased expression of COL3A1 protein] |
CTD |
PMID:24802182 PMID:29266779 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions increases expression |
EXP ISO |
[eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]; Curcumin analog inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA]; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA]]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA] |
CTD |
PMID:18682491 PMID:28700904 PMID:33270355 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
affects secretion |
ISO |
Glucose deficiency affects the secretion of COL4A2 protein |
CTD |
PMID:24802182 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of COL4A4 mRNA 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of COL4A4 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of COL4A4 mRNA] |
CTD |
PMID:33631230 |
|
NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
affects secretion |
ISO |
Glucose deficiency affects the secretion of COL5A1 protein |
CTD |
PMID:24802182 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of COL5A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
affects secretion |
ISO |
Glucose deficiency affects the secretion of COL6A1 protein |
CTD |
PMID:24802182 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
affects secretion |
ISO |
Glucose deficiency affects the secretion of COL6A2 protein |
CTD |
PMID:24802182 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col6a5 |
collagen type VI alpha 5 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of COL6A5 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of COL6A5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:106,483,806...106,584,114
Ensembl chr 8:106,483,799...106,584,113
|
|
G |
Col6a6 |
collagen type VI alpha 6 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of COL6A6 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of COL6A6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:106,318,010...106,473,419
Ensembl chr 8:106,306,422...106,473,472
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of COL7A1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Col8a2 |
collagen type VIII alpha 2 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of COL8A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:138,586,201...138,613,627
Ensembl chr 5:138,585,999...138,612,850
|
|
G |
Commd9 |
COMM domain containing 9 |
multiple interactions |
EXP |
COMMD9 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 3:88,175,909...88,190,427
Ensembl chr 3:88,175,987...88,190,439
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression |
ISO |
Glucose deficiency results in increased expression of COX4I1 mRNA |
CTD |
PMID:26811028 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
multiple interactions |
EXP |
COX5B protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of COX6A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cpe |
carboxypeptidase E |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CPE mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpq |
carboxypeptidase Q |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of CPQ mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 7:64,264,025...64,830,867
Ensembl chr 7:64,264,081...64,724,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of CPT1A protein (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Fenofibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA] Glucose results in decreased expression of CPT1A mRNA |
CTD |
PMID:23090186 PMID:32613381 PMID:36156098 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
affects expression |
EXP |
Glucose affects the expression of CPT2 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases activity multiple interactions |
ISO EXP |
Glucose results in increased activity of CREB1 protein [Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased phosphorylation of CREB1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:15767253 PMID:24726522 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CREB3L3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crlf1 |
cytokine receptor-like factor 1 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CRLF1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
CRMP1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Crtac1 |
cartilage acidic protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CRTAC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:241,091,679...241,233,677
Ensembl chr 1:241,078,864...241,233,421
|
|
G |
Cryaa |
crystallin, alpha A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CRYAA mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CRYAA mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Crybg2 |
crystallin beta-gamma domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CRYBG2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:146,286,406...146,318,417
Ensembl chr 5:146,286,925...146,323,666
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
ISO |
Glucose results in increased expression of CSRNP1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of CST6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:202,655,322...202,657,030
Ensembl chr 1:202,655,322...202,657,030
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
Glucose deficiency results in decreased expression of CTH mRNA; Glucose deficiency results in decreased expression of CTH protein |
CTD |
PMID:35577173 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression affects localization multiple interactions increases expression |
EXP ISO |
Glucose results in decreased expression of CTNNB1 mRNA; Glucose results in decreased expression of CTNNB1 protein Glucose affects the localization of CTNNB1 protein [Glucose co-treated with ICG 001] results in decreased expression of CTNNB1 protein; [ICG 001 co-treated with Glucose] affects the localization of CTNNB1 protein; DKK1 protein inhibits the reaction [Glucose results in increased expression of CTNNB1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of CTNNB1 protein]; Panax notoginseng extract inhibits the reaction [[Glucose co-treated with ICG 001] results in decreased expression of CTNNB1 protein]; Panax notoginseng extract inhibits the reaction [[ICG 001 co-treated with Glucose] affects the localization of CTNNB1 protein]; Panax notoginseng extract inhibits the reaction [Glucose affects the localization of CTNNB1 protein]; Panax notoginseng extract inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] Glucose results in increased expression of CTNNB1 mRNA; Glucose results in increased expression of CTNNB1 protein Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] |
CTD |
PMID:18004065 PMID:21818840 PMID:29163160 PMID:35385194 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases expression |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CTSB protein; Melatonin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CTSB protein] Glucose results in increased expression of CTSB mRNA |
CTD |
PMID:17178593 PMID:21392095 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsl |
cathepsin L |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of CTSL protein |
CTD |
PMID:24802182 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctsw |
cathepsin W |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CTSW mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:202,772,395...202,777,021
Ensembl chr 1:202,772,572...202,775,964
|
|
G |
Cttn |
cortactin |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of CTTN protein Eucalyptol inhibits the reaction [Glucose results in decreased expression of CTTN protein] |
CTD |
PMID:31483951 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CX3CL1 protein]; Clofibrate inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; Clofibrate inhibits the reaction [Glucose results in increased expression of CX3CL1 protein]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CX3CL1 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 protein] Glucose results in increased expression of CX3CL1 mRNA; Glucose results in increased expression of CX3CL1 protein |
CTD |
PMID:19132243 PMID:31655124 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CXCL10 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CXCL10 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Glucose results in increased expression of CXCL2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of CXCL1 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CXCL1 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CXCL9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[Glucose co-treated with Oxygen deficiency] results in decreased expression of CXCR4 mRNA; [Glucose co-treated with Oxygen deficiency] results in decreased expression of CXCR4 protein |
CTD |
PMID:18227068 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression decreases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of CYBA protein Glucose results in decreased expression of CYBA mRNA Glucose results in increased expression of CYBA mRNA; Glucose results in increased expression of CYBA protein [[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein; [[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species; CYBA protein promotes the reaction [Glucose results in increased chemical synthesis of Reactive Oxygen Species]; CYBA protein promotes the reaction [Glucose results in increased expression of FN1 protein]; farrerol inhibits the reaction [Glucose results in increased expression of CYBA mRNA]; farrerol inhibits the reaction [Glucose results in increased expression of CYBA protein]; pyrazolanthrone inhibits the reaction [Glucose results in increased expression of CYBA protein]; Resveratrol inhibits the reaction [[[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of CYBA mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CYBA protein] dorsomorphin inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in increased expression of CYBA protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of CYBA protein]; Rosiglitazone inhibits the reaction [Glucose results in increased expression of CYBA protein] |
CTD |
PMID:17916771 PMID:18088078 PMID:22245600 PMID:31838053 PMID:32942007 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions increases expression increases localization |
ISO EXP |
acetovanillone inhibits the reaction [Glucose results in increased expression of and results in increased activity of CYBB protein]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of CYBB protein]; Glucose results in increased expression of and results in increased activity of CYBB protein; Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB protein] Glucose results in increased expression of CYBB mRNA; Glucose results in increased expression of CYBB protein dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CYBB protein]]; Resveratrol inhibits the reaction [Glucose results in increased expression of CYBB protein] Glucose results in increased localization of CYBB protein [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CYBB protein; Prodigiosin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CYBB protein]; prolinedithiocarbamate inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CYBB protein] |
CTD |
PMID:19878672 PMID:21925195 PMID:22253932 PMID:26054749 PMID:31494106 PMID:31838053 PMID:34464088 More...
|
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions increases expression |
EXP ISO |
Glucose affects the localization of CYCS protein naringenin inhibits the reaction [Glucose affects the localization of CYCS protein] Glucose results in increased expression of CYCS mRNA; Glucose results in increased expression of CYCS protein [Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA; diallyl trisulfide inhibits the reaction [Glucose results in increased expression of CYCS protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA]; MitoTEMPO inhibits the reaction [Glucose results in increased expression of CYCS protein] |
CTD |
PMID:23192364 PMID:31115753 PMID:33962019 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cygb |
cytoglobin |
decreases expression |
ISO |
Glucose results in decreased expression of CYGB mRNA |
CTD |
PMID:32942007 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
Glucose results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:15017115 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Polyphenols promotes the reaction [Glucose results in increased expression of CYP1A1 mRNA] CYP1A1 protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:21682256 PMID:31776611 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP1A2 protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:31776611 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Oxygen co-treated with Glucose] inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of CYP1B1 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of CYP1B1 protein |
CTD |
PMID:28400208 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CYP26B1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP27B1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CYP2B10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP3A13 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CYP7B1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CYSRT1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:8,054,195...8,057,846
Ensembl chr 3:8,053,482...8,059,721
|
|
G |
Daxx |
death-domain associated protein |
multiple interactions affects localization |
ISO |
Glucose deficiency promotes the reaction [DAXX protein binds to MAP3K5 protein] Glucose deficiency affects the localization of DAXX protein |
CTD |
PMID:14505347 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucose results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Dbn1 |
drebrin 1 |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of DBN1 mRNA; Glucose results in decreased expression of DBN1 protein Curcumin inhibits the reaction [Glucose results in decreased expression of DBN1 mRNA] |
CTD |
PMID:23333261 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of DBP mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DBP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DCLK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dcx |
doublecortin |
increases expression |
ISO |
Glucose results in increased expression of DCX protein |
CTD |
PMID:23776576 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of DDIAS mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases expression multiple interactions increases expression |
ISO EXP |
Glucose results in decreased expression of DDIT3 mRNA Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of DDIT3 protein]; Metformin inhibits the reaction [Glucose results in increased expression of DDIT3 protein] [Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of DDIT3 protein] 2-aminoethoxydiphenyl borate inhibits the reaction [Glucose results in increased expression of DDIT3 protein]; DDIT3 affects the reaction [Glucose results in decreased expression of PPARGC1A mRNA]; Gadolinium inhibits the reaction [Glucose results in increased expression of DDIT3 protein]; Glucose inhibits the reaction [DDIT3 protein binds to PPARGC1A promoter]; TRPM7 protein affects the reaction [Glucose results in increased expression of DDIT3 protein]; waixenicin A inhibits the reaction [Glucose results in increased expression of DDIT3 protein] Glucose deficiency results in increased expression of DDIT3 mRNA; Glucose results in increased expression of DDIT3 mRNA; Glucose results in increased expression of DDIT3 protein Glucose deficiency results in increased expression of DDIT3 protein; Glucose results in increased expression of DDIT3 protein |
CTD |
PMID:17178593 PMID:21337367 PMID:24349266 PMID:27226639 PMID:28482072 PMID:29427785 PMID:30076216 PMID:34801538 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
increases degradation |
ISO |
Glucose deficiency results in increased degradation of DDX3X protein |
CTD |
PMID:30821613 |
|
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Defb24 |
defensin beta 24 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of DEFB19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:141,046,571...141,052,706
Ensembl chr 3:141,046,564...141,052,753
|
|
G |
Dek |
DEK proto-oncogene |
multiple interactions |
ISO |
DEK protein affects the chemical synthesis of and affects the uptake of Glucose |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of DEPP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Derl3 |
derlin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DERL3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Deup1 |
deuterosome assembly protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of DEUP1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DEUP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:12,380,300...12,442,649
Ensembl chr 8:12,380,302...12,442,199
|
|
G |
Dgkd |
diacylglycerol kinase, delta |
multiple interactions affects localization |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Glucose affects the localization of DGKD protein alternative form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose affects the localization of DGKD protein alternative form] |
CTD |
PMID:22974639 |
|
NCBI chr 9:88,516,686...88,607,349
Ensembl chr 9:88,516,715...88,607,345
|
|
G |
Dhh |
desert hedgehog signaling molecule |
increases expression |
ISO |
Glucose results in increased expression of DHH mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 7:130,050,910...130,056,406
Ensembl chr 7:130,050,910...130,056,406
|
|
G |
Dhps |
deoxyhypusine synthase |
multiple interactions |
EXP |
DHPS protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr19:23,082,454...23,086,544
Ensembl chr19:23,082,448...23,086,881
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DHRS9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of DHX58 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:85,620,352...85,631,776
Ensembl chr10:85,620,357...85,631,525
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions increases expression |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA] Glucose results in increased expression of DIABLO mRNA |
CTD |
PMID:33962019 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Diaph3 |
diaphanous-related formin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of DIAPH3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975
|
|
G |
Diras2 |
DIRAS family GTPase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of DIRAS2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:12,730,040...12,761,511
Ensembl chr17:12,725,149...12,761,663
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of DISC1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of DISC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Disp2 |
dispatched RND transporter family member 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of DISP2 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of DISP2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 3:105,762,303...105,777,826
Ensembl chr 3:105,762,305...105,777,800
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Glucose results in decreased expression of CDH1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in decreased expression of CDH1 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of CTNNB1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of LEF1 mRNA] |
CTD |
PMID:29163160 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of DLK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dmtn |
dematin actin binding protein |
increases methylation multiple interactions decreases expression |
ISO |
Glucose results in increased methylation of DMTN gene fucoxanthin inhibits the reaction [Glucose results in decreased expression of DMTN mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr15:45,677,974...45,702,261
Ensembl chr15:45,677,977...45,705,601
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucose results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucose results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of DNASE1L3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of DNM1L protein [Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA; diallyl trisulfide inhibits the reaction [Glucose results in increased expression of DNM1L protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA] cinnamic acid inhibits the reaction [Glucose results in increased expression of DNM1L protein]; Metformin inhibits the reaction [Glucose results in increased expression of DNM1L protein] |
CTD |
PMID:27684054 PMID:30144576 PMID:31115753 PMID:33962019 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
increases expression |
ISO |
Glucose results in increased expression of DNMT1 mRNA |
CTD |
PMID:29854080 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dok7 |
docking protein 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of DOK7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:75,665,444...75,699,413
Ensembl chr14:75,666,744...75,699,386
|
|
G |
Dpep2 |
dipeptidase 2 |
increases expression |
ISO |
Glucose results in increased expression of DPEP2 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of DPP6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dscaml1 |
DS cell adhesion molecule-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of DSCAML1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:45,740,298...46,057,322
Ensembl chr 8:45,740,298...46,057,320
|
|
G |
Duox1 |
dual oxidase 1 |
decreases expression |
ISO |
Glucose results in decreased expression of DUOX1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563
|
|
G |
Duox2 |
dual oxidase 2 |
decreases expression |
ISO |
Glucose results in decreased expression of DUOX2 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Glucose results in increased expression of DUSP1 mRNA |
CTD |
PMID:17178593 PMID:32942007 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp13b |
dual specificity phosphatase 13B |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of DUSP13B mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of DUSP13B mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr15:2,567,432...2,575,105
Ensembl chr15:2,533,547...2,575,539
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
increases expression |
ISO |
Glucose results in increased expression of DUSP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of DUSP5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
ISO |
Glucose results in increased expression of DUSP6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Ebln1 |
endogenous Bornavirus like nucleoprotein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of IGKV8-24 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:78,938,645...78,940,651
|
|
G |
Edaradd |
EDAR associated via death domain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of EDARADD mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucose results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 protein]; CAT protein inhibits the reaction [Glucose promotes the reaction [EDN1 protein results in increased chemical synthesis of Inositol 1,4,5-Trisphosphate]]; CEBPA protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPA protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; CEBPB protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPB protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; CEBPD protein affects the reaction [Glucose results in increased expression of and results in increased secretion of EDN1 protein]; CEBPD protein affects the reaction [Glucose results in increased expression of EDN1 mRNA]; diphenyleneiodonium inhibits the reaction [Glucose promotes the reaction [EDN1 protein results in increased chemical synthesis of Inositol 1,4,5-Trisphosphate]]; Glucose promotes the reaction [CEBPA protein binds to EDN1 promoter]; Glucose promotes the reaction [CEBPB protein binds to EDN1 promoter]; Glucose promotes the reaction [CEBPD protein binds to EDN1 promoter]; Glucose promotes the reaction [EDN1 protein results in increased chemical synthesis of Inositol 1,4,5-Trisphosphate]; pyrazolanthrone inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; resveratrol inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; U 0126 inhibits the reaction [Glucose results in increased expression of EDN1 mRNA] Glucose affects the reaction [EDN1 protein affects the abundance of and affects the localization of Calcium]; HIF1A protein affects the reaction [Glucose results in increased expression of EDN1 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of EDN1 protein]; resveratrol inhibits the reaction [Glucose results in increased expression of EDN1 protein]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of EDN1 protein]] Glucose results in increased expression of EDN1 mRNA; Glucose results in increased expression of EDN1 protein Glucose results in decreased expression of EDN1 mRNA |
CTD |
PMID:12821678 PMID:16428915 PMID:20691780 PMID:20960276 PMID:24376792 PMID:26891083 PMID:31655124 More...
|
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
EXP |
EDN3 protein inhibits the reaction [SLC5A2 protein results in increased uptake of Glucose] |
CTD |
PMID:15127950 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
Glucose results in increased expression of EDNRA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
EXP |
EEF1A1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
multiple interactions decreases phosphorylation |
ISO |
resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of EEF2 protein] |
CTD |
PMID:19765649 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
multiple interactions increases phosphorylation |
ISO |
resveratrol inhibits the reaction [Glucose results in increased phosphorylation of EEF2K protein] |
CTD |
PMID:19765649 |
|
NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Efhc1 |
EF-hand domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of EFHC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:23,375,815...23,414,283
Ensembl chr 9:23,375,840...23,414,283
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]; EGF protein promotes the reaction [Glucose results in increased expression of TGFA mRNA]; Glucose promotes the reaction [EGF protein results in increased expression of TGFA mRNA] |
CTD |
PMID:8638660 PMID:19816600 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
ISO |
Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]] Glucose results in increased expression of EGR1 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of EGR1 mRNA |
CTD |
PMID:17178593 PMID:19225232 PMID:37567420 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of EGR2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ehd3 |
EH-domain containing 3 |
multiple interactions |
EXP |
EHD3 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 6:21,640,861...21,665,601
Ensembl chr 6:21,639,290...21,665,236
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of EHHADH mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions increases phosphorylation |
ISO |
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Glucose results in increased phosphorylation of EIF2AK2 protein]; Glucose promotes the reaction [EIF2AK2 protein results in increased activity of MAPK14 protein] |
CTD |
PMID:18973755 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2AK3 protein] Glucose results in increased phosphorylation of EIF2AK3 protein Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2AK3 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:31022492 PMID:34801538 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO EXP |
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Glucose results in increased phosphorylation of EIF2S1 protein] Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2S1 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of EIF2S1 protein] 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2S1 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2S1 protein]] |
CTD |
PMID:18973755 PMID:31022492 PMID:34801538 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
increases degradation |
ISO |
Glucose deficiency results in increased degradation of EIF4A1 protein |
CTD |
PMID:30821613 |
|
NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation multiple interactions |
ISO |
Glucose results in increased phosphorylation of EIF4E protein Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]; resveratrol inhibits the reaction [Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]]; resveratrol inhibits the reaction [Glucose results in increased phosphorylation of EIF4E protein] |
CTD |
PMID:19765649 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP ISO |
resveratrol inhibits the reaction [Glucose results in increased phosphorylation of EIF4EBP1 protein] [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency] which results in increased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:15806154 PMID:20332614 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]; resveratrol inhibits the reaction [Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]] |
CTD |
PMID:19765649 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
increases degradation |
ISO |
Glucose deficiency results in increased degradation of EIF4H protein |
CTD |
PMID:30821613 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Elapor1 |
endosome-lysosome associated apoptosis and autophagy regulator 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ELAPOR1 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of ELAPOR1 mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr 2:196,089,199...196,169,055
Ensembl chr 2:196,091,646...196,168,716
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
increases expression |
ISO |
Glucose results in increased expression of ELK3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of ELOVL6 mRNA (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA] |
CTD |
PMID:15066988 PMID:16790840 PMID:32613381 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Emc1 |
ER membrane protein complex subunit 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of EMC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:151,608,557...151,633,888
Ensembl chr 5:151,608,568...151,633,888
|
|
G |
Endog |
endonuclease G |
multiple interactions affects localization |
ISO EXP |
[Glucose deficiency co-treated with Acetylcysteine] affects the localization of ENDOG protein; [Glucose deficiency co-treated with CAT] affects the localization of ENDOG protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] affects the localization of ENDOG protein Glucose affects the localization of ENDOG protein |
CTD |
PMID:17309078 PMID:23192364 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Enkur |
enkurin, TRPC channel interacting protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ENKUR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:83,690,105...83,714,756
Ensembl chr17:83,690,797...83,714,408
|
|
G |
Eno1 |
enolase 1 |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of ENO1 protein |
CTD |
PMID:24802182 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eno2 |
enolase 2 |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of ENO2 protein |
CTD |
PMID:24802182 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
increases expression |
ISO |
Glucose results in increased expression of ENTPD1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
Entpd4 |
ectonucleoside triphosphate diphosphohydrolase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ENTPD4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions increases expression |
ISO |
[cobaltous chloride co-treated with Glucose] promotes the reaction [HIF1A protein binds to EP300 protein]; ERCC1 protein affects the reaction [Glucose results in increased expression of EP300 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of EP300 mRNA]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:22228707 PMID:25192544 PMID:26045780 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx4 |
epoxide hydrolase 4 |
decreases expression |
ISO |
Glucose results in decreased expression of EPHX4 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
[EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA; [EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein; [EPO protein co-treated with Glucose] results in increased expression of SP7 mRNA; [EPO protein co-treated with Glucose] results in increased expression of SP7 protein |
CTD |
PMID:30894315 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epop |
elongin BC and polycomb repressive complex 2 associated protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of EPOP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:82,624,392...82,625,912
Ensembl chr10:82,624,392...82,625,912
|
|
G |
Eppk1 |
epiplakin 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of EPPK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:107,816,919...107,842,946
Ensembl chr 7:107,817,693...107,831,159
|
|
G |
Epsti1 |
epithelial stromal interaction 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of EPSTI1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein; Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
EXP |
[NRG1 protein binds to ERBB3 protein] which results in increased transport of Glucose |
CTD |
PMID:14711829 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions increases expression |
ISO |
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 protein]; ERCC1 protein affects the reaction [Glucose results in increased expression of EP300 mRNA]; ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 mRNA]; ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 protein]; ERCC1 protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; ERCC1 protein affects the reaction [Glucose results in increased expression of PARP1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 protein]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 protein] Glucose results in increased expression of ERCC1 mRNA; Glucose results in increased expression of ERCC1 protein |
CTD |
PMID:22228707 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ERCC4 mRNA; Glucose results in increased expression of ERCC4 protein 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 protein]; ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 mRNA]; ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 protein]; ERCC4 protein affects the reaction [Glucose results in increased expression of EP300 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 protein]; ERCC4 protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of PARP1 mRNA]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC4 protein] |
CTD |
PMID:22228707 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Glucose deficiency results in increased phosphorylation of ERN1 protein Glucose results in increased phosphorylation of ERN1 protein Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of ERN1 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of ERN1 protein] 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of ERN1 protein]; [Glucose co-treated with TGFB1 protein] results in increased phosphorylation of ERN1 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:31022492 PMID:34801538 PMID:35961541 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ern2 |
endoplasmic reticulum to nucleus signaling 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ERN2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:176,726,454...176,743,289
Ensembl chr 1:176,726,454...176,743,289
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
decreases expression increases expression multiple interactions |
ISO EXP |
Glucose results in decreased expression of ERO1A mRNA Glucose results in increased expression of ERO1A protein Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein]; Metformin inhibits the reaction [Glucose results in increased expression of ERO1A protein] |
CTD |
PMID:17178593 PMID:34801538 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression decreases expression multiple interactions increases phosphorylation increases abundance |
ISO EXP |
Glucose results in increased expression of ESR1 mRNA Glucose results in decreased expression of ESR1 mRNA ESR1 protein promotes the reaction [[resveratrol results in increased localization of SLC2A4 protein] which results in increased uptake of Glucose] Glucose results in increased phosphorylation of ESR1 protein ESR1 protein results in increased abundance of Glucose Endosulfan promotes the reaction [ESR1 protein results in increased abundance of Glucose] |
CTD |
PMID:16621514 PMID:18426865 PMID:23690508 PMID:31520823 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression decreases expression |
ISO |
Glucose results in increased expression of ESR2 mRNA Glucose results in decreased expression of ESR2 mRNA |
CTD |
PMID:16621514 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ESRP1 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of ESRP1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ESRRA protein resveratrol inhibits the reaction [Glucose results in decreased expression of ESRRA protein] |
CTD |
PMID:23090186 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Ezr |
ezrin |
multiple interactions decreases expression |
ISO |
Eucalyptol inhibits the reaction [Glucose results in decreased expression of EZR protein] |
CTD |
PMID:31483951 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of F13A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
Glucose results in decreased expression of F2R mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Fluorometholone inhibits the reaction [Glucose results in increased expression of F3 mRNA]; Fluorometholone inhibits the reaction [Glucose results in increased expression of F3 protein] Glucose results in increased expression of F3 mRNA; Glucose results in increased expression of F3 protein |
CTD |
PMID:35264022 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
F7 |
coagulation factor VII |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of F7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Glucose results in increased expression of FABP1 mRNA |
CTD |
PMID:36156098 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO EXP |
[Glucose deficiency co-treated with ALB protein] results in decreased expression of FABP4 mRNA; [Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of FABP4 mRNA; [Glucose deficiency co-treated with Clofibrate] results in increased expression of FABP4 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of FABP4 mRNA [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA] Glucose results in increased expression of FABP4 mRNA |
CTD |
PMID:3299706 PMID:8536680 PMID:32407875 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of FAM163A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fam163b |
family with sequence similarity 163, member B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FAM163B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:10,437,383...10,466,458
Ensembl chr 3:10,437,383...10,466,458
|
|
G |
Fam167a |
family with sequence similarity 167, member A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FAM167A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:37,685,221...37,715,472
Ensembl chr15:37,700,919...37,715,469
|
|
G |
Fam178b |
family with sequence similarity 178, member B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of FAM178B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:38,805,864...38,913,681
Ensembl chr 9:38,805,864...38,913,672
|
|
G |
Fam78b |
family with sequence similarity 78, member B |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of FAM78B mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of FAM78B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr13:79,162,393...79,250,958
Ensembl chr13:79,162,228...79,250,500
|
|
G |
Fam83c |
family with sequence similarity 83, member C |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of FAM83C mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 3:144,333,736...144,339,758
Ensembl chr 3:144,332,982...144,339,802
|
|
G |
Fam98c |
family with sequence similarity 98, member C |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of FAM98C mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of FAM98C mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:84,452,806...84,456,414
Ensembl chr 1:84,452,814...84,456,385
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression decreases expression multiple interactions |
ISO |
Glucose results in increased expression of FAS mRNA; Glucose results in increased expression of FAS protein Glucose results in decreased expression of FAS mRNA dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]]; dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS protein]]; platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]; platycodin D inhibits the reaction [Glucose results in increased expression of FAS protein]; STO 609 inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]] |
CTD |
PMID:23319015 PMID:31655124 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of FASLG mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of FASL mRNA |
CTD |
PMID:31655124 PMID:37567420 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of FASN mRNA Allopurinol inhibits the reaction [Glucose results in increased expression of FASN protein]; Glucose promotes the reaction [SREBF1 protein binds to FASN promoter]; Quercetin inhibits the reaction [Glucose results in increased expression of FASN protein] [Glucose results in increased expression of FASN protein] which results in increased abundance of Triglycerides; [INS protein co-treated with Glucose] results in increased expression of FASN mRNA; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [[Glucose results in increased expression of FASN protein] which results in increased abundance of Triglycerides]; Allopurinol inhibits the reaction [Glucose results in increased expression of FASN protein]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in increased expression of FASN protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of FASN protein]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of FASN protein]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of FASN mRNA] |
CTD |
PMID:15066988 PMID:18482975 PMID:19724016 PMID:22031849 PMID:23647015 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of FAT3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FAT3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135
|
|
G |
Faxc |
failed axon connections homolog, metaxin like GST domain containing |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FAXC mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:35,480,137...35,539,741
Ensembl chr 5:35,480,402...35,544,446
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of FBP2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fbxl13 |
F-box and leucine-rich repeat protein 13 |
increases expression |
ISO |
Glucose results in increased expression of FBXL13 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 4:13,414,880...13,607,079
Ensembl chr 4:13,414,926...13,641,494
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
FBXO32 protein affects the reaction [Glucose results in decreased expression of KCNN2 protein] Glucose results in increased expression of FBXO32 protein |
CTD |
PMID:30635400 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fbxo47 |
F-box protein 47 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FBXO47 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:82,849,514...82,880,337
Ensembl chr10:82,849,730...82,879,538
|
|
G |
Fbxo48 |
F-box protein 48 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of FBXO48 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FBXO48 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:91,380,857...91,382,314
Ensembl chr14:91,380,857...91,382,314
|
|
G |
Fbxw12 |
F-box and WD repeat domain containing 12 |
increases expression |
ISO |
Glucose results in increased expression of FBXW12 |
CTD |
PMID:36073553 |
|
NCBI chr 8:109,782,315...109,802,086
Ensembl chr 8:109,786,815...109,801,813
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
decreases expression |
ISO |
Glucose results in decreased expression of FCER1G mRNA |
CTD |
PMID:31525975 |
|
NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of FCGR4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fcho1 |
FCH and mu domain containing endocytic adaptor 1 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of FCHO1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr16:18,413,452...18,430,795
Ensembl chr16:18,413,363...18,435,104
|
|
G |
Fcrlb |
Fc receptor-like B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FCRLB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:83,148,685...83,157,157
Ensembl chr13:83,149,751...83,155,957
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of FEN1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fendrr |
FOXF1 adjacent non-coding developmental regulatory RNA |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of FENDRR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:49,127,225...49,152,780
Ensembl chr19:49,121,214...49,153,240
|
|
G |
Ffar1 |
free fatty acid receptor 1 |
decreases expression multiple interactions |
EXP ISO |
Glucose results in decreased expression of FFAR1 mRNA [FFAR1 protein affects the susceptibility to Dietary Fats] affects the reaction [Glucose results in increased secretion of INS1 protein]; FFAR1 protein affects the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:24349266 PMID:37217659 |
|
NCBI chr 1:86,111,368...86,112,272
Ensembl chr 1:86,111,368...86,112,272
|
|
G |
Ffar3 |
free fatty acid receptor 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of FFAR3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FFAR3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression multiple interactions decreases expression |
ISO |
Glucose results in increased expression of FGF1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of FGF1 mRNA] |
CTD |
PMID:31655124 PMID:33448797 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression multiple interactions decreases expression |
EXP ISO |
Glucose results in increased expression of FGF2 mRNA; Glucose results in increased expression of FGF2 protein Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] Glucose results in decreased expression of FGF2 mRNA |
CTD |
PMID:1518840 PMID:19759273 PMID:31655124 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
affects uptake increases secretion multiple interactions increases expression |
ISO |
FGF21 protein affects the uptake of Glucose Glucose results in increased secretion of FGF21 protein indolo(3,2-b)carbazole inhibits the reaction [Glucose deficiency results in increased expression of FGF21 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Glucose deficiency results in increased expression of FGF21 mRNA] indolo(3,2-b)carbazole inhibits the reaction [Glucose results in increased expression of FGF21 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased expression of FGF21 mRNA] |
CTD |
PMID:15902306 PMID:27226639 PMID:28123933 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
affects transport |
ISO |
FGF7 protein affects the transport of Glucose |
CTD |
PMID:12757114 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgg |
fibrinogen gamma chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FGG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Fgl2 |
fibrinogen-like 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of FGL2 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of FGL2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207
|
|
G |
Fhad1 |
forkhead associated phosphopeptide binding domain 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of FHAD1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:154,191,593...154,310,442
Ensembl chr 5:154,191,745...154,310,354
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of FIS1 protein [Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA] cinnamic acid inhibits the reaction [Glucose results in increased expression of FIS1 protein]; Metformin inhibits the reaction [Glucose results in increased expression of FIS1 protein] |
CTD |
PMID:27684054 PMID:30144576 PMID:33962019 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of FLG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Flg2 |
filaggrin 2 |
decreases methylation decreases expression |
ISO |
Glucose results in decreased methylation of FLG2 promoter Glucose results in decreased expression of FLG2 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:178,789,792...178,802,232
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of FLT1 mRNA; Glucose results in decreased expression of FLT1 protein [Glucose co-treated with ICG 001] results in decreased expression of FLT1 protein; Panax notoginseng extract inhibits the reaction [[Glucose co-treated with ICG 001] results in decreased expression of FLT1 protein]; Panax notoginseng extract inhibits the reaction [Glucose results in decreased expression of FLT1 protein] |
CTD |
PMID:31655124 PMID:35385194 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FMO3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fn1 |
fibronectin 1 |
increases expression increases secretion multiple interactions decreases expression decreases secretion |
ISO EXP |
Glucose results in increased expression of FN1 mRNA; Glucose results in increased expression of FN1 protein Glucose results in increased secretion of FN1 protein 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in increased expression of FN1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Glucose results in increased secretion of FN1 protein]; [Glucose results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased secretion of FN1 protein; acetovanillone inhibits the reaction [Glucose results in increased secretion of FN1 protein]; AKT activator SC79 inhibits the reaction [FOXP1 protein inhibits the reaction [Glucose results in increased expression of and results in increased secretion of FN1 protein]]; alpha-Tocopherol inhibits the reaction [Glucose results in increased expression of and results in increased secretion of FN1 protein]; Bosentan inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; Bosentan inhibits the reaction [Glucose results in increased expression of FN1 protein]; BQ 788 inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; calphostin C inhibits the reaction [Glucose results in increased secretion of FN1 protein]; chelerythrine inhibits the reaction [Glucose results in increased expression of FN1 protein]; Curcumin inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of FN1 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased secretion of FN1 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; ERCC1 protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of and results in increased secretion of FN1 protein]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; gingerol inhibits the reaction [Glucose results in increased secretion of FN1 protein]; Glucose results in increased expression of and results in increased secretion of FN1 protein; Indomethacin inhibits the reaction [Glucose results in increased secretion of FN1 protein]; MAPK14 protein promotes the reaction [Glucose results in increased secretion of FN1 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of FN1 protein]; Rotenone inhibits the reaction [Glucose results in increased secretion of FN1 protein]; sitaxsentan inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; SN50 peptide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; SN50 peptide inhibits the reaction [Glucose results in increased expression of FN1 protein]; trichostatin A inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; Troglitazone inhibits the reaction [Glucose results in increased expression of FN1 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 protein]]; Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; NFE2L2 protein affects the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]]; Resveratrol inhibits the reaction [Glucose results in increased expression of FN1 protein]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 protein]; TXNIP promotes the reaction [Glucose results in increased expression of FN1 mRNA] Glucose results in decreased expression of FN1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; [[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein; [Glucose results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1; [JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; [sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein; acetovanillone inhibits the reaction [Glucose results in increased expression of FN1 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased expression of FN1 protein]; cinnamaldehyde inhibits the reaction [Glucose results in increased expression of FN1 protein]; CYBA protein promotes the reaction [Glucose results in increased expression of FN1 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; diphenyliodonium inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; farrerol inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; farrerol inhibits the reaction [Glucose results in increased expression of FN1 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of FN1 protein]; LY2109761 inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; manumycin inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; MIR217 mRNA affects the reaction [Glucose results in increased expression of FN1 protein]; N,N-dimethylsphingosine inhibits the reaction [Glucose results in increased expression of FN1 protein]; NCF1 protein promotes the reaction [Glucose results in increased expression of FN1 protein]; Resveratrol inhibits the reaction [[[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of FN1 protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; SB 203580 inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of FN1 protein]]; SPHK1 mRNA affects the reaction [Glucose results in increased expression of FN1 protein]; SPHK1 protein inhibits the reaction [Glucose results in increased expression of FN1 protein]; Superoxides affects the reaction [Glucose results in increased expression of FN1 mRNA]; TXNIP protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; TXNIP protein affects the reaction [Glucose results in increased expression of FN1 protein]; Y 27632 inhibits the reaction [Glucose results in increased expression of FN1 protein] Glucose deficiency results in decreased secretion of FN1 protein Glucose results in decreased expression of FN1 mRNA |
CTD |
PMID:9225831 PMID:12388107 PMID:14520012 PMID:15086456 PMID:16320596 PMID:16572112 PMID:17178593 PMID:17199790 PMID:19765649 PMID:20060012 PMID:21829520 PMID:21998146 PMID:22228707 PMID:22245600 PMID:22406263 PMID:23376009 PMID:24802182 PMID:26045780 PMID:26891083 PMID:29031534 PMID:29163160 PMID:31494106 PMID:31655124 PMID:31838053 PMID:33270355 More...
|
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Folr1 |
folate receptor alpha |
decreases expression |
ISO |
Glucose results in decreased expression of FOLR1 mRNA |
CTD |
PMID:19616087 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of FOS mRNA [Glucose co-treated with Lipopolysaccharides] results in increased expression of FOS protein Dactinomycin inhibits the reaction [Glucose results in increased expression of FOS mRNA]; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:10723097 PMID:11123204 PMID:11557636 PMID:17178593 PMID:18180316 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of FOSL1 mRNA Glucose promotes the reaction [AGT protein results in increased expression of FOSL1 mRNA] |
CTD |
PMID:17178593 PMID:19225232 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
ISO |
Glucose results in increased expression of FOSL2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxa2 |
forkhead box A2 |
multiple interactions |
ISO |
[Metformin co-treated with Glucose] affects the localization of FOXA2 protein |
CTD |
PMID:16489446 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxa3 |
forkhead box A3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of FOXA3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155
|
|
G |
Foxf2 |
forkhead box F2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FOXF2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:32,835,730...32,842,547
Ensembl chr17:32,836,777...32,842,176
|
|
G |
Foxm1 |
forkhead box M1 |
increases expression |
ISO |
Glucose results in increased expression of FOXM1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo1 |
forkhead box O1 |
increases abundance multiple interactions decreases response to substance |
EXP ISO |
FOXO1 protein mutant form results in increased abundance of Glucose; FOXO1 protein results in increased abundance of Glucose 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased phosphorylation of and affects the localization of FOXO1 protein]]; Acetylcysteine inhibits the reaction [Glucose affects the localization of FOXO1 protein]; Calcitriol inhibits the reaction [Glucose results in decreased phosphorylation of and affects the localization of FOXO1 protein]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]]; Glucose results in decreased phosphorylation of and affects the localization of FOXO1 protein FOXO1 protein results in decreased susceptibility to Glucose Glucose results in increased acetylation of and results in decreased activity of FOXO1 protein; SIRT3 protein inhibits the reaction [Glucose results in increased acetylation of FOXO1 protein] FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]; FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]; FOXO1 protein promotes the reaction [resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]]; FOXO1 protein promotes the reaction [resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]]; Glucose results in increased phosphorylation of and results in decreased activity of FOXO1 protein; INS1 protein inhibits the reaction [FOXO1 protein results in increased abundance of Glucose]; INS1 protein promotes the reaction [FOXO1 protein mutant form results in increased abundance of Glucose]; resveratrol inhibits the reaction [Glucose results in increased phosphorylation of and results in decreased activity of FOXO1 protein]; resveratrol promotes the reaction [FOXO1 protein results in increased abundance of Glucose] |
CTD |
PMID:15788402 PMID:23494737 PMID:24413998 PMID:33450223 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions decreases expression increases phosphorylation increases localization |
ISO EXP |
[[resveratrol results in increased activity of SIRT1 protein] which results in increased phosphorylation of and results in decreased activity of FOXO3 protein] which results in decreased susceptibility to Glucose; AKT1 protein promotes the reaction [Glucose affects the phosphorylation of and affects the activity of FOXO3 protein]; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP1 protein]; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP3 protein]; Glucose affects the phosphorylation of and affects the activity of FOXO3 protein; resveratrol inhibits the reaction [Glucose results in increased phosphorylation of FOXO3 protein] polyethylene glycol loxenatide inhibits the reaction [Glucose results in decreased expression of FOXO3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose affects the localization of and results in increased phosphorylation of FOXO3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and affects the localization of FOXO3 protein]]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose affects the localization of and results in increased phosphorylation of FOXO3 protein]; Acetylcysteine inhibits the reaction [Glucose results in decreased phosphorylation of FOXO3 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased phosphorylation of FOXO3 protein]; Glucose results in decreased phosphorylation of and affects the localization of FOXO3 protein; Glucose results in increased phosphorylation of and affects the localization of FOXO3 protein; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and affects the localization of FOXO3 protein] Glucose results in increased localization of FOXO3 protein |
CTD |
PMID:20370652 PMID:23090186 PMID:23159718 PMID:25471227 PMID:37417536 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp1 |
forkhead box P1 |
multiple interactions decreases expression |
ISO |
AKT activator SC79 inhibits the reaction [FOXP1 protein inhibits the reaction [Glucose results in increased expression of and results in increased secretion of FN1 protein]]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of and results in increased secretion of FN1 protein]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of CYBB protein]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of NOX4 protein]; FOXP1 protein inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein] Glucose results in decreased expression of FOXP1 mRNA; Glucose results in decreased expression of FOXP1 protein |
CTD |
PMID:31494106 |
|
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
multiple interactions |
ISO |
FRK protein inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:17179392 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Frmd3 |
FERM domain containing 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FRMD3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:87,764,755...88,031,091
Ensembl chr 5:87,764,604...88,031,091
|
|
G |
Frmpd3 |
FERM and PDZ domain containing 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FRMPD3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:103,964,168...104,113,864
Ensembl chr X:104,043,194...104,111,968
|
|
G |
Fsbp |
fibrinogen silencer binding protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of FSBP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:25,058,003...25,064,276
Ensembl chr 5:25,032,066...25,104,616
|
|
G |
Fsip1 |
fibrous sheath interacting protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of FSIP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:105,074,584...105,217,180
Ensembl chr 3:105,068,543...105,217,167
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO EXP |
FTH1 protein inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species] [[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Oxygen] results in increased expression of [FTH1 protein binds to FTL protein] |
CTD |
PMID:16135072 PMID:18931039 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
EXP |
[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Oxygen] results in increased expression of [FTH1 protein binds to FTL protein] |
CTD |
PMID:16135072 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fut1 |
fucosyltransferase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of FUT1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616
|
|
G |
Fut2 |
fucosyltransferase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of FUT2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of FUT2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:96,119,549...96,139,567
Ensembl chr 1:96,119,371...96,140,360
|
|
G |
Fxyd5 |
FXYD domain-containing ion transport regulator 5 |
increases expression |
ISO |
Glucose results in increased expression of FXYD5 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
multiple interactions increases uptake |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased uptake of Glucose]; YWHAZ protein affects the reaction [G3BP1 protein results in increased uptake of Glucose] |
CTD |
PMID:35945655 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions decreases expression increases activity increases expression |
ISO EXP |
Glucose promotes the reaction [[ARNT protein binds to G6PC1 promoter] which results in increased expression of G6PC1 mRNA]; Glucose results in increased stability of and results in increased expression of G6PC1 mRNA Glucose results in decreased expression of G6PC1 mRNA Glucose results in increased activity of G6PC1 protein Glucose results in increased expression of G6PC1 mRNA Metformin inhibits the reaction [Glucose results in increased expression of G6PC1 mRNA]; tungstate inhibits the reaction [Glucose results in increased activity of G6PC1 protein]; Vanadates inhibits the reaction [Glucose results in increased activity of G6PC1 protein] [Glucose co-treated with S 4048] results in increased expression of G6PC1 mRNA |
CTD |
PMID:14988444 PMID:15767253 PMID:16920846 PMID:19576170 PMID:31974165 PMID:36156098 More...
|
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GABBR2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Gabrp |
gamma-aminobutyric acid type A receptor subunit pi |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of GABRP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
|
|
G |
Gabrq |
gamma-aminobutyric acid type A receptor subunit theta |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GABRQ mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:150,696,161...150,712,948
Ensembl chr X:150,696,427...150,709,919
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
GAD1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:25966616 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Glucose results in increased expression of GADD45G mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GALNT16 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of GALNT2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Galnt6 |
polypeptide N-acetylgalactosaminyltransferase 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GALNT6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions increases expression increases ADP-ribosylation |
ISO EXP |
SOD2 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein]; SOD2 protein inhibits the reaction [Glucose results in decreased activity of and results in increased ADP-ribosylation of GAPDH protein] Glucose results in increased expression of GAPDH mRNA [chloroacetaldehyde results in decreased activity of GAPDH protein] which results in decreased chemical synthesis of Glucose; UCP1 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein]; UCP1 protein inhibits the reaction [Glucose results in decreased activity of and results in increased ADP-ribosylation of GAPDH protein] Glucose results in increased ADP-ribosylation of GAPDH protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of GAPDH mRNA; PARP1 protein affects the reaction [Glucose results in increased ADP-ribosylation of GAPDH protein] |
CTD |
PMID:7826318 PMID:11050244 PMID:14523042 PMID:19733226 PMID:37567420 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gask1b |
golgi associated kinase 1B |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of GASK1B mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of GASK1B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477
|
|
G |
Gast |
gastrin |
increases secretion |
EXP |
Glucose results in increased secretion of GAST protein |
CTD |
PMID:19208342 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gata4 |
GATA binding protein 4 |
increases metabolic processing |
ISO |
GATA4 protein results in increased metabolism of Glucose |
CTD |
PMID:34087332 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GBP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gbp4 |
guanylate binding protein 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GBP3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GBP4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gbp7 |
guanylate binding protein 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GBP7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:231,275,521...231,297,289
Ensembl chr 2:231,275,640...231,297,278
|
|
G |
Gc |
GC, vitamin D binding protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of GC mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gcg |
glucagon |
multiple interactions increases secretion increases abundance decreases secretion |
ISO EXP |
Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein] [GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein]; isosteviol inhibits the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of GCG protein]]; Palmitic Acid promotes the reaction [Glucose results in increased secretion of GCG protein] GCG results in increased abundance of Glucose 9-phenanthrol inhibits the reaction [[GCG protein co-treated with Glucose] results in increased secretion of INS1 protein]; [GCG protein co-treated with Glucose] results in increased secretion of INS1 protein; [GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein]; Metformin inhibits the reaction [GCG results in increased abundance of Glucose]; Troglitazone inhibits the reaction [Glucose results in decreased secretion of GCG protein]; Zinc inhibits the reaction [Glucose results in increased secretion of GCG protein] |
CTD |
PMID:838844 PMID:12914525 PMID:15919803 PMID:18669601 PMID:19002567 PMID:22479612 PMID:29098165 More...
|
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gck |
glucokinase |
multiple interactions increases expression decreases expression |
ISO EXP |
[ebselen co-treated with Glucose] results in increased activity of GCK protein; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of GCK mRNA; Glucose inhibits the reaction [Alloxan results in decreased expression of GCK mRNA] Glucose results in increased expression of GCK mRNA Glucose results in decreased expression of and affects the localization of GCK protein; Metformin inhibits the reaction [Glucose results in decreased expression of GCK mRNA] |
CTD |
PMID:12137914 PMID:23795780 PMID:24349266 PMID:31974165 PMID:37567420 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gcsam |
germinal center-associated, signaling and motility |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of GCSAM mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:55,195,757...55,207,011
Ensembl chr11:55,196,712...55,206,992
|
|
G |
Gdap1l1 |
ganglioside-induced differentiation-associated protein 1-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GDAP1L1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711
|
|
G |
Gdf7 |
growth differentiation factor 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GDF7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:31,171,495...31,182,484
Ensembl chr 6:31,178,119...31,182,447
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
ISO |
Glucose results in increased expression of GEM mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
GH1 protein promotes the reaction [Glucose results in increased phosphorylation of TBC1D4 protein]; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein] |
CTD |
PMID:838844 PMID:21559284 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghrhr |
growth hormone releasing hormone receptor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GHRHR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:84,498,159...84,532,851
Ensembl chr 4:84,500,212...84,532,776
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
[homoeriodictyol co-treated with Glucose] results in increased secretion of GHRL protein |
CTD |
PMID:28834253 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression increases degradation multiple interactions increases expression |
ISO EXP |
Glucose results in decreased expression of GJA1 protein Glucose results in increased degradation of GJA1 protein resveratrol inhibits the reaction [Glucose results in increased degradation of GJA1 protein] Glucose results in increased expression of GJA1 mRNA Glucose results in increased expression of GJA1 protein Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of GJA1 protein]]; Chloroquine promotes the reaction [Glucose results in increased expression of GJA1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of GJA1 protein] |
CTD |
PMID:17178593 PMID:20578705 PMID:28713934 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
Glucose results in increased expression of GLA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Glb1 |
galactosidase, beta 1 |
increases expression increases activity multiple interactions |
ISO EXP |
Glucose results in increased expression of GLB1 protein Glucose results in increased activity of GLB1 protein NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; resveratrol inhibits the reaction [Glucose results in increased expression of GLB1 protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Fluorometholone inhibits the reaction [Glucose results in increased activity of GLB1 protein]]; Fluorometholone inhibits the reaction [Glucose results in increased activity of GLB1 protein]; Melatonin inhibits the reaction [Glucose results in increased expression of GLB1 protein]; Phytic Acid inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of GLB1 protein] |
CTD |
PMID:17075048 PMID:22561310 PMID:23494737 PMID:35264022 PMID:38000455 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions increases expression |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein] Glucose results in increased expression of GLI1 protein |
CTD |
PMID:27481074 PMID:33992720 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
affects localization multiple interactions |
ISO |
Glucose affects the localization of GLI2 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GLI2 mRNA |
CTD |
PMID:33992720 PMID:37567420 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Glipr1 |
GLI pathogenesis-related 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GLIPR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions decreases expression |
ISO EXP |
GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to HMGB1 promoter]]; GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to S100A12 promoter]]; GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to S100A8 promoter]]; GLO1 inhibits the reaction [Glucose promotes the reaction [RELA protein binds to AGER promoter]]; GLO1 inhibits the reaction [Glucose results in decreased expression of GLO1 protein]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER protein]; GLO1 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; GLO1 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of S100A12 mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of S100A8 protein]; SOD2 inhibits the reaction [Glucose results in decreased expression of GLO1 protein]; UCP1 inhibits the reaction [Glucose results in decreased expression of GLO1 protein] morroniside inhibits the reaction [Glucose results in decreased expression of GLO1 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of GLO1 protein] |
CTD |
PMID:19833897 PMID:32643284 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO EXP |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein] [GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein]; [Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein; exenatide inhibits the reaction [[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein] |
CTD |
PMID:18669601 PMID:22925809 |
|
NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
GLRX protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] promotes the reaction [Glutathione binds to SIRT1 protein]]; GLRX protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased oxidation of and results in decreased activity of SIRT1 protein] |
CTD |
PMID:24451382 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glt8d2 |
glycosyltransferase 8 domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of GLT8D2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:21,029,525...21,081,080
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
affects expression |
EXP |
Glucose affects the expression of GLUD1 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions decreases expression |
EXP |
Glucose results in decreased expression of and results in decreased activity of GLUL protein; Resveratrol inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of GLUL protein]; Resveratrol inhibits the reaction [Glucose results in decreased expression of GLUL mRNA] |
CTD |
PMID:26677078 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gna11 |
G protein subunit alpha 11 |
multiple interactions increases expression |
EXP |
acetovanillone inhibits the reaction [Glucose results in increased expression of GNA11 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNA11 protein] |
CTD |
PMID:20691780 |
|
NCBI chr 7:8,163,520...8,177,863
Ensembl chr 7:8,162,750...8,179,812
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of GNA15 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
ISO |
Glucose results in decreased expression of GNAI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions decreases expression |
ISO EXP |
GNAI2 gene mutant form inhibits the reaction [[Glucose co-treated with Amino Acids] results in increased secretion of INS1 protein]; GNAI2 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein] Glucose results in decreased expression of GNAI2 protein Acetylcysteine inhibits the reaction [Glucose results in decreased expression of GNAI2 protein]; alpha-Tocopherol inhibits the reaction [Glucose results in decreased expression of GNAI2 protein]; diphenyleneiodonium affects the reaction [Glucose results in decreased expression of GNAI2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased expression of GNAI2 protein]; Uric Acid inhibits the reaction [Glucose results in decreased expression of GNAI2 protein] |
CTD |
PMID:18441196 PMID:25205820 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions decreases expression |
EXP |
Acetylcysteine inhibits the reaction [Glucose results in decreased expression of GNAI3 protein]; alpha-Tocopherol inhibits the reaction [Glucose results in decreased expression of GNAI3 protein]; diphenyleneiodonium affects the reaction [Glucose results in decreased expression of GNAI3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased expression of GNAI3 protein]; Uric Acid inhibits the reaction [Glucose results in decreased expression of GNAI3 protein] |
CTD |
PMID:18441196 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnaq |
G protein subunit alpha q |
multiple interactions increases expression |
EXP ISO |
acetovanillone inhibits the reaction [Glucose results in increased expression of GNAQ protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNAQ protein] GNAQ protein affects the reaction [Glucose results in increased secretion of INS1 protein]; GNAQ protein affects the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:20691780 PMID:37217659 |
|
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
Gnat2 |
G protein subunit alpha transducin 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GNAT2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:195,726,371...195,735,866
Ensembl chr 2:195,726,762...195,735,866
|
|
G |
Gng2 |
G protein subunit gamma 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of GNG2 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of GNG2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gng8 |
G protein subunit gamma 8 |
decreases expression |
ISO |
Glucose results in decreased expression of GNG8 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371
|
|
G |
Golt1a |
golgi transport 1A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GOLT1A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:44,760,356...44,773,123
Ensembl chr13:44,760,380...44,773,122
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
increases expression |
ISO |
Glucose deficiency results in increased expression of GOT1 mRNA |
CTD |
PMID:26811028 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gp5 |
glycoprotein V (platelet) |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GP5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:70,443,613...70,446,705
Ensembl chr11:70,443,613...70,446,705
|
|
G |
Gp6 |
glycoprotein VI |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of GP6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:69,429,232...69,492,709
Ensembl chr 1:69,465,789...69,491,326
|
|
G |
Gp9 |
glycoprotein IX (platelet) |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GP9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:120,235,500...120,237,110
Ensembl chr 4:120,235,421...120,237,110
|
|
G |
Gpc5 |
glypican 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of GPC5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:92,207,275...93,644,054
Ensembl chr15:92,239,176...93,643,282
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
increases expression |
EXP |
Glucose results in increased expression of GPD1 mRNA |
CTD |
PMID:3299706 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
ISO |
[Glucose co-treated with S 4048] results in increased expression of GPD2 mRNA; [GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [Potassium Chloride co-treated with Diazoxide] inhibits the reaction [[GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased expression of TXNIP mRNA] |
CTD |
PMID:10199125 PMID:10464266 PMID:31974165 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpha2 |
glycoprotein hormone subunit alpha 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of GPHA2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:203,525,952...203,527,271
Ensembl chr 1:203,526,122...203,527,270
|
|
G |
Gpm6b |
glycoprotein m6b |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of GPM6B mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of GPM6B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
|
|
G |
Gpnmb |
glycoprotein nmb |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of GPNMB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr151 |
G protein-coupled receptor 151 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GPR151 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:34,568,907...34,570,301
Ensembl chr18:34,568,907...34,570,301
|
|
G |
Gpr171 |
G protein-coupled receptor 171 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of GPR171 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:143,360,402...143,365,494
Ensembl chr 2:143,359,564...143,366,698
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GPR85 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Gpr87 |
G protein-coupled receptor 87 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of GPR87 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190
|
|
G |
Gprin1 |
G protein-regulated inducer of neurite outgrowth 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of GPRIN1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:9,863,881...9,876,832
Ensembl chr17:9,863,571...9,876,915
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases secretion |
EXP ISO |
Glucose inhibits the reaction [(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid results in increased activity of GPT protein] Glucose results in increased secretion of GPT protein solanesol inhibits the reaction [Glucose results in increased secretion of GPT protein] |
CTD |
PMID:29479035 PMID:37586544 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
EXP ISO |
Glucose results in decreased expression of GPX1 mRNA naringenin inhibits the reaction [Glucose results in decreased expression of GPX1 mRNA] ebselen inhibits the reaction [GPX1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; GPX1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:21818840 PMID:23192364 PMID:23795780 PMID:32942007 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of GPX2 mRNA Glucose inhibits the reaction [4-Nitroquinoline-1-oxide results in increased expression of GPX2 protein] |
CTD |
PMID:28027979 PMID:32942007 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions increases expression |
ISO |
4-Nitroquinoline-1-oxide promotes the reaction [Glucose results in increased expression of GPX4 protein] |
CTD |
PMID:32942007 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grap2 |
GRB2-related adaptor protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GRAP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:112,117,142...112,190,880
Ensembl chr 7:112,117,142...112,190,877
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of GREM1 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of GREM1 mRNA |
CTD |
PMID:10026205 PMID:10744662 PMID:37567420 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of GREM2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:86,778,543...86,871,509
Ensembl chr13:86,778,500...86,871,615
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
EXP |
[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein; Genistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein] |
CTD |
PMID:27238724 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of GRIN1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of GRIN1 mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions increases expression increases cleavage |
ISO |
Glucose results in increased expression of and results in increased cleavage of GSDMD protein; GSDMD protein affects the reaction [Glucose results in increased secretion of IL18 protein]; GSDMD protein affects the reaction [Glucose results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of GSDMD protein]; IRF2 protein affects the reaction [Glucose results in increased expression of and results in increased cleavage of GSDMD protein]; IRF2 protein affects the reaction [Glucose results in increased expression of GSDMD mRNA] Glucose results in increased expression of GSDMD mRNA; Glucose results in increased expression of GSDMD protein loganin inhibits the reaction [Glucose results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [Glucose results in increased expression of GSDMD protein]; MIR200C mRNA affects the reaction [Glucose results in increased cleavage of GSDMD protein]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of GSDMD protein]] |
CTD |
PMID:34212273 PMID:35607288 PMID:37473909 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression decreases phosphorylation increases phosphorylation |
ISO EXP |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [Glucose co-treated with ICG 001] results in decreased phosphorylation of GSK3B protein; Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; Panax notoginseng extract inhibits the reaction [[Glucose co-treated with ICG 001] results in decreased phosphorylation of GSK3B protein]; Panax notoginseng extract inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein]; Panax notoginseng extract inhibits the reaction [Glucose results in increased expression of GSK3B protein] Glucose results in increased phosphorylation of GSK3B protein [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B protein; Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B mRNA]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B protein]; Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein] [Resveratrol results in increased phosphorylation of GSK3B protein] which results in increased uptake of Glucose; dorsomorphin inhibits the reaction [[Resveratrol results in increased phosphorylation of GSK3B protein] which results in increased uptake of Glucose]; Eucalyptol inhibits the reaction [Glucose results in increased expression of GSK3B protein]; RHOA protein inhibits the reaction [Eucalyptol inhibits the reaction [Glucose results in increased expression of GSK3B protein]]; RHOA protein promotes the reaction [Glucose results in increased expression of GSK3B protein] |
CTD |
PMID:18004065 PMID:21031461 PMID:22062806 PMID:22180358 PMID:23690508 PMID:23954465 PMID:26054749 PMID:29719095 PMID:31483951 PMID:35385194 More...
|
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsn |
gelsolin |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of GSN protein |
CTD |
PMID:24802182 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity decreases expression |
ISO EXP |
[Ascorbic Acid co-treated with GSR protein] affects the metabolism of Glucose; [Doxorubicin co-treated with GSR protein] affects the metabolism of Glucose; [Nitrofurantoin co-treated with GSR protein] affects the metabolism of Glucose; Furans analog inhibits the reaction [Glucose results in decreased activity of GSR protein] naringenin inhibits the reaction [Glucose results in decreased expression of GSR mRNA] |
CTD |
PMID:1901343 PMID:23192364 PMID:28911973 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gtf2i |
general transcription factor II I |
increases expression |
ISO |
Glucose results in increased expression of GTF2I mRNA |
CTD |
PMID:32942007 |
|
NCBI chr12:22,400,933...22,476,243
Ensembl chr12:22,401,431...22,476,243
|
|
G |
Gucy2d |
guanylate cyclase 2D, retinal |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of GUCY2E mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067
|
|
G |
Gypc |
glycophorin C |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of GYPC mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of GYPC mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204
|
|
G |
Gys1 |
glycogen synthase 1 |
increases phosphorylation multiple interactions |
EXP |
Glucose results in increased phosphorylation of GYS1 protein 3,4-Dihydroxyphenylacetic Acid inhibits the reaction [Glucose results in increased phosphorylation of GYS1 protein]; Catechin inhibits the reaction [Glucose results in increased phosphorylation of GYS1 protein] |
CTD |
PMID:29981789 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of GZMB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
Glucose results in increased expression of H1F2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
Glucose promotes the reaction [Bupivacaine results in increased expression of H2AX protein] Glucose results in increased expression of H2AX protein |
CTD |
PMID:31672611 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H2bc18 |
H2B clustered histone 18 |
decreases expression |
ISO |
Glucose results in decreased expression of H2BC18 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:183,838,331...183,842,769
Ensembl chr 2:183,838,334...183,841,529
|
|
G |
H3f4 |
H3.4 histone, cluster member |
multiple interactions |
EXP |
Glucose promotes the reaction [H3F4 protein modified form binds to PKLR promoter] |
CTD |
PMID:16644726 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
H4f16 |
H4 histone 16 |
multiple interactions |
EXP |
Glucose promotes the reaction [H4C16 protein modified form binds to PKLR promoter] |
CTD |
PMID:16644726 |
|
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of HAMP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of HAPLN1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
increases glycation |
ISO |
Glucose results in increased glycation of HBA1 protein |
CTD |
PMID:26163454 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions affects binding |
ISO EXP |
Furans analog inhibits the reaction [Glucose binds to HBB protein] Fructose promotes the reaction [Glucose binds to HBB protein]; geraniol inhibits the reaction [Fructose promotes the reaction [Glucose binds to HBB protein]]; Pioglitazone inhibits the reaction [Fructose promotes the reaction [Glucose binds to HBB protein]] |
CTD |
PMID:25679220 PMID:28911973 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Glucose results in increased expression of HBEGF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of HCRT mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [HDAC1 protein binds to TUG1 promoter] |
CTD |
PMID:32467232 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdc |
histidine decarboxylase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of HDC mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucose results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hhat |
hedgehog acyltransferase |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of HHAT mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of HHAT mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr13:104,024,507...104,283,580
Ensembl chr13:104,010,916...104,282,893
|
|
G |
Hhipl1 |
HHIP-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of HHIPL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:127,219,616...127,243,839
Ensembl chr 6:127,220,014...127,242,564
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of HIBCH protein |
CTD |
PMID:24802182 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression decreases expression |
ISO EXP |
2-Methoxyestradiol inhibits the reaction [Glucose results in increased expression of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Glucose results in increased expression of HIF1A protein]; [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in decreased activity of HIF1A protein] results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; [Glucose co-treated with Oxygen deficiency] inhibits the reaction [ARNT protein binds to HIF1A protein]; [Glucose co-treated with Oxygen deficiency] promotes the reaction [Pyruvaldehyde binds to and results in decreased activity of HIF1A protein]; [Glucose co-treated with SOD2 gene mutant form] results in decreased expression of HIF1A protein; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A protein; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein] Glucose results in increased expression of HIF1A mRNA Glucose results in decreased expression of HIF1A mRNA Glucose results in increased expression of HIF1A mRNA; Glucose results in increased expression of HIF1A protein [cobaltous chloride co-treated with Glucose] promotes the reaction [HIF1A protein binds to EP300 protein]; [cobaltous chloride co-treated with Glucose] results in increased expression of and results in decreased ubiquitination of HIF1A protein; [Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA; [Oxygen co-treated with Glucose] inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; epoxomicin inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; Glucose affects the reaction [Fusaric Acid affects the expression of HIF1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]; MG 262 inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; Particulate Matter inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] promotes the reaction [HIF1A protein binds to EP300 protein]]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of and results in decreased ubiquitination of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; Vehicle Emissions inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HIF1A protein] [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein] which results in increased expression of SLC8A1 mRNA; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HIF1A mRNA; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HIF1A protein; HIF1A protein affects the reaction [Glucose results in increased expression of CCN2 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of EDN1 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of FN1 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of TGFB1 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of VEGFA protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of HIF1A mRNA]; MIR217 mRNA affects the reaction [Glucose results in increased expression of HIF1A protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HIF1A mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HIF1A protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of HIF1A mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of HIF1A protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of HIF1A protein]] |
CTD |
PMID:18227068 PMID:19228841 PMID:19429140 PMID:21293012 PMID:21617913 PMID:23108914 PMID:23421680 PMID:25192544 PMID:26891083 PMID:28400208 PMID:31654802 PMID:31655124 PMID:33759271 PMID:33962019 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:82,810,708...82,821,080
Ensembl chr 1:82,810,708...82,821,077
|
|
G |
Hist1h2bc |
histone cluster 1, H2bc |
increases expression |
ISO |
Glucose results in increased expression of H2BC4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
Glucose results in increased expression of HK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hk3 |
hexokinase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of HK3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
increases expression |
ISO |
Glucose results in increased expression of HMGA2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression increases secretion |
ISO |
GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to HMGB1 promoter]]; GLO1 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; GLO1 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA]; Glucose promotes the reaction [JUN protein binds to HMGB1 promoter]; Glucose results in increased expression of and results in increased secretion of HMGB1 protein; JUN promotes the reaction [Glucose results in increased expression of HMGB1 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; SOD2 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; UCP1 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA] NLRP3 protein promotes the reaction [Glucose results in increased secretion of HMGB1 protein] |
CTD |
PMID:19833897 PMID:27783111 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of HMMR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases activity decreases expression increases expression affects expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]]; 4-Nitroquinoline-1-oxide inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]; [4-Nitroquinoline-1-oxide results in increased susceptibility to Glucose] which results in increased expression of HMOX1 protein; [Oxygen co-treated with Glucose] promotes the reaction [Vehicle Emissions promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein]]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein; Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; Glucose inhibits the reaction [4-Nitroquinoline-1-oxide affects the expression of HMOX1 protein]; Glucose promotes the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Glucose promotes the reaction [tin mesoporphyrin results in increased expression of HMOX1 mRNA]; Particulate Matter promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]; solanesol inhibits the reaction [Glucose results in decreased expression of HMOX1 mRNA]; solanesol inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]; spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]; Vehicle Emissions promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein] Glucose results in decreased activity of HMOX1 promoter Glucose results in decreased expression of HMOX1 mRNA; Glucose results in decreased expression of HMOX1 protein Glucose deficiency results in increased expression of HMOX1 mRNA; Glucose results in increased expression of HMOX1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of HMOX1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA; Antioxidants inhibits the reaction [Glucose results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; SMARCA4A protein promotes the reaction [Glucose results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]] Glucose results in increased expression of HMOX1 mRNA; Glucose results in increased expression of HMOX1 protein Glucose affects the expression of HMOX1 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[diallyl trisulfide co-treated with Glucose] results in increased expression of HMOX1 protein]; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased susceptibility to Glucose; [diallyl trisulfide co-treated with Glucose] results in increased expression of HMOX1 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein; Acetylcysteine affects the reaction [Glucose affects the expression of HMOX1 mRNA]; Antioxidants inhibits the reaction [Glucose results in increased expression of HMOX1]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]; cobaltiprotoporphyrin promotes the reaction [Glucose results in increased expression of HMOX1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein]; Glucose results in decreased activity of and results in increased expression of HMOX1 protein; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of NPPA mRNA]]; HMOX1 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin affects the reaction [Glucose affects the expression of HMOX1 mRNA]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA]; Propofol inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]; Propofol promotes the reaction [Glucose results in increased expression of HMOX1 protein]; Quercetin inhibits the reaction [Glucose results in decreased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol promotes the reaction [Glucose results in increased expression of HMOX1 protein]] Glucose affects the expression of HMOX1 protein |
CTD |
PMID:14766238 PMID:16464909 PMID:17928392 PMID:19489000 PMID:19924377 PMID:21333731 PMID:22111038 PMID:22643931 PMID:23453443 PMID:23770986 PMID:23954465 PMID:24810525 PMID:25896937 PMID:28400208 PMID:29457851 PMID:29649567 PMID:29719095 PMID:32602595 PMID:32942007 PMID:33270355 PMID:35191607 PMID:37567420 PMID:37586544 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
affects response to substance |
ISO |
HNF1A gene mutant form affects the susceptibility to Glucose |
CTD |
PMID:15787664 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf1b |
HNF1 homeobox B |
multiple interactions |
ISO |
HNF1B protein inhibits the reaction [bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]] |
CTD |
PMID:32623698 |
|
NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions decreases expression increases expression |
ISO |
Cerulenin inhibits the reaction [Glucose results in decreased expression of HNF4A mRNA]; Glucose affects the reaction [HNF4A protein binds to SHBG promoter] Glucose results in increased expression of HNF4A mRNA |
CTD |
PMID:17992261 PMID:31525975 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
EXP |
Glucose results in decreased expression of HNRNPK mRNA; Glucose results in decreased expression of HNRNPK protein |
CTD |
PMID:16837467 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hoxa2 |
homeobox A2 |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of HOXA2 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of HOXA2 mRNA |
CTD |
PMID:21818840 PMID:37567420 |
|
NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044
|
|
G |
Hp |
haptoglobin |
affects secretion multiple interactions |
ISO |
Glucose deficiency affects the secretion of HP protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HP mRNA |
CTD |
PMID:24802182 PMID:37567420 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
increases expression |
ISO |
Glucose results in increased expression of HPGDS mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
decreases expression |
ISO |
Glucose results in decreased expression of HPRT1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions increases activity |
EXP |
manumycin inhibits the reaction [Glucose results in increased activity of HRAS protein] |
CTD |
PMID:16572112 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hrg |
histidine-rich glycoprotein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of HRG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hs6st2 |
heparan sulfate 6-O-sulfotransferase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of HS6ST2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:130,966,547...131,261,629
Ensembl chr X:130,968,385...131,261,492
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression |
EXP |
Glucose results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:15017115 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
ISO |
Glucose results in increased expression of HSD3B1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Glucose results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsf2bp |
heat shock transcription factor 2 binding protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of HSF2BP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:10,035,562...10,123,059
Ensembl chr20:10,035,562...10,121,242
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases secretion |
ISO |
Glucose results in decreased expression of HSP90B1 mRNA Glucose deficiency results in increased secretion of HSP90B1 protein |
CTD |
PMID:17178593 PMID:24802182 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of HSPA12A protein KU-32 compound inhibits the reaction [Glucose results in decreased expression of HSPA12A protein] |
CTD |
PMID:22413817 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Hspa13 |
heat shock protein family A (Hsp70) member 13 |
decreases expression |
ISO |
Glucose results in decreased expression of HSPA13 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of HSPA1L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression decreases expression multiple interactions |
ISO EXP |
Glucose deficiency results in increased expression of HSPA5 mRNA; Glucose deficiency results in increased expression of HSPA5 protein; Glucose results in increased expression of HSPA5 mRNA; Glucose results in increased expression of HSPA5 protein Glucose results in decreased expression of HSPA5 mRNA Glucose deficiency results in increased expression of HSPA5 protein; Glucose results in increased expression of HSPA5 protein 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 mRNA]; 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]; [Glucose co-treated with TGFB1 protein] results in increased expression of HSPA5 protein; ATF6 protein modified form promotes the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of HSPA5 protein]; glucogallin inhibits the reaction [Glucose results in increased expression of HSPA5 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]; XBP1 mRNA alternative form promotes the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]] 2-aminoethoxydiphenyl borate inhibits the reaction [Glucose results in increased expression of HSPA5 protein]; Gadolinium inhibits the reaction [Glucose results in increased expression of HSPA5 protein]; Glucose affects the reaction [bisphenol A results in decreased expression of HSPA5 protein]; waixenicin A inhibits the reaction [Glucose results in increased expression of HSPA5 protein] Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of HSPA5 protein]; Metformin inhibits the reaction [Glucose results in increased expression of HSPA5 protein] |
CTD |
PMID:12147617 PMID:16380481 PMID:17178593 PMID:21337367 PMID:21705745 PMID:24349266 PMID:25451566 PMID:30076216 PMID:31022492 PMID:34801538 PMID:35961541 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
increases expression decreases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of HSPA9 protein Glucose results in decreased expression of HSPA9 protein KU-32 compound inhibits the reaction [Glucose results in decreased expression of HSPA9 protein] resveratrol inhibits the reaction [Glucose results in increased expression of HSPA9 protein] |
CTD |
PMID:22413817 PMID:24218232 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation increases secretion |
EXP ISO |
[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HSPB1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HSPB1 protein; resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HSPB1 mRNA]; resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of HSPB1 protein] Glucose results in increased phosphorylation of HSPB1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of HSPB1 protein]; U 0126 inhibits the reaction [Glucose results in increased phosphorylation of HSPB1 protein] Glucose deficiency results in increased secretion of HSPB1 protein |
CTD |
PMID:23421680 PMID:24802182 PMID:25373458 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression multiple interactions |
ISO |
Glucose deficiency results in decreased expression of HSPD1 protein Nitroprusside inhibits the reaction [Glucose deficiency results in decreased expression of HSPD1 protein] |
CTD |
PMID:17855661 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Htra3 |
HtrA serine peptidase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HTRA3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:75,068,917...75,097,315
Ensembl chr14:75,068,917...75,097,315
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of HUNK mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526
|
|
G |
Hyal4 |
hyaluronidase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of HYAL4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:53,256,179...53,274,819
Ensembl chr 4:53,256,179...53,274,819
|
|
G |
Hydin |
Hydin, axonemal central pair apparatus protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HYDIN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:38,236,996...38,583,271
Ensembl chr19:38,236,464...38,583,264
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Glucose results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Iapp |
islet amyloid polypeptide |
multiple interactions increases expression |
ISO EXP |
IAPP protein inhibits the reaction [Glucose results in increased secretion of INS protein]; Rosiglitazone inhibits the reaction [IAPP protein inhibits the reaction [Glucose results in increased secretion of INS protein]] Diazoxide inhibits the reaction [Glucose results in increased expression of IAPP mRNA]; Mannoheptulose inhibits the reaction [Glucose results in increased expression of IAPP mRNA]; Verapamil inhibits the reaction [Glucose results in increased expression of IAPP mRNA] |
CTD |
PMID:9142872 PMID:16204373 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Ica1l |
islet cell autoantigen 1-like |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ICA1L mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 9:61,410,959...61,469,884
Ensembl chr 9:61,412,091...61,470,134
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions increases secretion |
ISO EXP |
Glucose results in increased expression of ICAM1; Glucose results in increased expression of ICAM1 mRNA; Glucose results in increased expression of ICAM1 protein Curcumin analog inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Y 27632 inhibits the reaction [Glucose results in increased expression of ICAM1 protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Glucose results in increased expression of ICAM1]; 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; aspalathin inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [Glucose results in increased expression of ICAM1]; HTS 466284 inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; isoangustone A inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; manganese chloride inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased secretion of ICAM1 protein]; naringin inhibits the reaction [Glucose results in increased expression of ICAM1]; nothofagin inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; Polyphenols inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of ICAM1]; Rimonabant inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; sarpogrelate inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of ICAM1 protein] |
CTD |
PMID:15304054 PMID:16285992 PMID:21367880 PMID:21373835 PMID:21682256 PMID:22074828 PMID:23111892 PMID:23329836 PMID:23376009 PMID:24436987 PMID:24513509 PMID:25338943 PMID:28700904 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icam5 |
intercellular adhesion molecule 5 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ICAM5 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 8:19,567,390...19,575,588
Ensembl chr 8:19,568,600...19,575,588
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Glucose results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Glucose results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Ide |
insulin degrading enzyme |
decreases expression |
ISO |
Glucose results in decreased expression of IDE mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IDI1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifi27l2b |
interferon, alpha-inducible protein 27 like 2B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IFI27L2A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360
|
|
G |
Ifi44 |
interferon-induced protein 44 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of IFI44 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of IFI44 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IFIT2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:232,102,570...232,108,638
Ensembl chr 1:232,102,570...232,108,635
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IFIT3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
[IL1B protein co-treated with IFNG protein] promotes the reaction [Glucose results in increased secretion of INS protein] [IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; quercitrin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]] [TNF protein co-treated with IFNG protein co-treated with IL1B protein] inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; Quercetin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:10967106 PMID:19071154 PMID:23138875 PMID:31776611 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases uptake |
ISO |
IGF1 protein results in increased uptake of Glucose |
CTD |
PMID:29330302 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression multiple interactions increases expression |
ISO |
Glucose results in decreased expression of IGF1R protein Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Glucose results in increased expression of IGF1R mRNA |
CTD |
PMID:7826318 PMID:23954465 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2bp1 |
insulin-like growth factor 2 mRNA binding protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IGF2BP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:80,908,300...80,951,097
Ensembl chr10:80,908,076...80,951,129
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
EXP |
[Glucose co-treated with IGF2R protein modified form] results in decreased expression of IL6 protein; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NFKBIA protein; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NFKBIA protein modified form; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NOS2 protein; [Glucose co-treated with IGF2R protein modified form] results in increased expression of CASP9 protein; [Glucose co-treated with IGF2R protein modified form] results in increased expression of TNF protein; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein modified form]; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein] |
CTD |
PMID:36462176 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Glucose results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfn1 |
immunoglobulin-like and fibronectin type III domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of IGFN1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:47,395,618...47,427,506
Ensembl chr13:47,395,595...47,437,879
|
|
G |
Igkvl-ps13 |
immunoglobulin kappa variable like, pseudogene 13 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of IGKV1-133 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:96,968,574...96,969,477
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP ISO |
IKBKB affects the reaction [IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; IKBKB affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]] IKBKB protein affects the reaction [Particulate Matter promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:22558381 PMID:31095431 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
2-chloro-4'-methoxychalcone inhibits the reaction [Glucose results in increased expression of IL12B mRNA]; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of IL12B mRNA |
CTD |
PMID:21988173 PMID:37567420 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IL12RB2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases secretion increases expression |
ISO |
Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein]; Dactinomycin inhibits the reaction [Glucose results in increased secretion of IL17A protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of IL17A mRNA]; Resveratrol inhibits the reaction [Glucose results in increased secretion of IL17A protein] |
CTD |
PMID:18310510 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17ra |
interleukin 17 receptor A |
increases expression |
ISO |
Glucose results in increased expression of IL17RA mRNA |
CTD |
PMID:18310510 |
|
NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions increases secretion |
ISO EXP |
Glucose results in increased expression of IL18 mRNA GSDMD protein affects the reaction [Glucose results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [Glucose results in increased secretion of IL18 protein] Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of IL18 protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of IL18 protein]; loganin inhibits the reaction [Glucose results in increased expression of IL18 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL18 protein]; MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Glucose results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of IL18 protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL18 protein]]; swietenine inhibits the reaction [Glucose results in increased expression of IL18 protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein] Glucose results in increased expression of IL18 mRNA; Glucose results in increased expression of IL18 protein |
CTD |
PMID:34212273 PMID:35191607 PMID:35607288 PMID:36066211 PMID:37473909 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IL18RAP mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IL18RAP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression increases secretion |
ISO EXP |
2-chloro-4'-methoxychalcone inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; [cobaltiprotoporphyrin co-treated with IL1B protein] affects the susceptibility to Glucose; [Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [IL1B protein co-treated with IFNG protein] promotes the reaction [Glucose results in increased secretion of INS protein]; Acetylcysteine inhibits the reaction [Glucose results in increased expression of IL1B protein]; CDK9 protein affects the reaction [Glucose results in increased expression of IL1B mRNA]; Glucose inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucose inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of PTK2 protein]; GSDMD protein affects the reaction [Glucose results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [Glucose results in increased secretion of IL1B protein]; IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; IL1B protein inhibits the reaction [Glucose results in increased expression of MAFA mRNA]; IL1B protein inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]; Silymarin inhibits the reaction [[Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein] Glucose results in increased expression of IL1B mRNA; Glucose results in increased expression of IL1B protein [IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein; [TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of IL1B protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL1B protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Glucose results in increased secretion of IL1B protein]; farrerol inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; farrerol inhibits the reaction [Glucose results in increased secretion of IL1B protein]; Gallic Acid inhibits the reaction [Glucose results in increased secretion of IL1B protein]; IKBKB affects the reaction [IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; IL1B protein inhibits the reaction [Glucose results in increased abundance of Proteoglycans]; IL1B protein inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]; IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; morroniside inhibits the reaction [Glucose results in increased secretion of IL1B protein]; prolinedithiocarbamate inhibits the reaction [Glucose results in increased secretion of IL1B protein]; Quercetin inhibits the reaction [Glucose results in increased expression of IL1B protein]; quercitrin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; S-4-bromobenzylglutathione cyclopentyl diester inhibits the reaction [morroniside inhibits the reaction [Glucose results in increased secretion of IL1B protein]]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein] (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; [Glucose co-treated with Lipopolysaccharides] results in decreased expression of IL1B protein; [Glucose co-treated with Pam(3)CSK(4) peptide] results in decreased expression of IL1B protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of PPARG mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of PPARA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CXCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NFKB1 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of PPARD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of RELA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; Allopurinol inhibits the reaction [Glucose results in increased expression of IL1B protein]; Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of IL1B protein]]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL1B protein]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Carnosine inhibits the reaction [Glucose results in increased secretion of IL1B protein]; Catechin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Catechin inhibits the reaction [Glucose results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B protein]; Fenofibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Glucose promotes the reaction [Particulate Matter results in increased expression of IL1B mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of IL1B protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of IL1B protein]; loganin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B protein]; MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL1B protein]; MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Glucose results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of IL1B protein]]; Phytic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Quercetin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; rutecarpine inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; rutecarpine inhibits the reaction [Glucose results in increased expression of IL1B protein]; Rutin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Rutin inhibits the reaction [Glucose results in increased expression of IL1B protein]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL1B protein]]; swietenine inhibits the reaction [Glucose results in increased expression of IL1B protein] |
CTD |
PMID:10967106 PMID:11801247 PMID:15194409 PMID:19071154 PMID:19557821 PMID:19861503 PMID:20200188 PMID:21988173 PMID:22558381 PMID:23138875 PMID:23647015 PMID:24877639 PMID:26179980 PMID:26341651 PMID:27783111 PMID:29753610 PMID:30031708 PMID:30098273 PMID:30802477 PMID:31776611 PMID:31838053 PMID:31935362 PMID:32613381 PMID:32643284 PMID:33283391 PMID:33631230 PMID:34212273 PMID:35191607 PMID:35607288 PMID:36066211 PMID:36462176 PMID:36928891 PMID:37473909 PMID:38000455 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
EXP ISO |
IL1RN protein inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; IL1RN protein inhibits the reaction [Glucose results in increased expression of PTGS2 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of IL1RN mRNA |
CTD |
PMID:19861503 PMID:37567420 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il23r |
interleukin 23 receptor |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of IL23R mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of IL23R mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021
|
|
G |
Il24 |
interleukin 24 |
increases expression decreases expression multiple interactions |
ISO |
Glucose results in increased expression of IL24 mRNA Glucose results in decreased expression of IL24 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of IL24 mRNA] |
CTD |
PMID:17178593 PMID:33448797 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il27 |
interleukin 27 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IL27 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il31ra |
interleukin 31 receptor A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IL31RA mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of IL6 protein]]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Carnosine inhibits the reaction [Glucose results in increased secretion of IL6 protein]; chromic chloride inhibits the reaction [Glucose results in increased secretion of IL6 protein]; chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]; chromium nicotinic acid complex inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Fluorometholone inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Fluorometholone inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Glucose results in increased secretion of and results in increased expression of IL6 protein; MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of IL6 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased secretion of IL6 protein]; picolinic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Polyphenols inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Polyphenols inhibits the reaction [Glucose results in increased expression of IL6 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of IL6 protein]; rutecarpine inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; rutecarpine inhibits the reaction [Glucose results in increased expression of IL6 protein] Glucose results in increased expression of IL6 mRNA; Glucose results in increased expression of IL6 protein 2-chloro-4'-methoxychalcone inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased secretion of IL6 protein]; [Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; CDK9 protein affects the reaction [Glucose results in increased expression of IL6 mRNA]; CDK9 protein affects the reaction [Glucose results in increased secretion of IL6 protein]; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]]; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased expression of SOD2 protein]; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased phosphorylation of STAT3 protein]; Silymarin inhibits the reaction [[Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of IL6 protein; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of and results in increased secretion of IL6 protein; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of IL6 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein; Artesunate inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Curcumin analog inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; duanbanhuain A inhibits the reaction [Glucose results in increased secretion of IL6 protein]; duanbanhuain B inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Glucose results in increased secretion of IL6 protein]; farrerol inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; farrerol inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Gallic Acid inhibits the reaction [Glucose results in increased secretion of IL6 protein]; morroniside inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Oxygen promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 mRNA]; prolinedithiocarbamate inhibits the reaction [Glucose results in increased secretion of IL6 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of IL6 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased secretion of IL6 protein]; S-4-bromobenzylglutathione cyclopentyl diester inhibits the reaction [morroniside inhibits the reaction [Glucose results in increased secretion of IL6 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein] |
CTD |
PMID:11108930 PMID:15304054 PMID:15528032 PMID:17665966 PMID:20578705 PMID:21682256 PMID:21940958 PMID:21988173 PMID:22036992 PMID:23770986 PMID:24877639 PMID:26341651 PMID:27049278 PMID:28700904 PMID:29753610 PMID:30031708 PMID:30802477 PMID:31323227 PMID:31838053 PMID:31935362 PMID:32643284 PMID:33283391 PMID:33631230 PMID:35264022 PMID:36462176 PMID:36928891 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions |
ISO |
[[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]] promotes the reaction [IL6ST protein binds to and results in increased phosphorylation of STAT3 protein]; [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]; [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in increased oxidation of IL6RA protein; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]] |
CTD |
PMID:21940958 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
[[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]] promotes the reaction [IL6ST protein binds to and results in increased phosphorylation of STAT3 protein]; [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]; [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in increased oxidation of IL6ST protein; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]] |
CTD |
PMID:21940958 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Ins1 |
insulin 1 |
increases transport increases secretion increases import multiple interactions increases uptake decreases secretion increases metabolic processing decreases abundance decreases expression affects expression decreases chemical synthesis affects secretion increases expression |
EXP ISO |
INS1 protein results in increased transport of Glucose Glucose results in increased secretion of INS1 protein INS1 protein results in increased import of Glucose 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[4-(3-3,4-p-menthadien-(1,8)-yl)olivetol co-treated with Glucose] results in increased secretion of INS1 protein]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[O-1602 compound co-treated with Glucose] results in increased secretion of INS1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BLX 1002 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS1 protein results in increased uptake of Glucose]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [mono-(2-ethylhexyl)phthalate promotes the reaction [INS1 protein results in increased uptake of Glucose]]; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester inhibits the reaction [arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester inhibits the reaction [dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester inhibits the reaction [methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester promotes the reaction [Glucose results in increased secretion of INS1 protein]; 7-Ala-angiotensin (1-7) promotes the reaction [Glucose results in increased secretion of INS1 protein]; 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Acrolein inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Arsenic Trioxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; [4-(3-3,4-p-menthadien-(1,8)-yl)olivetol co-treated with Glucose] results in increased secretion of INS1 protein; [arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; [Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [Carbachol co-treated with Glucose] results in increased secretion of INS1 protein; [Chromium co-treated with Vanadates] promotes the reaction [INS1 protein results in increased uptake of Glucose]; [Chromium Compounds co-treated with Vanadates] promotes the reaction [INS1 protein results in increased uptake of Glucose]; [Dietary Fats affects the susceptibility to INS1 protein] which affects the oxidation of Glucose; [Dietary Fats affects the susceptibility to INS1 protein] which affects the uptake of Glucose; [FFAR1 protein affects the susceptibility to Dietary Fats] affects the reaction [Glucose results in increased secretion of INS1 protein]; [GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein]; [Glucose co-treated with Amino Acids] results in increased secretion of INS1 protein; [Glucose co-treated with Dichlorodiphenyl Dichloroethylene] results in increased secretion of INS1 protein; [Glucose co-treated with INS1 protein] affects the expression of KAT6B mRNA; [Glucose co-treated with INS1 protein] affects the expression of KDM1B mRNA; [Glucose co-treated with INS1 protein] affects the expression of KDM4B mRNA; [Glucose co-treated with INS1 protein] affects the localization of PDX1 protein; [GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [lead nitrate results in increased abundance of Lead] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [Mercuric Chloride results in increased abundance of Mercury] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [MME protein results in increased cleavage of angiotensin I (1-7)] affects the reaction [Glucose results in increased secretion of INS1 protein]; [molybdenum trioxide results in increased abundance of Molybdenum] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [O-1602 compound co-treated with Glucose] results in increased secretion of INS1 protein; [Pertussis Toxin co-treated with FR900359] promotes the reaction [Glucose results in increased secretion of INS1 protein]; [Pertussis Toxin co-treated with Glucose] results in increased secretion of INS1 protein; [Potassium Chloride co-treated with Diazoxide] inhibits the reaction [[GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; [Tetradecanoylphorbol Acetate co-treated with Glucose] results in increased secretion of INS1 protein; [Tolbutamide co-treated with FR900359] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Acetylcysteine inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Acrolein inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Akt-I-1,2 compound inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Akt-I-1,2 compound inhibits the reaction [mono-(2-ethylhexyl)phthalate promotes the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein modified form inhibits the reaction [arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein modified form inhibits the reaction [monomethylarsonous acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; angiotensin I (1-7) promotes the reaction [Glucose results in increased secretion of INS1 protein]; Arecoline inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Arsenic Trioxide inhibits the reaction [Estradiol promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Arsenic Trioxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Arsenic Trioxide promotes the reaction [Estrogens deficiency inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; arsenite inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester promotes the reaction [Glucose results in increased secretion of INS1 protein]]; arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]; arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Benzamides promotes the reaction [INS1 protein results in increased uptake of Glucose]; bisphenol A inhibits the reaction [Glucose results in increased secretion of INS1 protein]; bisphenol A inhibits the reaction [INS1 protein results in increased metabolism of Glucose]; bisphenol A promotes the reaction [Glucose results in increased secretion of INS1 protein]; bisphenol S inhibits the reaction [Glucose results in increased secretion of INS1 protein]; BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]; BLX 1002 promotes the reaction [Glucose results in increased secretion of INS1 protein]; Bumetanide inhibits the reaction [SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]]; celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the oxidation of Glucose]; celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the uptake of Glucose]; Chromium Compounds promotes the reaction [INS1 protein results in increased uptake of Glucose]; Chromium promotes the reaction [INS1 protein results in increased uptake of Glucose]; cis-9, trans-11-conjugated linoleic acid promotes the reaction [INS1 protein affects the transport of Glucose]; cobaltiprotoporphyrin inhibits the reaction [Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]; copper bis(3,5-diisopropylsalicylate) inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; CYP1A1 protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; CYP1A2 protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Cytochalasin B inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Cytochalasin B inhibits the reaction [mono-(2-ethylhexyl)phthalate promotes the reaction [INS1 protein results in increased uptake of Glucose]]; Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Diethylhexyl Phthalate inhibits the reaction [Glucose results in increased secretion of INS1 protein]; dimethylarsine analog inhibits the reaction [INS1 protein results in increased uptake of Glucose]; dimethylarsinous acid inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester promotes the reaction [Glucose results in increased secretion of INS1 protein]]; dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]; DX600 peptide inhibits the reaction [angiotensin I (1-7) promotes the reaction [Glucose results in increased secretion of INS1 protein]]; DX600 peptide promotes the reaction [Glucose results in increased secretion of INS1 protein]; ebselen inhibits the reaction [GPX1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; ebselen inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; ebselen promotes the reaction [Glucose results in increased secretion of INS1 protein]; Estradiol inhibits the reaction [Arsenic Trioxide promotes the reaction [Estrogens deficiency inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; Estradiol inhibits the reaction [Estrogens deficiency inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Estradiol inhibits the reaction [INS1 protein results in increased transport of Glucose]; Estradiol promotes the reaction [Glucose results in increased secretion of INS1 protein]; Estrogens deficiency inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Exenatide inhibits the reaction [FR900359 inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Exenatide promotes the reaction [Glucose results in increased secretion of INS1 protein]; ferrostatin-1 inhibits the reaction [Acrolein inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; FFAR1 protein affects the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]]; FR900359 inhibits the reaction [Exenatide promotes the reaction [Glucose results in increased secretion of INS1 protein]]; FR900359 inhibits the reaction [Glucose results in increased secretion of INS1 protein]; FR900359 inhibits the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]]; FR900359 inhibits the reaction [TUG-469 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; FRK protein inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Fulvestrant inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Glyburide inhibits the reaction [Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; GNAI2 gene mutant form inhibits the reaction [[Glucose co-treated with Amino Acids] results in increased secretion of INS1 protein]; GNAI2 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; GNAQ protein affects the reaction [Glucose results in increased secretion of INS1 protein]; GNAQ protein affects the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]]; GPX1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; IKBKB protein affects the reaction [Particulate Matter promotes the reaction [Glucose results in increased secretion of INS1 protein]]; isosteviol inhibits the reaction [Palmitic Acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; kaempferol promotes the reaction [INS1 protein results in increased uptake of Glucose]; mercaptosteroid 4 inhibits the reaction [Glucose results in increased secretion of INS1 protein]; mercaptosteroid 6 inhibits the reaction [Glucose results in increased secretion of INS1 protein]; methylarsine oxide inhibits the reaction [INS1 protein results in increased uptake of Glucose]; methylarsonite inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester promotes the reaction [Glucose results in increased secretion of INS1 protein]]; methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]; MME protein affects the reaction [angiotensin I (1-7) promotes the reaction [Glucose results in increased secretion of INS1 protein]]; mono-(2-ethylhexyl)phthalate promotes the reaction [INS1 protein results in increased uptake of Glucose]; monomethylarsonic acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]; naringin inhibits the reaction [Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; naringin promotes the reaction [Glucose results in increased secretion of INS1 protein]; Ozone promotes the reaction [INS1 protein results in decreased abundance of Glucose]; Palmitic Acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]; Particulate Matter promotes the reaction [Glucose results in increased secretion of INS1 protein]; perfluorooctane sulfonic acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Pioglitazone promotes the reaction [INS1 protein results in increased uptake of Glucose]; platyconic acid promotes the reaction [INS1 protein results in increased uptake of Glucose]; POMC inhibits the reaction [INS1 results in increased uptake of Glucose]; Potassium Chloride inhibits the reaction [FR900359 inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Potassium Chloride promotes the reaction [Glucose results in increased secretion of INS1 protein]; Progesterone inhibits the reaction [INS1 protein results in increased transport of Glucose]; Quercetin promotes the reaction [INS1 protein results in increased uptake of Glucose]; Resveratrol inhibits the reaction [Acrolein inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Ro 32-0432 inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Rosiglitazone inhibits the reaction [Acrolein inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; rutamarin promotes the reaction [INS1 protein results in increased uptake of Glucose]; Sildenafil Citrate promotes the reaction [INS1 protein results in increased import of Glucose]; SIRT3 protein inhibits the reaction [sodium arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]; SLC30A3 results in increased susceptibility to [Glucose co-treated with INS1 protein]; SLC30A8 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; SOD2 protein inhibits the reaction [sodium arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]; sodium arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]; sodium arsenite promotes the reaction [INS1 protein results in decreased chemical synthesis of Glucose]; Sodium Selenite inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Streptozocin inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Testosterone inhibits the reaction [INS1 protein results in increased transport of Glucose]; Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Tolbutamide inhibits the reaction [arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide promotes the reaction [Glucose results in increased secretion of INS1 protein]; tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]; TUG-469 promotes the reaction [Glucose results in increased secretion of INS1 protein]; UGT1A6A protein affects the reaction [Glucose results in increased secretion of INS1 protein]; Vanadates promotes the reaction [INS1 protein results in increased uptake of Glucose]; Wortmannin inhibits the reaction [BLX 1002 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Wortmannin inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Wortmannin inhibits the reaction [mono-(2-ethylhexyl)phthalate promotes the reaction [INS1 protein results in increased uptake of Glucose]]; YM-254890 inhibits the reaction [Glucose results in increased secretion of INS1 protein]; YM-254890 inhibits the reaction [Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Zinc promotes the reaction [INS1 protein results in increased uptake of Glucose] Glucose results in decreased secretion of INS1 protein (+)-JQ1 compound promotes the reaction [Glucose results in increased secretion of INS1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin promotes the reaction [Glucose results in increased secretion of INS1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]; 3-(4-((2',6'-dimethylbiphenyl-3-yl)methoxy)-2-fluorophenyl)propanoic acid promotes the reaction [Glucose results in increased secretion of INS1 protein]; 3-(4-((2,6-dichloropyridin-4-yl)ethynyl)phenyl)propanoic acid promotes the reaction [Glucose results in increased secretion of INS1 protein]; 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene inhibits the reaction [Glucose results in increased secretion of INS1 protein]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; 7-nitroindazole inhibits the reaction [[INS1 protein co-treated with Glucose] results in increased transport of Zinc]; 9-phenanthrol inhibits the reaction [[GCG protein co-treated with Glucose] results in increased secretion of INS1 protein]; 9-phenanthrol inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [4-methylcatechol co-treated with Glucose] results in increased secretion of INS1 protein; [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [[valyl-histidyl-threonyl-aspartamide binds to Zinc] results in increased activity of [INS1 protein binds to INS1 protein binds to INS1 protein binds to INS1 protein binds to INS1 protein binds to INS1 protein]] which results in decreased abundance of Glucose; [Alloxan co-treated with Homocysteine] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [GCG protein co-treated with Glucose] results in increased secretion of INS1 protein; [GCG protein modified form binds to and results in increased activity of GLP1R protein] promotes the reaction [Glucose results in increased secretion of INS1 protein]; [Glucose co-treated with 3,4-dihydroxyphenylethanol] results in increased secretion of INS1 protein; [Glucose co-treated with dihydroxyethyldithiocarbamate] results in decreased expression of INS1; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; [Glucose co-treated with INS1 protein] results in increased secretion of LEP protein; [Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein; [Glucose co-treated with Plant Extracts] results in increased secretion of INS1 protein; [IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [INS1 protein co-treated with Glucose] results in increased activity of PARP1 protein; [INS1 protein co-treated with Glucose] results in increased transport of Zinc; [TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Acetylcysteine inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]; alpha-methylbenzylaminobenzotriazole inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]; arachidonyltrifluoromethane inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; argan oil inhibits the reaction [Glucose results in increased expression of INS1 protein]; Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]; benazepril inhibits the reaction [Glucose results in increased secretion of INS1 protein]; benazepril promotes the reaction [INS1 protein results in increased metabolism of Glucose]; bisphenol A affects the reaction [Glucose results in increased secretion of INS1 protein]; bisphenol A promotes the reaction [Glucose results in increased secretion of INS1 protein]; BL 11282 analog promotes the reaction [Glucose results in increased secretion of INS1 protein]; BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]; Budesonide inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Budesonide inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Bumetanide inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Calcium deficiency inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; Cannabidiol promotes the reaction [Glucose results in increased secretion of INS1 protein]; Capsaicin promotes the reaction [Glucose results in increased secretion of INS1 protein]; Chlorpyrifos inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Colchicine inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]; cordycepin promotes the reaction [Glucose results in increased secretion of INS1 protein]; Corn Oil inhibits the reaction [Glucose results in increased expression of INS1 protein]; Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Dexamethasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Diazoxide inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; Dietary Fats affects the reaction [INS1 protein results in increased uptake of Glucose]; Dietary Fats inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Diethylhexyl Phthalate inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Diethylhexyl Phthalate inhibits the reaction [INS1 protein results in increased metabolism of Glucose]; Dithiothreitol inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Exenatide inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Exenatide inhibits the reaction [Palmitic Acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Fluticasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Fluticasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Fulvestrant inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucose inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucose inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Homocysteine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Hydrocortisone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Hydrogen Peroxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]; INS1 protein inhibits the reaction [Dichlorvos results in increased abundance of Glucose]; INS1 protein inhibits the reaction [FOXO1 protein results in increased abundance of Glucose]; INS1 protein promotes the reaction [FOXO1 protein mutant form results in increased abundance of Glucose]; INS1 protein promotes the reaction [Glucose results in increased expression of LEP mRNA]; INS1 protein promotes the reaction [Glucose results in increased secretion of LEP protein]; INS1 protein results in increased transport of and results in increased oxidation of Glucose; KMUP 1 inhibits the reaction [Glucose results in decreased secretion of INS1 protein]; Lenalidomide inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]]; LEP promotes the reaction [Glucose results in increased secretion of INS1 protein]; Manganese deficiency inhibits the reaction [INS1 protein results in increased oxidation of Glucose]; manganese(III)-tetrakis(4-benzoic acid)porphyrin affects the reaction [Glucose affects the expression of INS1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin affects the reaction [Glucose affects the secretion of INS1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; Metformin inhibits the reaction [Glucose results in increased secretion of INS1 protein]; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; N-(-4-(N-(biphenyl-2-ylmethyl)-N-2-methylpropylamino)- 1-(2-(2,4-difluorobenzoyl)benzoyl)pyrrolidin- 2-yl)methyl-3-(4-(2,4-dioxothiazolidin-5-ylidenemethyl) phenyl)acrylamide inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]]; NFE2L2 protein affects the reaction [Exenatide inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; nickel chloride inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; nymphayol promotes the reaction [INS1 protein results in increased uptake of Glucose]; Oleic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]; oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of Glucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Palmitic Acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Palmitic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]; pimobendan promotes the reaction [Glucose results in increased secretion of INS1 protein]; PPARA protein promotes the reaction [Glucose results in increased secretion of INS1 protein]; PPARG protein inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [INS1 protein results in increased transport of and results in increased oxidation of Glucose]; quercitrin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Resveratrol inhibits the reaction [Dietary Fats inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Resveratrol inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Ro 31-8220 inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Ro 32-0432 inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS1 protein]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased expression of INS1 protein]; SLC30A8 protein affects the reaction [Glucose results in increased secretion of INS1 protein]; SOD1 protein inhibits the reaction [[INS1 protein co-treated with Glucose] results in increased activity of PARP1 protein]; sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]; sodium arsenite promotes the reaction [Glucose results in increased secretion of INS1 protein]; Sorbitol promotes the reaction [Glucose results in increased secretion of INS1 protein]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Taurine inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Glucose results in increased secretion of INS1 protein]; TRIB3 protein affects the reaction [INS1 protein results in increased uptake of Glucose]; tributyltin promotes the reaction [Glucose results in increased secretion of INS1 protein]; trichostatin A inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]; tubacin inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; tubacin promotes the reaction [Glucose results in increased secretion of INS1 protein]; UCP2 protein inhibits the reaction [SIRT1 protein promotes the reaction [Glucose results in increased expression of INS1 protein]]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; Wortmannin inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Zinc inhibits the reaction [Glucose results in increased secretion of INS1 protein] [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; bisphenol A inhibits the reaction [INS1 protein results in increased uptake of Glucose]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; Quercetin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; tributyltin promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] Glucose results in decreased expression of INS1 mRNA INS1 protein results in increased uptake of Glucose; INS1 results in increased uptake of Glucose |
CTD |
PMID:222008 PMID:1324726 PMID:2185640 PMID:2204694 PMID:2262933 PMID:2645939 PMID:7498292 PMID:9030901 PMID:9453242 PMID:9492047 PMID:9662045 PMID:9751766 PMID:10199125 PMID:10221768 PMID:10464266 PMID:10535451 PMID:10623569 PMID:10780946 PMID:11289044 PMID:11574405 PMID:11893929 PMID:14578291 PMID:15028607 PMID:15276423 PMID:15516700 PMID:15788402 PMID:15878969 PMID:15919478 PMID:15919803 PMID:16366736 PMID:16413591 PMID:16842748 PMID:17069794 PMID:17179392 PMID:17198541 PMID:17241282 PMID:17327424 PMID:17339113 PMID:17520061 PMID:17578889 PMID:17723306 PMID:17922229 PMID:18262572 PMID:18310442 PMID:18545258 PMID:18597805 PMID:18615583 PMID:18669601 PMID:19052259 PMID:19070612 PMID:19071154 PMID:19393637 PMID:19450229 PMID:19463741 PMID:19479076 PMID:19492079 PMID:19540215 PMID:20406654 PMID:20471953 PMID:20723550 PMID:21190014 PMID:21319751 PMID:21394550 PMID:21847688 PMID:21854074 PMID:21888768 PMID:22384078 PMID:22415589 PMID:22479612 PMID:22643931 PMID:22872759 PMID:22951486 PMID:23138875 PMID:23236509 PMID:23328667 PMID:23795780 PMID:24349194 PMID:24349266 PMID:25205820 PMID:25228148 PMID:25280772 PMID:25343247 PMID:25499137 PMID:25543134 PMID:25851902 PMID:25859628 PMID:25979314 PMID:26512966 PMID:26875785 PMID:26942597 PMID:27008626 PMID:27317948 PMID:27415824 PMID:27836638 PMID:27939242 PMID:28027979 PMID:28180948 PMID:28242381 PMID:28559246 PMID:29098165 PMID:29111283 PMID:29161229 PMID:29165388 PMID:29183753 PMID:29473434 PMID:29658312 PMID:29905828 PMID:30562058 PMID:30660605 PMID:30761839 PMID:30918868 PMID:30940548 PMID:31054273 PMID:31095431 PMID:31170414 PMID:31332465 PMID:31776611 PMID:31778773 PMID:32407875 PMID:32553926 PMID:33026256 PMID:33038468 PMID:33253011 PMID:33359794 PMID:33922211 PMID:34225579 PMID:34813903 PMID:35196519 PMID:35199402 PMID:35457000 PMID:35679966 PMID:37217659 More...
|
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions affects response to substance increases uptake increases expression increases secretion decreases expression decreases secretion decreases chemical synthesis increases activity |
ISO EXP |
(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; 1-Methyl-3-isobutylxanthine promotes the reaction [Glucose results in increased secretion of INS protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; 3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose results in increased expression of INS protein]; 3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [SIRT1 protein inhibits the reaction [Resveratrol promotes the reaction [Glucose results in increased secretion of INS protein]]]; [6alpha-ethyl-23(S)-methylcholic acid co-treated with Glucose] results in increased secretion of INS protein; [Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Glucose results in increased secretion of INS protein]; [chromic chloride results in increased activity of INS protein modified form] which results in increased import of Glucose; [Glucose affects the susceptibility to INS protein] which affects the phosphorylation of AKT1 protein; [Glucose affects the susceptibility to INS protein] which affects the uptake of Glucose; [Glucose co-treated with INS protein] affects the localization of PDX1 protein; [Glucose co-treated with sodium arsenite] results in increased secretion of INS protein; [Glyburide co-treated with Glucose] results in increased expression of INS protein; [INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide; [INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein; [INS protein co-treated with Glucose] results in increased expression of ACACA mRNA; [INS protein co-treated with Glucose] results in increased expression of FASN mRNA; [INS protein co-treated with Glucose] results in increased expression of SREBF1 mRNA; [Lithocholic Acid co-treated with Glucose] results in increased secretion of INS protein; [manganese chloride results in increased abundance of Manganese] inhibits the reaction [Glucose results in increased secretion of INS protein]; [Oleanolic Acid co-treated with Glucose] results in increased secretion of INS protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of PPARG mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of PPARA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CXCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NFKB1 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of PPARD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of RELA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein; [SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; [sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Glucose results in increased secretion of INS protein]; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; [Wortmannin co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased expression of INS protein]; Acetylcysteine inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS protein]]; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol promotes the reaction [Glucose results in increased secretion of INS protein]; Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]; baicalein promotes the reaction [Glucose results in increased secretion of INS protein]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]; bisphenol A promotes the reaction [Glucose results in increased secretion of INS protein]; Cadmium Chloride promotes the reaction [Glucose results in increased secretion of INS protein]; Chlorpropamide inhibits the reaction [Glucose results in decreased secretion of INS protein]; Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS protein]; Dexamethasone inhibits the reaction [INS protein results in increased uptake of Glucose]; Diazoxide inhibits the reaction [Glucose results in increased secretion of INS protein]; Dichlorodiphenyl Dichloroethylene promotes the reaction [Glucose results in increased secretion of INS protein]; Diethylhexyl Phthalate affects the reaction [Glucose results in increased secretion of INS protein]; Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]; Exenatide inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]]; Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]; Fenofibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Fulvestrant inhibits the reaction [bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]]; Fulvestrant inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS protein]]; fumosorinone promotes the reaction [INS protein results in increased uptake of Glucose]; Glucose inhibits the reaction [INS protein results in increased chemical synthesis of Glycogen]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]; Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]; Glyburide inhibits the reaction [Glucose results in decreased secretion of INS protein]; GW8510 promotes the reaction [Glucose results in increased secretion of INS protein]; HNF1B protein inhibits the reaction [bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]]; IAPP protein inhibits the reaction [Glucose results in increased secretion of INS protein]; INS protein inhibits the reaction [Glucose results in decreased expression of ATP1A1 protein]; INS protein mutant form results in decreased uptake of and results in decreased oxidation of Glucose; IRS1 protein polymorphism inhibits the reaction [Glucose results in increased secretion of INS protein]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; mercaptosteroid 6 inhibits the reaction [Glucose results in increased secretion of INS protein]; Metformin inhibits the reaction [[Glucose affects the susceptibility to INS protein] which affects the uptake of Glucose]; Metformin promotes the reaction [Glucose results in increased secretion of INS protein]; methylarsine oxide inhibits the reaction [Glucose results in increased secretion of INS protein]; Methylcholanthrene promotes the reaction [Glucose results in increased secretion of INS protein alternative form]; MIR133A1 affects the reaction [Glucose results in decreased chemical synthesis of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Glucose results in increased secretion of INS protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]]; Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein]; NKX6-1 protein promotes the reaction [Glucose results in increased secretion of INS protein]; palmitoyl trifluoromethyl ketone inhibits the reaction [Glucose results in increased secretion of INS protein]; PARP1 protein affects the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]]; perfluorooctane sulfonic acid promotes the reaction [Glucose results in increased secretion of INS protein]; perfluorooctanoic acid inhibits the reaction [Glucose results in increased secretion of INS protein]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Plant Extracts inhibits the reaction [[Glucose affects the susceptibility to INS protein] which affects the uptake of Glucose]; PPARG protein affects the reaction [Fulvestrant inhibits the reaction [bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]]]; Quercetin inhibits the reaction [Glucose results in increased expression of INS protein]; Resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]; Resveratrol promotes the reaction [Glucose results in increased secretion of INS protein]; Ro 32-0432 inhibits the reaction [tributyltin promotes the reaction [Glucose results in increased secretion of INS protein]]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Rosiglitazone inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; Rosiglitazone inhibits the reaction [IAPP protein inhibits the reaction [Glucose results in increased secretion of INS protein]]; Rosiglitazone promotes the reaction [INS protein results in increased uptake of Glucose]; Saquinavir inhibits the reaction [INS protein results in increased import of Glucose]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]]; SIRT1 protein inhibits the reaction [Resveratrol promotes the reaction [Glucose results in increased secretion of INS protein]]; SLC30A8 protein promotes the reaction [Glucose results in increased secretion of INS protein]; sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]; sodium arsenite inhibits the reaction [INS protein results in increased uptake of Glucose]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of ACACA mRNA]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of FASN mRNA]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of SREBF1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; Thapsigargin inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; Thioctic Acid inhibits the reaction [Glucose results in increased expression of INS protein]; TNF protein inhibits the reaction [INS protein results in increased uptake of Glucose]; TPH1 protein affects the reaction [Glucose results in increased secretion of INS protein]; TPH1 protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]]; TPH1 protein affects the reaction [UGT1A6A protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]]]; tributyltin promotes the reaction [Glucose results in increased secretion of INS protein]; triphenyl phosphate promotes the reaction [Glucose results in increased secretion of INS protein]; Troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Glucose]]; UCP3 protein promotes the reaction [Glucose results in increased secretion of INS protein]; UGT1A6A protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]] Acetylcysteine inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS protein]]; Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS protein]; IKBKB affects the reaction [IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; IKBKB affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Glucose]; Quercetin inhibits the reaction [INS protein results in increased uptake of Glucose]; sodium bisulfide inhibits the reaction [INS protein results in increased uptake of Glucose] Glucose results in increased expression of INS mRNA; Glucose results in increased expression of INS2 mRNA alternative form 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [triphenyl phosphate promotes the reaction [INS protein results in increased import of Glucose]]; 3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [INS protein results in increased uptake of Glucose]; [IL1B protein co-treated with IFNG protein] promotes the reaction [Glucose results in increased secretion of INS protein]; bisphenol A promotes the reaction [Glucose results in increased secretion of INS protein]; Estradiol promotes the reaction [Glucose results in increased secretion of INS2 protein]; IL1B protein inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; MIR338 mRNA affects the reaction [Glucose results in increased secretion of INS protein]; Palmitic Acid inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]; PDX1 protein affects the reaction [bisphenol A promotes the reaction [Glucose results in increased secretion of INS protein]]; perfluorooctane sulfonic acid promotes the reaction [INS protein results in increased uptake of Glucose]; Resveratrol inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [INS protein results in increased uptake of Glucose]]; TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; triphenyl phosphate promotes the reaction [INS protein results in increased import of Glucose] Glucose results in increased secretion of INS protein; Glucose results in increased secretion of INS2 protein Glucose results in decreased expression of INS2 mRNA Glucose results in increased secretion of INS protein; Glucose results in increased secretion of INS protein alternative form; INS protein results in increased secretion of Glucose Glucose results in increased activity of INS promoter |
CTD |
PMID:838844 PMID:3511099 PMID:7956951 PMID:8725009 PMID:9032110 PMID:9142872 PMID:10430617 PMID:10967106 PMID:11305519 PMID:11574405 PMID:11786383 PMID:12914525 PMID:14625208 PMID:15153144 PMID:15277403 PMID:15531508 PMID:15642492 PMID:15864539 PMID:16204373 PMID:16452552 PMID:16489446 PMID:16505238 PMID:16984975 PMID:17192482 PMID:17965850 PMID:18167556 PMID:18266981 PMID:18328801 PMID:18347054 PMID:18446233 PMID:19188863 PMID:19531641 PMID:19724016 PMID:20100676 PMID:20520763 PMID:20960276 PMID:21031461 PMID:21163946 PMID:21888768 PMID:22162761 PMID:22242153 PMID:22558381 PMID:23022524 PMID:24231106 PMID:24651439 PMID:25796170 PMID:25851902 PMID:26548598 PMID:28163246 PMID:28180948 PMID:28774890 PMID:28951307 PMID:29330302 PMID:29526746 PMID:30562058 PMID:30914352 PMID:31555879 PMID:31776611 PMID:32613381 PMID:32623698 PMID:35457000 PMID:35563431 PMID:35577173 More...
|
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
increases phosphorylation multiple interactions decreases expression decreases degradation increases expression |
ISO EXP |
Glucose results in increased phosphorylation of INSR protein 3,4-Dihydroxyphenylacetic Acid inhibits the reaction [Glucose results in decreased expression of and results in decreased phosphorylation of INSR protein]; Catechin inhibits the reaction [Glucose results in decreased expression of and results in decreased phosphorylation of INSR protein]; Glucose results in decreased expression of and results in decreased phosphorylation of INSR protein Glucose results in decreased expression of INSR protein; Glucose results in decreased expression of INSR protein modified form Catechin inhibits the reaction [Glucose results in decreased expression of INSR protein modified form]; Catechin inhibits the reaction [Glucose results in decreased expression of INSR protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]]; PARP1 protein affects the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of INSR protein modified form]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of INSR protein] Glucose results in decreased degradation of INSR mRNA Glucose results in increased expression of INSR mRNA |
CTD |
PMID:7826318 PMID:21031461 PMID:24262486 PMID:29981789 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Insyn2a |
inhibitory synaptic factor 2A |
increases expression |
ISO |
Glucose results in increased expression of INSYN2A mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 1:189,697,856...189,753,194
Ensembl chr 1:189,697,878...189,752,922
|
|
G |
Ip6k3 |
inositol hexakisphosphate kinase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of IP6K3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:5,223,863...5,245,443
Ensembl chr20:5,224,120...5,245,428
|
|
G |
Ipcef1 |
interaction protein for cytohesin exchange factors 1 |
decreases expression |
ISO |
Glucose results in decreased expression of IPCEF1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 1:43,237,903...43,451,735
Ensembl chr 1:43,269,202...43,427,969
|
|
G |
Irag1 |
inositol 1,4,5-triphosphate receptor associated 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of IRAG1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of IRAG1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:164,981,716...165,094,232
Ensembl chr 1:164,981,716...165,094,176
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein; Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein] |
CTD |
PMID:16135072 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IRF1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Irf2 |
interferon regulatory factor 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of IRF2 mRNA Hirudins inhibits the reaction [Glucose results in increased expression of IRF2 mRNA]; IRF2 protein affects the reaction [Glucose results in increased expression of and results in increased cleavage of GSDMD protein]; IRF2 protein affects the reaction [Glucose results in increased expression of GSDMD mRNA] |
CTD |
PMID:34212273 |
|
NCBI chr16:45,439,215...45,550,054
Ensembl chr16:45,439,225...45,550,024
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of IRF7 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IRF7 mRNA; fucoxanthin inhibits the reaction [Glucose results in increased expression of IRF7 mRNA] |
CTD |
PMID:33448797 PMID:37567420 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Irgm |
immunity-related GTPase M |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IRGM1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions decreases phosphorylation decreases expression increases phosphorylation |
ISO |
ACACB protein affects the reaction [Glucose results in decreased phosphorylation of IRS1 protein]; Catechin inhibits the reaction [Glucose results in decreased expression of IRS1 protein modified form]; Catechin inhibits the reaction [Glucose results in decreased expression of IRS1 protein]; Glucose promotes the reaction [PIK3R1 protein binds to IRS1 protein]; IRS1 protein polymorphism inhibits the reaction [Glucose results in increased secretion of INS protein]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of IRS1 protein modified form]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of IRS1 protein] Glucose results in decreased expression of IRS1 protein; Glucose results in decreased expression of IRS1 protein modified form Glucose results in increased phosphorylation of IRS1 protein |
CTD |
PMID:10430617 PMID:24262486 PMID:33957017 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
increases phosphorylation decreases expression multiple interactions increases abundance |
ISO |
Glucose results in increased phosphorylation of IRS2 protein Glucose results in decreased expression of IRS2 protein; Glucose results in decreased expression of IRS2 protein modified form Catechin inhibits the reaction [Glucose results in decreased expression of IRS2 protein modified form]; Catechin inhibits the reaction [Glucose results in decreased expression of IRS2 protein]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of IRS2 protein modified form]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of IRS2 protein] IRS2 gene mutant form results in increased abundance of Glucose |
CTD |
PMID:10430617 PMID:20028942 PMID:24262486 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Islr2 |
immunoglobulin superfamily containing leucine-rich repeat 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ISLR2 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ISLR2 mRNA |
CTD |
PMID:31525975 PMID:37567420 |
|
NCBI chr 8:58,608,165...58,616,246
Ensembl chr 8:58,608,709...58,614,650
|
|
G |
Ism2 |
isthmin 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ISM2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ISM2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:106,921,213...106,944,291
Ensembl chr 6:106,926,175...106,944,514
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]] |
CTD |
PMID:18413191 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itga3 |
integrin subunit alpha 3 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of ITGA3 mRNA; Glucose results in decreased expression of ITGA3 protein notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein] |
CTD |
PMID:25503068 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itga5 |
integrin subunit alpha 5 |
decreases expression |
ISO |
Glucose results in decreased expression of ITGA5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
|
|
G |
Itgav |
integrin subunit alpha V |
decreases expression |
ISO |
Glucose results in decreased expression of ITGAV mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of ITGB1 mRNA; Glucose results in increased expression of ITGB1 protein Glucose results in decreased expression of ITGB1 mRNA notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein] Glucose results in decreased expression of ITGB1 mRNA; Glucose results in decreased expression of ITGB1 protein rosiglitazone inhibits the reaction [Glucose results in increased expression of ITGB1 mRNA]; rosiglitazone inhibits the reaction [Glucose results in increased expression of ITGB1 protein] |
CTD |
PMID:17441352 PMID:25503068 PMID:31655124 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions decreases expression |
ISO |
Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]] Glucose results in decreased expression of ITGB3 mRNA |
CTD |
PMID:18413191 PMID:31655124 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ITIH2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Izumo1 |
izumo sperm-oocyte fusion 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of IZUMO1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:96,090,817...96,096,893
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases phosphorylation |
ISO EXP |
(3,4-dihydroxyphenylamino)-2-imidazoline inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; acetovanillone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]; Rotenone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]] Glucose results in increased phosphorylation of JAK2 protein alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Glucose results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:15677497 PMID:20060012 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions affects localization increases phosphorylation increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of JUN protein]; [Glucose co-treated with Lipopolysaccharides] results in increased expression of JUN protein; Aspirin inhibits the reaction [Glucose results in increased expression of JUN protein]; Clofibrate inhibits the reaction [Glucose results in increased expression of JUN protein]; Fenofibrate inhibits the reaction [Glucose results in increased expression of JUN protein]; GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to HMGB1 promoter]]; GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to S100A12 promoter]]; GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to S100A8 promoter]]; Glucose promotes the reaction [JUN protein binds to HMGB1 promoter]; Glucose promotes the reaction [JUN protein binds to MMP9 promoter]; Glucose promotes the reaction [JUN protein binds to S100A12 promoter]; Glucose promotes the reaction [JUN protein binds to S100A8 promoter]; JUN promotes the reaction [Glucose results in increased expression of HMGB1 mRNA]; JUN promotes the reaction [Glucose results in increased expression of S100A12 mRNA]; JUN promotes the reaction [Glucose results in increased expression of S100A8 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose promotes the reaction [JUN protein binds to MMP9 promoter]]; PARP1 protein affects the reaction [Glucose promotes the reaction [JUN protein binds to MMP9 promoter]]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of JUN protein] Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein] Dactinomycin inhibits the reaction [Glucose results in increased expression of JUN mRNA]; diphenyliodonium inhibits the reaction [Glucose results in increased phosphorylation of JUN protein]; Quercetin inhibits the reaction [Glucose affects the localization of JUN protein]; Superoxides affects the reaction [Glucose results in increased phosphorylation of JUN protein] |
CTD |
PMID:11123204 PMID:11557636 PMID:16572112 PMID:16600694 PMID:17178593 PMID:18180316 PMID:19132243 PMID:19833897 PMID:19861503 PMID:20542118 PMID:28478229 PMID:30098273 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Glucose results in increased expression of JUNB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
multiple interactions |
ISO |
[Glucose co-treated with INS1 protein] affects the expression of KAT6B mRNA |
CTD |
PMID:22951486 |
|
NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
increases import multiple interactions |
ISO |
KCND2 protein results in increased import of Glucose [[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased import of Glucose; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased import of Glucose |
CTD |
PMID:34418280 |
|
NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of KCNG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
|
|
G |
Kcng3 |
potassium voltage-gated channel modifier subfamily G member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of KCNG3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:11,051,311...11,099,264
Ensembl chr 6:11,051,134...11,099,264
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of KCNH1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of KCNH1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:103,722,140...104,024,762
Ensembl chr13:103,722,245...104,024,740
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases expression decreases activity |
ISO EXP |
[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein; alpha-Tocopherol inhibits the reaction [Glucose results in decreased activity of KCNH2 protein]; Deoxyglucose inhibits the reaction [Glucose results in decreased activity of KCNH2 protein]; Deoxyglucose promotes the reaction [Glucose deficiency results in decreased activity of KCNH2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased activity of KCNH2 protein]; Pyruvic Acid inhibits the reaction [[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein]; Sodium Cyanide inhibits the reaction [Glucose results in decreased activity of KCNH2 protein] Glucose results in decreased expression of KCNH2 protein Glucose deficiency results in decreased activity of KCNH2 protein; Glucose results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 PMID:31729781 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnh6 |
potassium voltage-gated channel subfamily H member 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KCNH6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:90,949,240...90,970,746
Ensembl chr10:90,949,846...90,970,701
|
|
G |
Kcnip2 |
potassium voltage-gated channel interacting protein 2 |
decreases expression multiple interactions increases methylation |
ISO |
Glucose results in decreased expression of KCNIP2 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of KCNIP2 mRNA; fucoxanthin inhibits the reaction [Glucose results in decreased expression of KCNIP2 mRNA]; fucoxanthin inhibits the reaction [Glucose results in increased methylation of KCNIP2 gene] Glucose results in increased methylation of KCNIP2 gene; Glucose results in increased methylation of KCNIP2 promoter |
CTD |
PMID:31525975 PMID:33448797 PMID:37567420 |
|
NCBI chr 1:244,641,147...244,664,939
Ensembl chr 1:244,641,150...244,664,874
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
increases expression |
ISO |
Glucose results in increased expression of KCNJ15 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]; Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]; Tamoxifen inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; Tamoxifen inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]; Tetraethylammonium promotes the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of KCNMA1 mRNA |
CTD |
PMID:21413024 PMID:37567420 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Kcnmb1 |
potassium calcium-activated channel subfamily M regulatory beta subunit 1 |
multiple interactions |
ISO |
Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]; Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]; Tamoxifen inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; Tamoxifen inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]; Tetraethylammonium promotes the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]] |
CTD |
PMID:21413024 |
|
NCBI chr10:18,557,510...18,614,824
Ensembl chr10:18,557,904...18,565,798
|
|
G |
Kcnmb3 |
potassium calcium-activated channel subfamily M regulatory beta subunit 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of KCNMB3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:115,255,788...115,270,142
Ensembl chr 2:115,253,761...115,270,142
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of KCNN2 protein FBXO32 protein affects the reaction [Glucose results in decreased expression of KCNN2 protein] |
CTD |
PMID:30635400 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kctd8 |
potassium channel tetramerization domain containing 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of KCTD8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:38,773,274...39,018,182
Ensembl chr14:38,773,634...39,017,554
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions |
EXP |
KDM1A protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm1b |
lysine demethylase 1B |
multiple interactions |
ISO |
[Glucose co-treated with INS1 protein] affects the expression of KDM1B mRNA |
CTD |
PMID:22951486 |
|
NCBI chr17:17,602,961...17,643,865
Ensembl chr17:17,602,961...17,643,800
|
|
G |
Kdm4b |
lysine demethylase 4B |
multiple interactions |
ISO |
[Glucose co-treated with INS1 protein] affects the expression of KDM4B mRNA |
CTD |
PMID:22951486 |
|
NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions increases expression decreases expression |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of KDR protein Glucose results in increased expression of KDR mRNA [Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA] Glucose results in decreased expression of KDR mRNA |
CTD |
PMID:19228841 PMID:31655124 PMID:33962019 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions increases expression |
ISO EXP |
[NFE2L2 protein co-treated with KEAP1 protein] affects the abundance of Glucose solanesol inhibits the reaction [Glucose results in increased expression of KEAP1 mRNA]; solanesol inhibits the reaction [Glucose results in increased expression of KEAP1 protein] Glucose results in increased expression of KEAP1 mRNA; Glucose results in increased expression of KEAP1 protein [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]] |
CTD |
PMID:23017736 PMID:35191607 PMID:37586544 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif19b |
kinesin family member 19B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of KIF19B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:14,144,163...14,196,259
Ensembl chr12:14,144,118...14,193,648
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression |
EXP |
Glucose results in increased expression of KIF1A protein |
CTD |
PMID:23776493 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kif20b |
kinesin family member 20B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of KIF20B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif27 |
kinesin family member 27 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of KIF27 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:6,299,544...6,375,106
Ensembl chr17:6,299,569...6,369,768
|
|
G |
Kif4a |
kinesin family member 4A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of KIF4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Kif5b |
kinesin family member 5B |
decreases expression |
EXP |
Glucose results in decreased expression of KIF5B protein |
CTD |
PMID:23776493 |
|
NCBI chr17:51,489,904...51,527,508
Ensembl chr17:51,489,944...51,527,508
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
Glucose results in decreased expression of KIT mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf10 |
KLF transcription factor 10 |
multiple interactions increases expression |
ISO |
Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]] Glucose results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 PMID:19225232 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Klf13 |
KLF transcription factor 13 |
multiple interactions |
EXP |
[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of KLF13 mRNA |
CTD |
PMID:29122578 |
|
NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression |
ISO |
Glucose results in increased expression of KLF6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klf9 |
KLF transcription factor 9 |
increases expression |
ISO |
Glucose results in increased expression of KLF9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Klkb1 |
kallikrein B1 |
increases expression |
ISO |
Glucose results in increased expression of KLKB1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Klrd1 |
killer cell lectin like receptor D1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KLRD1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:163,044,920...163,056,568
Ensembl chr 4:163,045,067...163,056,518
|
|
G |
Klrg1 |
killer cell lectin like receptor G1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of KLRG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:155,455,465...155,467,301
Ensembl chr 4:155,455,495...155,467,424
|
|
G |
Knl1 |
kinetochore scaffold 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of KNL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:106,029,627...106,091,915
Ensembl chr 3:106,029,661...106,091,915
|
|
G |
Krt17 |
keratin 17 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of KRT17 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KRT17 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
|
|
G |
Krt20 |
keratin 20 |
multiple interactions decreases expression |
ISO |
[Glucose co-treated with TGFB1 protein] results in decreased expression of KRT20 protein; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of KRT20 protein]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of KRT20 mRNA]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of KRT20 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of KRT20 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KRT20 mRNA Glucose results in decreased expression of KRT20 mRNA; Glucose results in decreased expression of KRT20 protein |
CTD |
PMID:21829520 PMID:37567420 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KRT5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Kynu |
kynureninase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of KYNU mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucose results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamb2 |
laminin subunit beta 2 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucose results in increased expression of LAMB2 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Lamb3 |
laminin subunit beta 3 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucose results in increased expression of LAMB3 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucose results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
increases expression |
EXP |
Glucose results in increased expression of LAMP1 protein |
CTD |
PMID:22253932 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of LAMP2 protein |
CTD |
PMID:21392095 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lax1 |
lymphocyte transmembrane adaptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of LAX1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:45,134,825...45,145,381
Ensembl chr13:45,134,834...45,145,381
|
|
G |
Lca5l |
lebercilin LCA5 like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of LCA5L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:35,460,646...35,495,133
Ensembl chr11:35,461,118...35,495,047
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LCN2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lct |
lactase |
multiple interactions increases hydrolysis |
EXP |
[Aspirin results in decreased activity of LCT protein] which results in decreased transport of Glucose; [nimesulide results in decreased activity of LCT protein] which results in decreased transport of Glucose LCT protein results in increased hydrolysis of Glucose |
CTD |
PMID:14701853 PMID:16382204 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions increases activity increases expression |
EXP ISO |
LDHA protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] Glucose results in increased activity of LDHA protein Glucose affects the reaction [Fusaric Acid results in increased expression of LDHA mRNA]; Panax notoginseng extract inhibits the reaction [Glucose results in increased activity of LDHA protein] Glucose results in increased expression of LDHA protein |
CTD |
PMID:21124846 PMID:27566995 PMID:31654802 PMID:35385194 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects metabolic processing |
ISO |
LDHB protein affects the metabolism of Glucose |
CTD |
PMID:23437403 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Ldhd |
lactate dehydrogenase D |
increases expression |
ISO |
Glucose results in increased expression of LDHD mRNA |
CTD |
PMID:31525975 |
|
NCBI chr19:39,583,529...39,588,397
Ensembl chr19:39,573,621...39,595,575
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:26875785 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of LEF1 mRNA DKK1 protein inhibits the reaction [Glucose results in increased expression of LEF1 mRNA] |
CTD |
PMID:29163160 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
multiple interactions increases secretion increases expression increases response to substance |
ISO EXP |
Glucose promotes the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species]; LEP protein promotes the reaction [Glucose results in increased chemical synthesis of Reactive Oxygen Species] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LEP mRNA; [LEP gene mutant form results in increased susceptibility to [Methionine co-treated with Choline]] which results in decreased abundance of Glucose Glucose results in increased secretion of LEP protein Glucose results in increased expression of LEP mRNA; Glucose results in increased expression of LEP protein Glucose results in increased susceptibility to LEP protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased secretion of LEP protein; argan oil inhibits the reaction [Glucose results in increased expression of LEP protein]; Calcium deficiency inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; Corn Oil inhibits the reaction [Glucose results in increased expression of LEP protein]; Diazoxide inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; INS1 protein promotes the reaction [Glucose results in increased expression of LEP mRNA]; INS1 protein promotes the reaction [Glucose results in increased secretion of LEP protein]; LEP promotes the reaction [Glucose results in increased secretion of INS1 protein]; naringin inhibits the reaction [Glucose results in increased expression of LEP protein]; nickel chloride inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein] |
CTD |
PMID:9751766 PMID:10780946 PMID:11342529 PMID:18627777 PMID:24399619 PMID:27712037 PMID:29165388 PMID:37567420 More...
|
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects abundance increases expression multiple interactions decreases response to substance |
ISO EXP |
LEPR affects the abundance of Glucose; LEPR protein affects the abundance of Glucose Glucose results in increased expression of LEPR protein naringin inhibits the reaction [Glucose results in increased expression of LEPR protein] Hesperidin affects the reaction [LEPR protein affects the abundance of Glucose]; naringin affects the reaction [LEPR protein affects the abundance of Glucose] LEPR results in decreased susceptibility to Glucose |
CTD |
PMID:16427799 PMID:20567778 PMID:24399619 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lgals3bp |
galectin 3 binding protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of LGALS3BP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:103,619,912...103,629,251
Ensembl chr10:103,619,908...103,629,256
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions increases expression |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]] Glucose results in increased expression of LIF mRNA |
CTD |
PMID:17178593 PMID:19225232 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lin7b |
lin-7 homolog B, crumbs cell polarity complex component |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of LIN7B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:95,846,888...95,849,628
Ensembl chr 1:95,846,243...95,849,977
|
|
G |
Lipg |
lipase G, endothelial type |
decreases expression |
ISO |
Glucose results in decreased expression of LIPG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Lipn |
lipase, family member N |
increases expression |
ISO |
Glucose results in increased expression of LIPN mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 1:231,584,950...231,603,456
Ensembl chr 1:231,584,956...231,603,468
|
|
G |
Llcfc1 |
LLLL and CFNLAS motif containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of LLCFC1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LLCFC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:70,566,206...70,567,592
Ensembl chr 4:70,566,295...70,567,586
|
|
G |
Lmod3 |
leiomodin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of LMOD3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:129,843,964...129,858,684
Ensembl chr 4:129,843,970...129,858,244
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions decreases expression |
EXP |
LONP1 protein affects the reaction [SRT1720 inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of ACO2 protein]]; LONP1 protein affects the reaction [SRT1720 inhibits the reaction [Glucose results in decreased expression of LONP1 protein]]; SRT1720 inhibits the reaction [Glucose results in decreased expression of LONP1 protein] |
CTD |
PMID:31639451 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of LPCAT1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:29,766,070...29,816,401
Ensembl chr 1:29,766,071...29,816,401
|
|
G |
Lpl |
lipoprotein lipase |
decreases activity multiple interactions |
ISO |
Glucose analog results in decreased activity of LPL protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of LPL mRNA LPL protein promotes the reaction [Fatty Acids results in increased uptake of Glucose] |
CTD |
PMID:9414485 PMID:20628023 PMID:37567420 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrch4 |
leucine rich repeats and calponin homology domain containing 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of LRCH4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:19,057,582...19,072,573
Ensembl chr12:19,057,587...19,068,577
|
|
G |
Lrrc26 |
leucine rich repeat containing 26 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LRRC26 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:8,102,361...8,103,687
Ensembl chr 3:8,102,361...8,103,687
|
|
G |
Lrrc3b |
leucine rich repeat containing 3B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LRRC3B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:9,973,580...10,050,891
Ensembl chr15:9,969,983...10,051,066
|
|
G |
Lrrc61 |
leucine rich repeat containing 61 |
decreases methylation multiple interactions increases expression |
ISO |
Glucose results in decreased methylation of LRRC61 gene fucoxanthin inhibits the reaction [Glucose results in increased expression of LRRC61 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 4:77,503,882...77,523,909
Ensembl chr 4:77,503,857...77,524,020
|
|
G |
Lrrn2 |
leucine rich repeat neuronal 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of LRRN2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:44,321,944...44,382,454
Ensembl chr13:44,321,364...44,382,482
|
|
G |
LRRTM1 |
leucine rich repeat transmembrane neuronal 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of LRRTM1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:109,701,815...109,718,924
Ensembl chr 4:109,701,815...109,717,184
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of LST1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
|
|
G |
Ltc4s |
leukotriene C4 synthase |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of LTC4S mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Glucose results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of LY96 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Mafa |
MAF bZIP transcription factor A |
multiple interactions affects expression increases expression |
ISO EXP |
3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] Glucose affects the expression of MAFA mRNA 3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3,4-dihydro-5-methyl-1(2H)-isoquinolinone inhibits the reaction [Glucose results in decreased expression of MAFA protein]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein]; lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of MAFA mRNA] IL1B protein inhibits the reaction [Glucose results in increased expression of MAFA mRNA]; lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of MAFA mRNA]; Palmitic Acid inhibits the reaction [Glucose results in increased expression of MAFA mRNA]; TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of MAFA mRNA]] |
CTD |
PMID:16505238 PMID:22558381 PMID:24349266 |
|
NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
Glucose results in increased expression of MAFF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Magt1 |
magnesium transporter 1 |
decreases expression |
ISO |
Glucose results in decreased expression of MAGT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699
|
|
G |
Mak |
male germ cell-associated kinase |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MAK mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of MAK mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr17:23,683,753...23,731,125
Ensembl chr17:23,693,878...23,730,001
|
|
G |
Mall |
mal, T-cell differentiation protein-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MALL mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:114,927,897...114,950,840
Ensembl chr 3:114,927,897...114,950,785
|
|
G |
Mamdc2 |
MAM domain containing 2 |
decreases expression multiple interactions increases methylation |
ISO |
Glucose results in decreased expression of MAMDC2 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of MAMDC2 mRNA] Glucose results in increased methylation of MAMDC2 gene |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr 1:220,863,959...221,016,493
Ensembl chr 1:220,863,976...221,016,354
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of MAOB mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MAOB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions decreases lipidation increases expression decreases expression |
EXP ISO |
3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Inositol inhibits the reaction [Glucose results in decreased lipidation of MAP1LC3B protein]; N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; ULK1 protein affects the reaction [Glucose results in decreased expression of MAP1LC3B protein]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]] Glucose deficiency results in increased expression of MAP1LC3B protein; Glucose deficiency results in increased expression of MAP1LC3B protein modified form U 0126 inhibits the reaction [Glucose deficiency results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:29128638 PMID:34580807 PMID:35243728 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Glucose |
CTD |
PMID:27278863 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of MAP3K1 mRNA [MAP3K1 gene mutant form results in increased activity of MAP3K1 protein] which results in increased susceptibility to Glucose resveratrol inhibits the reaction [Glucose results in increased expression of MAP3K1 mRNA] |
CTD |
PMID:24659233 PMID:27278863 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k13 |
mitogen-activated protein kinase kinase kinase 13 |
increases methylation multiple interactions decreases expression |
ISO |
Glucose results in increased methylation of MAP3K13 gene fucoxanthin inhibits the reaction [Glucose results in decreased expression of MAP3K13 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr11:79,094,087...79,235,181
Ensembl chr11:79,097,247...79,235,181
|
|
G |
Map3k4 |
mitogen activated protein kinase kinase kinase 4 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of MAP3K4 mRNA resveratrol inhibits the reaction [Glucose results in increased expression of MAP3K4 mRNA] |
CTD |
PMID:24659233 |
|
NCBI chr 1:48,431,801...48,519,358
Ensembl chr 1:48,431,830...48,519,358
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions increases expression |
ISO |
Glucose deficiency promotes the reaction [DAXX protein binds to MAP3K5 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAP3K5 protein [[[[Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA] which results in increased expression of TXNIP protein] promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; [Glucose promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; Glucose results in increased phosphorylation of and results in increased activity of MAP3K5 protein Glucose results in increased expression of MAP3K5 protein |
CTD |
PMID:14505347 PMID:16731828 PMID:26660634 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity increases phosphorylation multiple interactions affects phosphorylation increases expression decreases phosphorylation |
ISO EXP |
Glucose deficiency results in increased activity of MAPK1 protein Glucose results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK1 protein]; Catechin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; EUK-134 inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Fulvestrant inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]]; Glucose deficiency results in increased expression of and results in increased phosphorylation of MAPK1 protein; Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK1 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein; Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Phytic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Quercetin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Rutin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Glucose deficiency results in increased activity of MAPK1 protein] Glucose affects the phosphorylation of MAPK1 protein Glucose results in increased expression of MAPK1 protein modified form 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of MAPK1 protein modified form]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; [sphingosine 1-phosphate co-treated with Glucose] results in increased expression of MAPK1 protein modified form; cinnamaldehyde inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; diphenyliodonium inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; farrerol inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]; MAPK1 protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]]; PRKCB protein affects the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; ruboxistaurin inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Glucose results in increased expression of MAPK1 protein modified form]; U 0126 inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK1 protein; CDK9 protein affects the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; Glucose promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK1 protein]; Silymarin promotes the reaction [Glucose promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK1 protein] Glucose results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:14711829 PMID:16572112 PMID:17309078 PMID:18057711 PMID:18310510 PMID:19020779 PMID:19228841 PMID:19303870 PMID:19557821 PMID:19587355 PMID:19861503 PMID:20060012 PMID:20200188 PMID:20860660 PMID:20962025 PMID:22162761 PMID:22406263 PMID:23690508 PMID:24682241 PMID:24971582 PMID:29753610 PMID:30098273 PMID:31838053 PMID:33631230 PMID:34060177 PMID:34580807 PMID:38000455 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions decreases phosphorylation increases activity |
ISO |
CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK14 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of KRT20 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of VIM protein]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of CDH1 protein]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of KRT20 mRNA]; MAPK14 protein promotes the reaction [Glucose results in decreased expression of KRT20 protein]; MAPK14 protein promotes the reaction [Glucose results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [Glucose results in increased expression of SNAI1 mRNA]; MAPK14 protein promotes the reaction [Glucose results in increased expression of VIM mRNA]; MAPK14 protein promotes the reaction [Glucose results in increased secretion of FN1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Glucose deficiency results in increased activity of MAPK14 protein] [resveratrol co-treated with Glucose] results in decreased expression of MAPK14 mRNA; Glucose promotes the reaction [EIF2AK2 protein results in increased activity of MAPK14 protein] Glucose results in decreased phosphorylation of MAPK14 protein |
CTD |
PMID:17309078 PMID:18973755 PMID:20200188 PMID:21829520 PMID:24659233 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity increases phosphorylation multiple interactions increases expression affects phosphorylation decreases phosphorylation |
ISO EXP |
Glucose deficiency results in increased activity of MAPK3 protein Glucose results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK3 protein]; Catechin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; EUK-134 inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]]; Glucose deficiency results in increased expression of and results in increased phosphorylation of MAPK3 protein; Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK3 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein; Heparin analog inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Phytic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Quercetin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Rutin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Glucose deficiency results in increased activity of MAPK3 protein] Glucose results in increased expression of MAPK3 protein modified form Glucose affects the phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of MAPK3 protein modified form]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; [sphingosine 1-phosphate co-treated with Glucose] results in increased expression of MAPK3 protein modified form; cinnamaldehyde inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; diphenyliodonium inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; farrerol inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]; MAPK3 protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]]; PRKCB protein affects the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; ruboxistaurin inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Glucose results in increased expression of MAPK3 protein modified form]; U 0126 inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK3 protein; CDK9 protein affects the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; Glucose promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]; Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK3 protein]; Silymarin promotes the reaction [Glucose promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK3 protein] Glucose results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:14711829 PMID:16572112 PMID:17309078 PMID:18057711 PMID:18310510 PMID:19020779 PMID:19228841 PMID:19303870 PMID:19557821 PMID:19587355 PMID:19861503 PMID:20060012 PMID:20200188 PMID:20860660 PMID:20962025 PMID:22162761 PMID:22406263 PMID:23690508 PMID:24682241 PMID:24971582 PMID:29753610 PMID:30098273 PMID:31838053 PMID:33631230 PMID:34060177 PMID:34580807 PMID:38000455 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO EXP |
Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein]]; Glucose deficiency results in increased activity of and results in increased phosphorylation of MAPK8 protein; rutecarpine inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein] [[Paraquat results in increased phosphorylation of MAPK8 protein] which results in decreased abundance of Insulin] which results in increased abundance of Glucose; Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:14505347 PMID:19861503 PMID:34801538 PMID:36394833 PMID:36928891 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
EXP |
Glucose results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:19861503 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression multiple interactions |
EXP ISO |
Glucose results in decreased expression of MAS1 mRNA NFE2L2 protein affects the reaction [Glucose results in decreased expression of MAS1 mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA] CEBPB protein inhibits the reaction [Glucose results in decreased expression of MAS1 protein] |
CTD |
PMID:29211853 PMID:29266779 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mcub |
mitochondrial calcium uniporter dominant negative subunit beta |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MCUB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:218,479,301...218,549,594
Ensembl chr 2:218,479,301...218,549,593
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
increases expression |
EXP ISO |
Glucose results in increased expression of MDH1 mRNA Glucose deficiency results in increased expression of MDH1 mRNA |
CTD |
PMID:24349266 PMID:26811028 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Mdk |
midkine |
increases expression |
ISO |
Glucose results in increased expression of MDK protein |
CTD |
PMID:17607302 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Meig1 |
meiosis/spermiogenesis associated 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MEIG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:74,810,791...74,828,433
Ensembl chr17:74,814,632...74,828,433
|
|
G |
Meiob |
meiosis specific with OB-fold |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MEIOB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MESP2 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MESP2 mRNA |
CTD |
PMID:31525975 PMID:37567420 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mfap3 |
microfibril associated protein 3 |
multiple interactions |
EXP |
MFAP3 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr10:41,696,788...41,711,490
Ensembl chr10:41,696,771...41,710,406
|
|
G |
Mfap4 |
microfibril associated protein 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MFAP4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G |
Mfap5 |
microfibril associated protein 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MFAP5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:155,727,925...155,750,458
|
|
G |
Mff |
mitochondrial fission factor |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of MFF mRNA [Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr 9:84,007,798...84,036,039
Ensembl chr 9:84,007,798...84,036,039
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
EXP ISO |
Glucose results in decreased expression of MFN1 protein Glucose results in decreased expression of MFN1 mRNA |
CTD |
PMID:27684054 PMID:33962019 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
cinnamic acid inhibits the reaction [Glucose results in decreased expression of MFN2 protein]; Metformin inhibits the reaction [Glucose results in decreased expression of MFN2 protein]; Oxygen deficiency inhibits the reaction [Glucose results in increased expression of MFN2 protein]; Sevoflurane inhibits the reaction [Oxygen deficiency inhibits the reaction [Glucose results in increased expression of MFN2 protein]] [Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA; Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA] |
CTD |
PMID:27684054 PMID:30144576 PMID:33962019 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MFSD2A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mfsd3 |
major facilitator superfamily domain containing 3 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of MFSD3 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 7:108,419,644...108,423,469
Ensembl chr 7:108,421,350...108,423,461
|
|
G |
Mgam |
maltase-glucoamylase |
multiple interactions |
ISO |
[MGAM protein results in increased metabolism of maltodextrin] which results in increased abundance of Glucose; [MGAM protein results in increased metabolism of Maltose] which results in increased abundance of Glucose |
CTD |
PMID:17585022 |
|
NCBI chr 4:69,441,626...69,602,068
Ensembl chr 4:69,446,150...69,692,715
|
|
G |
Miat |
myocardial infarction associated transcript |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MIAT mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:44,414,620...44,429,852
|
|
G |
Mief2 |
mitochondrial elongation factor 2 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr10:45,408,055...45,414,144
Ensembl chr10:45,408,082...45,414,144
|
|
G |
Mir133a1 |
microRNA 133a-1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of MIR133A1 mRNA MIR133A1 affects the reaction [Glucose results in decreased chemical synthesis of INS protein] |
CTD |
PMID:20520763 |
|
NCBI chr18:1,885,082...1,885,168
|
|
G |
Mir135a |
microRNA 135a |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of MIR135A mRNA; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA]]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of HMOX1 mRNA]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B mRNA]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSK3B protein] |
CTD |
PMID:29719095 |
|
NCBI chr 7:26,611,990...26,612,089
Ensembl chr 7:26,611,990...26,612,089
|
|
G |
Mir141 |
microRNA 141 |
increases expression |
ISO |
Glucose results in increased expression of MIR141 mRNA |
CTD |
PMID:26548909 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir144 |
microRNA 144 |
multiple interactions |
ISO |
[MIR144 mRNA results in decreased expression of SMARCA4 protein] affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of MIR144 mRNA; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 mRNA]; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 protein]; MIR144 mRNA promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein] |
CTD |
PMID:29457851 |
|
NCBI chr10:62,961,348...62,961,430
Ensembl chr10:62,961,348...62,961,430
|
|
G |
Mir145 |
microRNA 145 |
increases expression |
ISO |
Glucose results in increased expression of MIR145 mRNA |
CTD |
PMID:24223694 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir146a |
microRNA 146a |
increases expression decreases expression multiple interactions |
ISO |
Glucose results in increased expression of MIR146A mRNA Glucose results in decreased expression of MIR146 mRNA Polyphenols inhibits the reaction [Glucose results in increased expression of MIR146A mRNA] |
CTD |
PMID:20520763 PMID:21682256 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir148a |
microRNA 148a |
decreases expression |
ISO |
Glucose results in decreased expression of MIR148A mRNA |
CTD |
PMID:21682256 |
|
NCBI chr 4:80,333,762...80,333,858
Ensembl chr 4:80,333,762...80,333,858
|
|
G |
Mir17 |
microRNA 17 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MIR17 mRNA [[[[Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA] which results in increased expression of TXNIP protein] promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; [Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA; [Glucose results in decreased expression of MIR17 mRNA] which results in increased stability of TXNIP protein |
CTD |
PMID:26660634 |
|
NCBI chr15:92,180,629...92,180,712
Ensembl chr15:92,180,629...92,180,712
|
|
G |
Mir184 |
microRNA 184 |
increases expression |
EXP |
Glucose results in increased expression of MIR184 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mir186 |
microRNA 186 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of MIR186 mRNA; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein] |
CTD |
PMID:33759271 |
|
NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891
|
|
G |
Mir195 |
microRNA 195 |
increases expression |
EXP |
Glucose results in increased expression of MIR195 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr10:54,951,838...54,951,924
Ensembl chr10:54,951,838...54,951,924
|
|
G |
Mir200a |
microRNA 200a |
decreases expression |
ISO |
Glucose results in decreased expression of MIR200A mRNA |
CTD |
PMID:23776576 |
|
NCBI chr 5:166,648,494...166,648,582
|
|
G |
Mir200b |
microRNA 200b |
decreases expression |
ISO |
Glucose results in decreased expression of MIR200B mRNA |
CTD |
PMID:23776576 |
|
NCBI chr 5:166,649,272...166,649,366
Ensembl chr 5:166,649,272...166,649,366
|
|
G |
Mir200c |
microRNA 200c |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of MIR200C mRNA MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]; MIR200C mRNA affects the reaction [Glucose results in increased cleavage of GSDMD protein]; MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL18 protein]; MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL1B protein]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of GSDMD protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL18 protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL1B protein]] |
CTD |
PMID:35607288 |
|
NCBI chr 4:157,523,679...157,523,747
|
|
G |
Mir210 |
microRNA 210 |
multiple interactions increases expression |
ISO EXP |
MIR210 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA]; MIR210 mRNA results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] Glucose results in increased expression of MIR210 mRNA |
CTD |
PMID:23108914 PMID:31729781 |
|
NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454
|
|
G |
Mir217 |
microRNA 217 |
multiple interactions decreases expression increases expression |
EXP ISO |
MIR217 mRNA affects the reaction [Glucose results in decreased expression of SIRT1 mRNA]; MIR217 mRNA affects the reaction [Glucose results in decreased expression of SIRT1 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of EDN1 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of FN1 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of HIF1A mRNA]; MIR217 mRNA affects the reaction [Glucose results in increased expression of HIF1A protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of TGFB1 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of VEGFA protein] MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of IL1B protein]; MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of IL6 protein]; MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of TNF protein] Glucose results in decreased expression of MIR217 mRNA Glucose results in increased expression of MIR217 mRNA |
CTD |
PMID:26891083 PMID:33283391 |
|
NCBI chr14:102,531,505...102,531,609
Ensembl chr14:102,531,505...102,531,609
|
|
G |
Mir23b |
microRNA 23b |
decreases import multiple interactions |
ISO |
MIR23B mRNA results in decreased import of Glucose [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased import of Glucose |
CTD |
PMID:34418280 |
|
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mir27b |
microRNA 27b |
multiple interactions |
ISO |
MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]; MIR27B mRNA affects the reaction [Glucose results in increased expression of TNF protein]; SNHG1 affects the reaction [MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]]; SNHG1 affects the reaction [MIR27B mRNA affects the reaction [Glucose results in increased expression of TNF protein]] |
CTD |
PMID:36243327 |
|
NCBI chr17:1,813,427...1,813,523
Ensembl chr17:1,813,426...1,813,529
|
|
G |
Mir29a |
microRNA 29a |
multiple interactions |
EXP |
MIR29A mRNA inhibits the reaction [Glucose results in increased expression of CNR1 mRNA]; MIR29A mRNA inhibits the reaction [Glucose results in increased expression of CNR1 protein] |
CTD |
PMID:30642005 |
|
NCBI chr 4:59,650,608...59,650,695
|
|
G |
Mir32 |
microRNA 32 |
decreases expression |
EXP |
Glucose results in decreased expression of MIR32 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr 5:71,596,083...71,596,152
Ensembl chr 5:71,596,083...71,596,152
|
|
G |
Mir322 |
microRNA 322 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MIR322 MIR322 affects the reaction [Glucose results in increased cleavage of CASP3 protein]; tempol inhibits the reaction [Glucose results in decreased expression of MIR322] |
CTD |
PMID:25516495 |
|
NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688
|
|
G |
Mir331 |
microRNA 331 |
increases expression |
EXP |
Glucose results in increased expression of MIR331 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr 7:28,527,390...28,527,485
Ensembl chr 7:28,527,390...28,527,485
|
|
G |
Mir3588 |
microRNA 3588 |
decreases expression |
EXP |
Glucose results in decreased expression of MIR3588 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr11:16,245,611...16,245,716
Ensembl chr11:16,245,611...16,245,716
|
|
G |
Mir484 |
microRNA 484 |
increases expression |
EXP |
Glucose results in increased expression of MIR484 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr10:887,684...887,760
Ensembl chr10:887,684...887,760
|
|
G |
Mir503 |
microRNA 503 |
increases expression |
EXP |
Glucose results in increased expression of MIR503 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr X:132,806,303...132,806,373
Ensembl chr X:132,806,303...132,806,373
|
|
G |
Mir6216 |
microRNA 6216 |
increases expression |
EXP |
Glucose results in increased expression of MIR6216 mRNA |
CTD |
PMID:31729781 |
|
NCBI chr 3:44,756,861...44,756,938
Ensembl chr 3:44,756,861...44,756,938
|
|
G |
Mir99a |
microRNA 99a |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MIR99A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[cobaltous chloride co-treated with Glucose] results in increased expression of MKI67 mRNA; [cobaltous chloride co-treated with Glucose] results in increased expression of MKI67 protein; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of MKI67 mRNA]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of MKI67 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MKI67 mRNA |
CTD |
PMID:25192544 PMID:37567420 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlx |
MAX dimerization protein MLX |
multiple interactions |
ISO |
Glucose promotes the reaction [MLX protein binds to TUG1 promoter] |
CTD |
PMID:32467232 |
|
NCBI chr10:86,019,216...86,024,326
Ensembl chr10:86,019,588...86,032,350
|
|
G |
Mlxip |
MLX interacting protein |
multiple interactions affects localization |
ISO |
Glucose promotes the reaction [MLXIP protein binds to TUG1 promoter] Glucose affects the localization of MLXIP protein pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose affects the localization of MLXIP protein]; RELA protein affects the reaction [Glucose affects the localization of MLXIP protein]; SRI protein inhibits the reaction [Glucose affects the localization of MLXIP protein] |
CTD |
PMID:32467232 PMID:33930463 |
|
NCBI chr12:33,128,524...33,192,300
Ensembl chr12:33,128,520...33,192,374
|
|
G |
Mlxipl |
MLX interacting protein-like |
increases expression multiple interactions |
EXP ISO |
Glucose results in increased expression of MLXIPL protein Glucose results in increased expression of MLXIPL mRNA alternative form [Glucose co-treated with S 4048] results in increased expression of MLXIPL mRNA; Glucose promotes the reaction [MLXIPL protein binds to TUG1 promoter] |
CTD |
PMID:16644726 PMID:16790840 PMID:31974165 PMID:32467232 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MME mRNA [MME protein results in increased cleavage of angiotensin I (1-7)] affects the reaction [Glucose results in increased secretion of INS1 protein]; MME protein affects the reaction [angiotensin I (1-7) promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:17178593 PMID:28559246 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions decreases expression |
ISO |
CD14 protein affects the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]] Glucose inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucose inhibits the reaction [IL1B protein results in increased expression of MMP1 protein] Glucose results in decreased expression of MMP1 mRNA |
CTD |
PMID:18180316 PMID:30098273 PMID:31655124 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MMP12 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
ISO |
isoangustone A inhibits the reaction [Glucose results in decreased expression of MMP14 protein] |
CTD |
PMID:21367880 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp19 |
matrix metallopeptidase 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MMP19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:1,221,229...1,229,555
Ensembl chr 7:1,221,343...1,229,555
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression increases activity increases expression |
ISO EXP |
CEBPB protein inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of MMP2 protein]; Glucose results in decreased expression of and results in decreased activity of MMP2 protein; Resveratrol inhibits the reaction [Glucose results in increased activity of MMP2 protein]; Valsartan inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of MMP2 protein] Glucose results in decreased expression of MMP2 mRNA; Glucose results in decreased expression of MMP2 protein Glucose promotes the reaction [Air Pollutants results in increased activity of MMP2 protein]; Glucose promotes the reaction [Air Pollutants results in increased expression of MMP2 mRNA]; Glucose promotes the reaction [Particulate Matter results in increased activity of MMP2 protein]; Glucose promotes the reaction [Particulate Matter results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP2 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP2 protein]] farrerol inhibits the reaction [Glucose results in decreased expression of MMP2 mRNA]; farrerol inhibits the reaction [Glucose results in decreased expression of MMP2 protein]; Rosiglitazone inhibits the reaction [Glucose results in increased expression of MMP2 mRNA]; Rosiglitazone inhibits the reaction [Glucose results in increased expression of MMP2 protein] Glucose results in increased expression of MMP2 mRNA; Glucose results in increased expression of MMP2 protein |
CTD |
PMID:18665442 PMID:24659233 PMID:26179980 PMID:29266779 PMID:31838053 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MMP25 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MMP7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases activity decreases expression increases expression |
ISO EXP |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 protein; [Resveratrol co-treated with Glucose] results in decreased activity of MMP9 protein; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 mRNA]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of MMP9 protein] Glucose deficiency results in decreased activity of MMP9 protein Glucose results in decreased expression of MMP9 protein Glucose results in increased expression of MMP9 mRNA [Glucose co-treated with Resveratrol] results in decreased expression of MMP9 mRNA; Glucose promotes the reaction [Air Pollutants results in increased activity of MMP9 protein]; Glucose promotes the reaction [Air Pollutants results in increased expression of MMP9 mRNA]; Glucose promotes the reaction [JUN protein binds to MMP9 promoter]; Glucose promotes the reaction [PARP1 protein binds to MMP9 promoter]; Glucose promotes the reaction [Particulate Matter results in increased activity of MMP9 protein]; Glucose promotes the reaction [Particulate Matter results in increased expression of MMP9 mRNA]; Glucose promotes the reaction [RELA protein binds to MMP9 promoter]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose promotes the reaction [JUN protein binds to MMP9 promoter]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose promotes the reaction [RELA protein binds to MMP9 promoter]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased expression of MMP9 mRNA]; PARP1 protein affects the reaction [Glucose promotes the reaction [JUN protein binds to MMP9 promoter]]; PARP1 protein affects the reaction [Glucose promotes the reaction [RELA protein binds to MMP9 promoter]]; PARP1 protein affects the reaction [Glucose results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP9 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP9 protein]]; SIRT1 protein inhibits the reaction [Glucose promotes the reaction [PARP1 protein binds to MMP9 promoter]] [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; farrerol inhibits the reaction [Glucose results in decreased expression of MMP9 mRNA]; farrerol inhibits the reaction [Glucose results in decreased expression of MMP9 protein]; Glucose affects the reaction [Azoxymethane affects the expression of MMP9 protein] |
CTD |
PMID:22467055 PMID:24064760 PMID:24659233 PMID:24682241 PMID:26179980 PMID:28478229 PMID:31655124 PMID:31838053 PMID:35427737 More...
|
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of IFI204 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mogat2 |
monoacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MOGAT2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:153,521,813...153,545,756
Ensembl chr 1:153,521,815...153,545,756
|
|
G |
Morc2 |
MORC family CW-type zinc finger 2 |
decreases expression |
ISO |
Glucose results in decreased expression of MORC2A mRNA |
CTD |
PMID:32467232 |
|
NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343
|
|
G |
Morf4l2 |
mortality factor 4 like 2 |
multiple interactions |
EXP |
MORF4L2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr X:100,082,562...100,093,658
Ensembl chr X:100,082,404...100,093,728
|
|
G |
Morn4 |
MORN repeat containing 4 |
multiple interactions |
EXP |
MORN4 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 1:240,888,338...240,898,644
Ensembl chr 1:240,888,344...240,898,716
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases expression |
EXP ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of MPO protein; Quercetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of MPO protein] Glucose results in increased expression of MPO mRNA |
CTD |
PMID:23758074 PMID:32942007 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
decreases expression |
EXP |
Glucose deficiency results in decreased expression of MPST mRNA |
CTD |
PMID:35577173 |
|
NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141
|
|
G |
Mpv17 |
mitochondrial inner membrane protein MPV17 |
increases expression |
ISO |
Glucose results in increased expression of MPV17 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 6:25,221,668...25,236,241
Ensembl chr 6:25,222,896...25,236,244
|
|
G |
Mpv17l |
MPV17 mitochondrial inner membrane protein like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MPV17L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:1,988,451...2,025,300
Ensembl chr10:1,988,136...2,007,649
|
|
G |
Mrap |
melanocortin 2 receptor accessory protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MRAP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:29,991,974...30,003,024
Ensembl chr11:29,992,034...30,003,024
|
|
G |
Mras |
muscle RAS oncogene homolog |
multiple interactions increases activity |
EXP |
manumycin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein] |
CTD |
PMID:18569938 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Mro |
maestro |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of MRO mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MRO mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:67,450,186...67,467,593
Ensembl chr18:67,450,595...67,467,044
|
|
G |
Ms4a1 |
membrane spanning 4-domains A1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of MS4A1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MS4A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512
|
|
G |
Ms4a6a |
membrane spanning 4-domains A6A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MS4A6C mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:208,401,465...208,414,831
Ensembl chr 1:208,401,466...208,414,758
|
|
G |
Msh4 |
mutS homolog 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MSH4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:242,785,392...242,844,609
Ensembl chr 2:242,792,661...242,843,487
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MSR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
affects response to substance |
EXP |
ATP6 protein affects the susceptibility to Glucose |
CTD |
PMID:18273840 |
|
NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein |
CTD |
PMID:25997894 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
increases expression |
ISO |
Glucose deficiency results in increased expression of COX2 mRNA |
CTD |
PMID:26811028 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt-cyb |
mitochondrially encoded cytochrome b |
multiple interactions decreases expression |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in decreased expression of CYTB mRNA]; PARP1 protein affects the reaction [Glucose results in decreased expression of CYTB mRNA] |
CTD |
PMID:28478229 |
|
NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions affects expression |
EXP |
Glucose results in increased expression of MT1A mRNA manganese(III)-tetrakis(4-benzoic acid)porphyrin affects the reaction [Glucose affects the expression of MT1A mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Glucose results in increased expression of MT1A mRNA]; zinc chloride promotes the reaction [Glucose results in increased expression of MT1A mRNA] |
CTD |
PMID:22643931 PMID:23056475 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
EXP |
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Glucose results in increased expression of MT2A mRNA]; zinc chloride promotes the reaction [Glucose results in increased expression of MT2A mRNA] |
CTD |
PMID:23056475 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mt3 |
metallothionein 3 |
decreases expression |
ISO |
Glucose results in decreased expression of MT3 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of MTHFD2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtm1 |
myotubularin 1 |
decreases expression |
ISO |
Glucose results in decreased expression of MTM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:488,923...506,882
Ensembl chr 6:488,969...506,860
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases activity increases phosphorylation multiple interactions decreases uptake increases expression |
ISO EXP |
Glucose results in increased activity of MTOR protein Glucose results in increased phosphorylation of MTOR protein Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein] [Glucose promotes the reaction [MTOR protein binds to YY1 protein]] which results in increased expression of YY1 protein; FOXP1 protein inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein] MTOR gene mutant form results in decreased uptake of Glucose Glucose results in increased expression of MTOR protein; Glucose results in increased expression of MTOR protein modified form HU 308 inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein]; Resveratrol inhibits the reaction [Glucose results in increased activity of MTOR protein] |
CTD |
PMID:19765649 PMID:22561310 PMID:28713934 PMID:29384525 PMID:30459625 PMID:31494106 PMID:35445903 More...
|
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtx1 |
Metaxin 1 |
increases expression |
ISO |
Glucose results in increased expression of MTX1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:174,615,460...174,621,383
Ensembl chr 2:174,615,461...174,620,982
|
|
G |
Muc16 |
mucin 16, cell surface associated |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MUC16 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:16,164,531...16,323,126
|
|
G |
Muc19 |
mucin 19, oligomeric |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of MUC19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:123,017,896...123,139,053
Ensembl chr 7:123,017,896...123,139,053
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of MX1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Mxd1 |
max dimerization protein 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [MXD1 protein binds to TUG1 promoter] |
CTD |
PMID:32467232 |
|
NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression affects expression |
ISO EXP |
MYC protein affects the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose] Glucose results in increased expression of MYC protein manganese(III)-tetrakis(4-benzoic acid)porphyrin affects the reaction [Glucose affects the expression of MYC mRNA] Glucose affects the reaction [Dexamethasone results in increased expression of MYC mRNA]; Glucose affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of MYC mRNA] |
CTD |
PMID:2558650 PMID:11990355 PMID:22643931 PMID:33992720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of MYD88 protein artesunate inhibits the reaction [Glucose results in increased expression of MYD88 protein] |
CTD |
PMID:30031708 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh1 |
myosin heavy chain 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MYH1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myh15 |
myosin, heavy chain 15 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of MYH15 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:51,621,924...51,763,037
Ensembl chr11:51,622,413...51,762,971
|
|
G |
Myh2 |
myosin heavy chain 2 |
multiple interactions |
ISO |
MYH2 protein affects the reaction [SLC2A4 protein results in increased uptake of Glucose] |
CTD |
PMID:18773891 |
|
NCBI chr10:51,856,738...51,883,236
Ensembl chr10:51,856,738...51,883,236
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions increases expression increases uptake |
ISO |
ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose]; ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK protein] Glucose results in increased expression of MYLK mRNA; Glucose results in increased expression of MYLK protein |
CTD |
PMID:18773891 PMID:34464088 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myo5a |
myosin VA |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MYO5A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918
|
|
G |
Myo7b |
myosin VIIb |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of MYO7B mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of MYO7B mRNA] |
CTD |
PMID:31525975 PMID:33448797 |
|
NCBI chr18:23,588,307...23,669,841
Ensembl chr18:23,588,307...23,669,809
|
|
G |
Myom3 |
myomesin 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of MYOM3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274
|
|
G |
Nalcn |
sodium leak channel, non-selective |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NALCN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
decreases expression multiple interactions increases secretion increases expression |
ISO |
Glucose results in decreased expression of NAMPT mRNA Diazoxide inhibits the reaction [Glucose results in increased secretion of NAMPT protein]; Nifedipine inhibits the reaction [Glucose results in increased secretion of NAMPT protein] Glucose results in increased expression of NAMPT mRNA |
CTD |
PMID:20068143 PMID:23536823 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nanp |
N-acetylneuraminic acid phosphatase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of NANP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:139,826,549...139,841,655
Ensembl chr 3:139,826,549...139,841,648
|
|
G |
Napa |
NSF attachment protein alpha |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of NAPA protein |
CTD |
PMID:22314686 |
|
NCBI chr 1:76,787,036...76,805,869
Ensembl chr 1:76,786,932...76,805,869
|
|
G |
Nat2 |
N-acetyltransferase 2 |
increases expression multiple interactions increases activity |
ISO |
Glucose results in increased expression of NAT2 mRNA; Glucose results in increased expression of NAT2 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the activity of NAT2 polymorphism] which affects the chemical synthesis of Glucose; [2-amino-3,4-dimethylimidazo(4,5-f)quinoline affects the activity of NAT2 polymorphism] which affects the chemical synthesis of Glucose; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline affects the activity of NAT2 polymorphism] which affects the chemical synthesis of Glucose Glucose results in increased activity of NAT2 protein |
CTD |
PMID:36156098 PMID:37423373 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nbea |
neurobeachin |
decreases expression |
ISO |
Glucose results in decreased expression of NBEA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:139,780,021...140,338,639
Ensembl chr 2:139,780,021...140,340,584
|
|
G |
Ncapg |
non-SMC condensin I complex, subunit G |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NCAPG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases phosphorylation increases expression affects localization |
ISO EXP |
acetovanillone inhibits the reaction [Glucose results in increased expression of and results in increased activity of NCF1 protein]; bisindolylmaleimide I inhibits the reaction [Glucose affects the localization of NCF1 protein]; Glucose results in increased expression of and results in increased activity of NCF1 protein; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of NCF1 protein]; PRKAA1 protein affects the reaction [rosiglitazone inhibits the reaction [Glucose affects the localization of NCF1 protein]]; rosiglitazone inhibits the reaction [Glucose affects the localization of NCF1 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NCF1 mRNA Glucose results in increased phosphorylation of NCF1 protein Glucose results in increased expression of NCF1 mRNA; Glucose results in increased expression of NCF1 protein [[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein; [[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of and results in increased phosphorylation of NCF1 protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of NCF1 protein]]; Glucose results in increased expression of and results in increased phosphorylation of NCF1 protein; NCF1 protein promotes the reaction [Glucose results in increased chemical synthesis of Reactive Oxygen Species]; NCF1 protein promotes the reaction [Glucose results in increased expression of FN1 protein]; pyrazolanthrone inhibits the reaction [Glucose results in increased expression of NCF1 protein]; Resveratrol inhibits the reaction [[[[Glucose results in increased expression of CYBA protein] co-treated with [Glucose results in increased expression of NCF1 protein]] results in increased chemical synthesis of Reactive Oxygen Species] which results in increased expression of FN1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of NCF1 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of NCF1 protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of NCF1 protein] |
CTD |
PMID:12821678 PMID:17320767 PMID:17916771 PMID:18088078 PMID:19878672 PMID:22245600 PMID:24971582 PMID:26054749 PMID:37567420 More...
|
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions increases expression |
EXP |
dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of NCF2 protein]]; Resveratrol inhibits the reaction [Glucose results in increased expression of NCF2 protein] |
CTD |
PMID:26054749 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of NCF4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389
|
|
G |
Nckap5 |
NCK-associated protein 5 |
increases expression |
ISO |
Glucose results in increased expression of NCKAP5 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr13:37,369,948...38,283,257
Ensembl chr13:37,370,792...38,283,268
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [NCOR1 protein binds to SRI promoter]; NCOR1 protein affects the reaction [Glucose results in decreased expression of SRI protein] |
CTD |
PMID:33930463 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NCR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558
|
|
G |
Ndel1 |
nudE neurodevelopment protein 1-like 1 |
increases expression |
ISO |
Glucose results in increased expression of NDEL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:53,505,628...53,582,025
Ensembl chr10:53,516,491...53,570,907
|
|
G |
Ndrg2 |
NDRG family member 2 |
multiple interactions |
EXP ISO |
[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of NDRG2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2 protein; NDRG2 protein affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; TP53 protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2] NDRG2 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein] |
CTD |
PMID:23451161 |
|
NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein |
CTD |
PMID:25997894 |
|
NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
decreases phosphorylation |
EXP |
Glucose results in decreased phosphorylation of NEDD4L protein |
CTD |
PMID:31729781 |
|
NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137
|
|
G |
Nek2 |
NIMA-related kinase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NEK2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NFE2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of NFE2L1 mRNA; Glucose results in increased expression of NFE2L1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein]; Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein] |
CTD |
PMID:33838154 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression affects localization decreases expression affects response to substance increases localization |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]]; [Oxygen co-treated with Glucose] inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L2 protein]; NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; Particulate Matter inhibits the reaction [[Oxygen co-treated with Glucose] inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; solanesol inhibits the reaction [Glucose results in decreased expression of NFE2L2 mRNA]; solanesol inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; Vehicle Emissions inhibits the reaction [[Oxygen co-treated with Glucose] inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]] Glucose results in increased expression of NFE2L2 mRNA; Glucose results in increased expression of NFE2L2 protein Glucose affects the localization of NFE2L2 protein [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein; diallyl trisulfide promotes the reaction [Glucose results in increased expression of and affects the localization of NFE2L2 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]; Glucose results in increased expression of and affects the localization of NFE2L2 protein; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]]; Inositol inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NFE2L2 protein]; NFE2L2 mutant form inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; NFE2L2 protein affects the reaction [Exenatide inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; NFE2L2 protein affects the reaction [Glucose results in decreased expression of ACE2 mRNA]; NFE2L2 protein affects the reaction [Glucose results in decreased expression of MAS1 mRNA]; NFE2L2 protein affects the reaction [Glucose results in increased expression of ACE mRNA]; NFE2L2 protein affects the reaction [Glucose results in increased expression of AGT mRNA]; NFE2L2 protein affects the reaction [Glucose results in increased expression of NQO1 mRNA]; NFE2L2 protein mutant form affects the reaction [plumbagin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; NFE2L2 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; Quercetin inhibits the reaction [Glucose results in decreased expression of NFE2L2 mRNA]; Quercetin inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; SRT1720 inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein] Glucose results in decreased expression of NFE2L2 mRNA; Glucose results in decreased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Glucose 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [SMARCA4A protein affects the reaction [Glucose affects the localization of NFE2L2 protein]]; [NFE2L2 protein binds to TXNIP promoter] inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; [NFE2L2 protein co-treated with KEAP1 protein] affects the abundance of Glucose; [NFE2L2 protein mutant form co-treated with Streptozocin] results in increased abundance of Glucose; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of FN1 mRNA]]; NFE2L2 protein inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; SMARCA4A protein affects the reaction [Glucose affects the localization of NFE2L2 protein] Glucose deficiency results in increased localization of NFE2L2 protein Glucose deficiency results in increased expression of NFE2L2 mRNA; Glucose deficiency results in increased expression of NFE2L2 protein; Glucose results in increased expression of NFE2L2; Glucose results in increased expression of NFE2L2 mRNA; Glucose results in increased expression of NFE2L2 protein |
CTD |
PMID:17928392 PMID:20028456 PMID:20086057 PMID:20103708 PMID:21333731 PMID:21818840 PMID:22869588 PMID:23017736 PMID:23453443 PMID:23770986 PMID:23954465 PMID:25896937 PMID:27939242 PMID:28400208 PMID:29211853 PMID:29649567 PMID:29719095 PMID:31639451 PMID:32602595 PMID:33270355 PMID:33359794 PMID:33838154 PMID:33962019 PMID:35191607 PMID:35243728 PMID:37586544 PMID:38000455 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of NFKB1 mRNA; Glucose results in increased expression of NFKB1 protein [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NFKB1 protein; Glucose results in increased activity of and affects the localization of NFKB1 protein; INO 1001 inhibits the reaction [Glucose results in increased activity of and affects the localization of NFKB1 protein]; NFKB1 protein inhibits the reaction [SOD1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein]]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased activity of NFKB1 protein] [Glucose results in increased susceptibility to sodium arsenite] which results in increased expression of NFKB1 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NFKB1 mRNA; Polyphenols inhibits the reaction [Glucose results in increased expression of NFKB1 mRNA] |
CTD |
PMID:16395278 PMID:17065336 PMID:18180316 PMID:21682256 PMID:28264687 PMID:32613381 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation increases expression decreases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein]; Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Glucose results in increased degradation of and results in decreased expression of NFKBIA protein; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Quercetin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Rutin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in decreased expression of NFKBIA protein]; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NFKBIA protein; [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NFKBIA protein modified form; Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein; prolinedithiocarbamate inhibits the reaction [Glucose results in decreased expression of NFKBIA protein]; pyrazolanthrone inhibits the reaction [Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Quercetin inhibits the reaction [Glucose results in increased expression of NFKBIA protein modified form]; Quercetin inhibits the reaction [Glucose results in increased expression of NFKBIA protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Y 27632 inhibits the reaction [Glucose results in decreased expression of NFKBIA protein] Glucose results in increased expression of NFKBIA protein; Glucose results in increased expression of NFKBIA protein modified form Glucose results in increased expression of NFKBIA mRNA [Oxygen deficiency co-treated with Glucose deficiency] results in increased degradation of NFKBIA protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of and results in increased degradation of NFKBIA protein; [Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein]; INO 1001 inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein]; Prodigiosin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased degradation of NFKBIA protein]; prolinedithiocarbamate inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased degradation of NFKBIA protein] |
CTD |
PMID:16395278 PMID:17065336 PMID:17178593 PMID:19132243 PMID:19557821 PMID:21925195 PMID:22245600 PMID:23376009 PMID:23770986 PMID:24971582 PMID:30101366 PMID:31323227 PMID:36462176 More...
|
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbid |
NFKB inhibitor delta |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NFKBID mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:85,679,353...85,690,415
Ensembl chr 1:85,680,861...85,690,447
|
|
G |
Ngf |
nerve growth factor |
multiple interactions decreases activity decreases expression |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein] Glucose results in decreased activity of NGF protein |
CTD |
PMID:19501110 PMID:23954465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nkd2 |
NKD inhibitor of WNT signaling pathway 2 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of NKD2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:29,442,898...29,470,839
Ensembl chr 1:29,441,328...29,470,821
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NKG7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nkpd1 |
NTPase, KAP family P-loop domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of NKPD1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:79,165,642...79,175,126
Ensembl chr 1:79,167,130...79,174,234
|
|
G |
Nkx6-1 |
NK6 homeobox 1 |
multiple interactions |
ISO |
NKX6-1 protein promotes the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:18347054 |
|
NCBI chr14:7,969,756...7,976,689
Ensembl chr14:7,969,756...7,976,681
|
|
G |
Nlrc5 |
NLR family, CARD domain containing 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NLRC5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases response to substance increases expression |
ISO EXP |
[Glucose co-treated with TGFB1 protein] results in increased expression of NLRP3 protein; Allopurinol inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of NLRP3 protein]; Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of NLRP3 protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of NLRP3 protein]; loganin inhibits the reaction [Glucose results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of NLRP3 protein]]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of NLRP3 protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; swietenine inhibits the reaction [Glucose results in increased expression of NLRP3 protein] NLRP3 protein results in increased susceptibility to Glucose NLRP3 protein promotes the reaction [Glucose results in decreased expression of TJP1 protein]; NLRP3 protein promotes the reaction [Glucose results in decreased expression of TJP2 protein]; NLRP3 protein promotes the reaction [Glucose results in increased secretion of HMGB1 protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NLRP3 protein; Allopurinol inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; Artesunate inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NLRP3 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; prolinedithiocarbamate inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of NLRP3 protein] Glucose results in increased expression of NLRP3 mRNA; Glucose results in increased expression of NLRP3 protein |
CTD |
PMID:23647015 PMID:27783111 PMID:29031534 PMID:30031708 PMID:35191607 PMID:35961541 PMID:36066211 PMID:37473909 More...
|
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nmu |
neuromedin U |
increases expression decreases methylation |
ISO |
Glucose results in increased expression of NMU mRNA Glucose results in decreased methylation of NMU promoter |
CTD |
PMID:31525975 |
|
NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nnt |
nicotinamide nucleotide transhydrogenase |
affects response to substance decreases metabolic processing |
ISO |
NNT protein affects the susceptibility to Glucose NNT protein results in decreased metabolism of Glucose |
CTD |
PMID:23504317 |
|
NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823
|
|
G |
Nobox |
NOBOX oogenesis homeobox |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of NOBOX mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:72,128,931...72,134,436
Ensembl chr 4:72,128,931...72,134,436
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of NOG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nol6 |
nucleolar protein 6 |
multiple interactions |
EXP |
NOL6 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 5:56,259,919...56,270,540
Ensembl chr 5:56,260,830...56,270,336
|
|
G |
Nono |
non-POU domain containing, octamer-binding |
affects metabolic processing |
ISO |
NONO gene mutant form affects the metabolism of Glucose |
CTD |
PMID:29358041 |
|
NCBI chr X:66,554,131...66,571,992
Ensembl chr X:66,554,098...66,571,952
|
|
G |
Nos1 |
nitric oxide synthase 1 |
decreases expression multiple interactions |
ISO |
Glucose deficiency results in decreased expression of NOS1 protein Nitroprusside inhibits the reaction [Glucose deficiency results in decreased expression of NOS1 protein] |
CTD |
PMID:17855661 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of NOS2 mRNA; Glucose results in increased expression of NOS2 protein [Glucose co-treated with IGF2R protein modified form] results in decreased expression of NOS2 protein; [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; [Oxygen co-treated with Glucose] promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOS2 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOS2 protein; PRKCB protein affects the reaction [Glucose results in increased expression of NOS2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of NOS2 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of NOS2 protein]; ruboxistaurin inhibits the reaction [Glucose results in increased expression of NOS2 protein] SOD1 protein inhibits the reaction [Glucose results in increased expression of NOS2 mRNA]; SOD1 protein inhibits the reaction [Glucose results in increased expression of NOS2 protein] 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of NOS2 mRNA]; [Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOS2 protein; CDK9 protein affects the reaction [Glucose results in increased expression of NOS2 mRNA]; Prodigiosin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOS2 protein]; prolinedithiocarbamate inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOS2 protein]; Silymarin inhibits the reaction [[Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein] |
CTD |
PMID:19587355 PMID:21925195 PMID:22363694 PMID:22425406 PMID:22467055 PMID:23061969 PMID:23770986 PMID:29753610 PMID:30076216 PMID:32942007 PMID:33631230 PMID:36462176 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression increases expression multiple interactions increases O-linked glycosylation decreases phosphorylation |
ISO EXP |
Glucose deficiency results in decreased expression of NOS3 protein; Glucose results in decreased expression of NOS3 mRNA; Glucose results in decreased expression of NOS3 protein Glucose results in increased expression of NOS3 mRNA; Glucose results in increased expression of NOS3 protein Glucose results in decreased expression of and results in decreased phosphorylation of NOS3 protein; pimagedine inhibits the reaction [Glucose results in decreased expression of and results in decreased phosphorylation of NOS3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of NOS3 protein]]; [Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [salvianolic acid co-treated with Glucose] inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased phosphorylation of NOS3 protein]; acetovanillone inhibits the reaction [Glucose results in decreased expression of NOS3 protein]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of NOS3 protein]; Glucose inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased phosphorylation of NOS3 protein]; Glucose results in increased expression of and results in increased activity of NOS3 protein; Nitroprusside inhibits the reaction [Glucose deficiency results in decreased expression of NOS3 protein]; Resveratrol inhibits the reaction [Glucose results in decreased expression of NOS3 mRNA]; Rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of NOS3 protein]; salvianolic acid inhibits the reaction [Glucose results in decreased phosphorylation of NOS3 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of NOS3 mRNA]]; TRPM7 affects the reaction [Glucose results in decreased expression of NOS3 protein]; U 0126 inhibits the reaction [TRPM7 affects the reaction [Glucose results in decreased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]]; Wortmannin inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of NOS3 protein]] Glucose results in increased O-linked glycosylation of NOS3 protein |
CTD |
PMID:10502298 PMID:11696579 PMID:15490108 PMID:17075048 PMID:17090780 PMID:17855661 PMID:18483403 PMID:19767878 PMID:19878672 PMID:19924377 PMID:20960276 PMID:24223965 PMID:30431688 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions increases expression |
ISO |
Glucose results in increased expression of and results in increased activity of NOX1 protein; resveratrol inhibits the reaction [Glucose results in increased expression of and results in increased activity of NOX1 protein]; resveratrol inhibits the reaction [Glucose results in increased expression of NOX1 mRNA] |
CTD |
PMID:23731528 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of NOX4 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOX4 mRNA; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NOX4 mRNA]; diphenyliodonium inhibits the reaction [Glucose results in increased expression of NOX4 protein]; farrerol inhibits the reaction [Glucose results in increased expression of NOX4 mRNA]; farrerol inhibits the reaction [Glucose results in increased expression of NOX4 protein] Glucose results in increased expression of NOX4 mRNA; Glucose results in increased expression of NOX4 protein [Glucose co-treated with TGFB1 protein] results in increased expression of NOX4 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of NOX4 protein]; FOXP1 protein inhibits the reaction [Glucose results in increased expression of NOX4 protein] |
CTD |
PMID:29702141 PMID:31494106 PMID:31838053 PMID:35961541 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npas3 |
neuronal PAS domain protein 3 |
decreases expression |
ISO |
Glucose results in decreased expression of NPAS3 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
cinnamic acid inhibits the reaction [Glucose results in increased expression of NPPA protein]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of NPPA mRNA]]; Metformin inhibits the reaction [Glucose results in increased expression of NPPA protein]; NPPA protein inhibits the reaction [SLC5A2 protein results in increased uptake of Glucose]; Propofol inhibits the reaction [Glucose results in increased expression of NPPA mRNA]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of NPPA mRNA]] Glucose results in increased expression of NPPA mRNA; Glucose results in increased expression of NPPA protein |
CTD |
PMID:15127950 PMID:24810525 PMID:30144576 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Npr1 |
natriuretic peptide receptor 1 |
increases expression |
ISO |
Glucose results in increased expression of NPR1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505
|
|
G |
Npy |
neuropeptide Y |
increases expression multiple interactions decreases expression |
EXP ISO |
Glucose deficiency results in increased expression of NPY mRNA; Glucose results in increased expression of NPY protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NPY mRNA 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased expression of NPY protein]]; Dexamethasone inhibits the reaction [Glucose results in increased expression of NPY protein] Glucose results in decreased expression of NPY mRNA; Glucose results in decreased expression of NPY protein |
CTD |
PMID:11177238 PMID:16210367 PMID:18627777 PMID:31778773 PMID:37567420 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
Glucose results in increased expression of NQO1 mRNA; Glucose results in increased expression of NQO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein promotes the reaction [Glucose results in increased expression of NQO1 protein]]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; NQO1 gene mutant form promotes the reaction [Glucose results in increased chemical synthesis of Hydrogen Peroxide]; SMARCA4A protein promotes the reaction [Glucose results in increased expression of NQO1 protein] [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein]; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA]]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [Glucose results in increased expression of NQO1 mRNA] Glucose deficiency results in increased expression of NQO1 protein Glucose results in decreased expression of NQO1 mRNA; Glucose results in decreased expression of NQO1 protein solanesol inhibits the reaction [Glucose results in decreased expression of NQO1 mRNA]; solanesol inhibits the reaction [Glucose results in decreased expression of NQO1 protein] |
CTD |
PMID:17178593 PMID:27558805 PMID:29211853 PMID:29457851 PMID:29649567 PMID:29719095 PMID:33270355 PMID:35191607 PMID:37586544 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose |
CTD |
PMID:22062806 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
decreases expression |
ISO |
Glucose results in decreased expression of NR1D2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of NR1H2 mRNA; Glucose results in decreased expression of NR1H2 protein morroniside inhibits the reaction [Glucose results in decreased expression of NR1H2 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of NR1H2 protein] |
CTD |
PMID:34485530 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of NR1H3 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of NR1H3 protein] |
CTD |
PMID:23647015 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
ISO |
Glucose affects the expression of NR1H4 mRNA |
CTD |
PMID:36156098 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
decreases expression increases expression multiple interactions decreases activity |
ISO |
Glucose results in decreased expression of NR1I2 mRNA Glucose results in increased expression of NR1I2 mRNA [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; Ketoconazole inhibits the reaction [NR1I2 protein results in decreased uptake of and results in decreased metabolism of Glucose]; NR1I2 protein results in decreased uptake of and results in decreased metabolism of Glucose; Polyphenols inhibits the reaction [Glucose results in decreased activity of NR1I2 protein]; resveratrol inhibits the reaction [NR1I2 protein results in decreased uptake of and results in decreased metabolism of Glucose]; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose] |
CTD |
PMID:21682256 PMID:22363694 PMID:24204015 PMID:26616219 PMID:36156098 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases metabolic processing |
ISO |
NR1I3 mRNA results in decreased metabolism of Glucose |
CTD |
PMID:32428594 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
Glucose affects the reaction [NR2F1 protein binds to SHBG promoter] |
CTD |
PMID:17992261 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
NR3C1 protein affects the metabolism of and affects the abundance of Glucose |
CTD |
PMID:15919808 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrbp2 |
nuclear receptor binding protein 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of NRBP2 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of NRBP2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 7:107,798,642...107,805,225
Ensembl chr 7:107,799,497...107,805,230
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions increases transport |
EXP ISO |
[NRG1 protein binds to ERBB3 protein] which results in increased transport of Glucose; MAPK1 protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; MAPK3 protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; PDK1 protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; PRKCZ protein promotes the reaction [NRG1 protein results in increased transport of Glucose]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [NRG1 protein results in increased transport of Glucose] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of NRG1 mRNA |
CTD |
PMID:14711829 PMID:37567420 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrip2 |
nuclear receptor interacting protein 2 |
decreases expression |
ISO |
Glucose results in decreased expression of NRIP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:161,673,964...161,684,055
Ensembl chr 4:161,639,356...161,684,070
|
|
G |
Nt5c1a |
5'-nucleotidase, cytosolic IA |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of NT5C1A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:135,473,107...135,494,400
Ensembl chr 5:135,473,231...135,499,338
|
|
G |
Nt5dc2 |
5'-nucleotidase domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NT5DC2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537
|
|
G |
Ntm |
neurotrimin |
multiple interactions increases expression |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of NTM mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NTM mRNA; fucoxanthin inhibits the reaction [Glucose results in increased expression of NTM mRNA] |
CTD |
PMID:33448797 PMID:37567420 |
|
NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595
|
|
G |
Nts |
neurotensin |
increases transport |
EXP |
NTS protein results in increased transport of Glucose |
CTD |
PMID:11208724 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
ISO |
Glucose results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nudt8 |
nudix hydrolase 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NUDT8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:201,293,660...201,295,233
Ensembl chr 1:201,292,619...201,295,224
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of NUF2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases abundance |
ISO |
NUPR1 results in decreased abundance of Glucose |
CTD |
PMID:16822955 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Nutm1 |
NUT midline carcinoma, family member 1 |
decreases expression |
ISO |
Glucose results in decreased expression of NUTM1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 3:99,053,510...99,064,311
Ensembl chr 3:99,053,510...99,064,311
|
|
G |
Nxnl1 |
nucleoredoxin-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of NXNL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:18,270,604...18,279,797
Ensembl chr16:18,262,688...18,279,987
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of NXPE3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694
|
|
G |
Nxpe4 |
neurexophilin and PC-esterase domain family member 4 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of NXPE4 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of NXPE4 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 8:48,502,697...48,744,101
Ensembl chr 8:48,722,440...48,744,100
|
|
G |
Nxph4 |
neurexophilin 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of NXPH4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:63,367,758...63,376,579
Ensembl chr 7:63,367,761...63,376,579
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of OAS1G mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of OAS2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Oas3 |
2'-5'-oligoadenylate synthetase 3 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of OAS3 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of OAS3 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr12:35,779,028...35,802,781
Ensembl chr12:35,779,022...35,802,781
|
|
G |
Oasl |
2'-5'-oligoadenylate synthetase-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of OASL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Obscn |
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of OBSCN mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of OBSCN mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of OBSCN mRNA |
CTD |
PMID:31525975 PMID:37567420 |
|
NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of OCLN mRNA; Glucose results in decreased expression of OCLN protein MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN protein] |
CTD |
PMID:21617913 PMID:31655124 PMID:34464088 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Glucose results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Olfml1 |
olfactomedin-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of OLFML1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:161,478,129...161,502,541
Ensembl chr 1:161,478,242...161,502,537
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions increases expression |
ISO |
acetovanillone inhibits the reaction [Glucose results in increased expression of OLR1 mRNA] |
CTD |
PMID:19878672 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
decreases expression multiple interactions increases expression |
EXP ISO |
Glucose results in decreased expression of OPA1 protein [Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA] Glucose results in increased expression of OPA1 mRNA cinnamic acid inhibits the reaction [Glucose results in decreased expression of OPA1 protein]; Metformin inhibits the reaction [Glucose results in decreased expression of OPA1 protein] |
CTD |
PMID:27684054 PMID:30144576 PMID:33962019 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Orc4 |
origin recognition complex, subunit 4 |
decreases expression |
ISO |
Glucose results in decreased expression of ORC4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:33,290,844...33,334,022
Ensembl chr 3:33,294,355...33,333,824
|
|
G |
Otop1 |
otopetrin 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of OTOP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:72,505,036...72,532,497
Ensembl chr14:72,503,592...72,532,497
|
|
G |
Ovol3 |
ovo-like zinc finger 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of OVOL3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:85,484,956...85,488,592
Ensembl chr 1:85,484,956...85,488,592
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
ISO |
Glucose results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of P2RX2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
EXP |
Glucose results in increased expression of P2RX7 mRNA |
CTD |
PMID:21832250 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry10 |
P2Y receptor family member 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of P2RY10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:72,121,558...72,207,174
Ensembl chr X:72,111,264...72,212,265
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
increases expression |
ISO |
Glucose deficiency results in increased expression of P4HA1 protein |
CTD |
PMID:22314686 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of P4HB protein Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of P4HB protein]; Metformin inhibits the reaction [Glucose results in increased expression of P4HB protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pabpc1l |
poly(A) binding protein, cytoplasmic 1-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PABPC1L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:152,692,825...152,725,997
Ensembl chr 3:152,693,700...152,725,997
|
|
G |
Pacsin1 |
protein kinase C and casein kinase substrate in neurons 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of PACSIN1 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of PACSIN1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr20:5,718,134...5,768,064
Ensembl chr20:5,719,857...5,765,313
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
increases expression |
ISO |
Glucose results in increased expression of PAFAH1B1 protein |
CTD |
PMID:23776576 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Paip2 |
poly(A) binding protein interacting protein 2 |
multiple interactions |
ISO |
Glucose promotes the reaction [PAIP2 protein binds to SLC2A5 3' UTR] |
CTD |
PMID:12820898 |
|
NCBI chr18:27,199,762...27,218,359
Ensembl chr18:27,199,796...27,214,863
|
|
G |
Pak3 |
p21 (RAC1) activated kinase 3 |
decreases expression |
ISO |
Glucose results in decreased expression of PAK3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314
|
|
G |
Pappa2 |
pappalysin 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PAPPA2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:70,873,918...71,147,874
Ensembl chr13:70,876,794...71,147,779
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression increases activity multiple interactions increases expression increases cleavage affects localization increases acetylation |
EXP ISO |
Glucose results in decreased expression of PARP1 mRNA Glucose results in increased activity of PARP1 protein [INS1 protein co-treated with Glucose] results in increased activity of PARP1 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; Quercetin inhibits the reaction [Glucose results in increased cleavage of PARP1 protein]; sesamin inhibits the reaction [Glucose results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein]; SOD1 protein inhibits the reaction [[INS1 protein co-treated with Glucose] results in increased activity of PARP1 protein] Glucose results in increased expression of PARP1 mRNA; Glucose results in increased expression of PARP1 protein modified form [Glucose co-treated with Oxygen deficiency] results in increased activity of PARP1 protein; [Glucose deficiency co-treated with Acetylcysteine] results in increased cleavage of PARP1 protein; [Glucose deficiency co-treated with CAT] results in increased cleavage of PARP1 protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [Glucose results in increased activity of PARP1 protein]; ERCC1 protein affects the reaction [Glucose results in increased expression of PARP1 mRNA]; ERCC4 protein affects the reaction [Glucose results in increased expression of PARP1 mRNA]; Glucose promotes the reaction [PARP1 protein binds to MMP9 promoter]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of INSR protein]]; PARP1 protein affects the reaction [Glucose promotes the reaction [JUN protein binds to MMP9 promoter]]; PARP1 protein affects the reaction [Glucose promotes the reaction [RELA protein binds to MMP9 promoter]]; PARP1 protein affects the reaction [Glucose results in decreased expression of CYTB mRNA]; PARP1 protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]; PARP1 protein affects the reaction [Glucose results in increased expression of MMP9 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of PARP1 protein modified form]; SIRT1 protein inhibits the reaction [Glucose promotes the reaction [PARP1 protein binds to MMP9 promoter]]; SIRT1 protein inhibits the reaction [Glucose results in increased acetylation of PARP1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased activity of PARP1 protein] Glucose deficiency inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]; PARP1 protein affects the reaction [Glucose results in increased ADP-ribosylation of GAPDH protein] Glucose affects the localization of PARP1 protein |
CTD |
PMID:14523042 PMID:17309078 PMID:18004065 PMID:18545258 PMID:21031461 PMID:21818840 PMID:22228707 PMID:22524206 PMID:22639866 PMID:24218232 PMID:27288104 PMID:28478229 PMID:29095437 PMID:35191607 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp14 |
poly (ADP-ribose) polymerase family, member 14 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PARP14 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:64,902,848...64,934,916
Ensembl chr11:64,902,785...64,934,916
|
|
G |
Pax3 |
paired box 3 |
multiple interactions decreases expression |
ISO EXP |
alpha-Tocopherol inhibits the reaction [Glucose results in decreased expression of PAX3 mRNA]; S-ethyl glutathione inhibits the reaction [Glucose results in decreased expression of PAX3 mRNA] |
CTD |
PMID:12739027 PMID:21818840 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pax5 |
paired box 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PAX5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pax6 |
paired box 6 |
decreases expression multiple interactions |
EXP ISO |
Glucose results in decreased expression of PAX6 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of PAX6 mRNA |
CTD |
PMID:21818840 PMID:37567420 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pbk |
PDZ binding kinase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PBK mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pbld1 |
phenazine biosynthesis-like protein domain containing 1 |
increases expression |
ISO |
Glucose results in increased expression of PBLD1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr20:25,551,274...25,566,543
Ensembl chr20:25,551,275...25,565,614
|
|
G |
Pbx4 |
PBX homeobox 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PBX4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:19,555,089...19,590,054
Ensembl chr16:19,555,090...19,590,014
|
|
G |
Pc |
pyruvate carboxylase |
increases oxidation affects expression |
ISO EXP |
PC protein results in increased oxidation of Glucose Glucose affects the expression of PC mRNA |
CTD |
PMID:23504317 PMID:24349266 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pcdh10 |
protocadherin 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PCDH10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190
|
|
G |
Pcdh17 |
protocadherin 17 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of PCDH17 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999
|
|
G |
Pcdhga8 |
protocadherin gamma subfamily A, 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of PCDHGA8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:29,553,882...29,667,865
Ensembl chr18:29,493,954...29,667,868
|
|
G |
Pcdhgb6 |
protocadherin gamma subfamily B, 6 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of PCDHGB6 mRNA] |
CTD |
PMID:33448797 |
|
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
ISO |
[Glucose deficiency co-treated with ALB protein] results in decreased expression of PCK1 mRNA; [Glucose deficiency co-treated with alpha-Linolenic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Clofibrate] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Docosahexaenoic Acids] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Linoleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with palmitoleic acid] results in increased expression of PCK1 mRNA Glucose results in increased expression of PCK1 mRNA |
CTD |
PMID:8536680 PMID:36156098 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
multiple interactions increases expression |
ISO |
Catechin inhibits the reaction [Glucose results in increased expression of PCK2 protein]; Plant Extracts inhibits the reaction [Glucose results in increased expression of PCK2 protein] |
CTD |
PMID:24262486 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
decreases expression |
ISO |
Glucose results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
EXP ISO |
resveratrol inhibits the reaction [Glucose results in increased expression of PCNA protein]; rosiglitazone inhibits the reaction [Glucose results in increased expression of PCNA protein] [cobaltous chloride co-treated with Glucose] results in increased expression of PCNA mRNA; [cobaltous chloride co-treated with Glucose] results in increased expression of PCNA protein; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of PCNA mRNA]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of PCNA protein] |
CTD |
PMID:18665442 PMID:24971582 PMID:25192544 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of PCSK2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of PCSK9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pde11a |
phosphodiesterase 11A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PDE11A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions |
ISO |
Glucose inhibits the reaction [Dichloroacetic Acid results in decreased phosphorylation of PDHA1 protein] |
CTD |
PMID:31654802 |
|
NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pdhb |
pyruvate dehydrogenase E1 subunit beta |
affects expression |
EXP |
Glucose affects the expression of PDHB mRNA |
CTD |
PMID:24349266 |
|
NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
ISO |
Glucose results in decreased expression of PDIA3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Glucose results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
decreases expression |
ISO |
Glucose results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects expression |
EXP ISO |
PDK1 protein promotes the reaction [NRG1 protein results in increased transport of Glucose] Glucose affects the reaction [Fusaric Acid results in increased expression of PDK1 mRNA]; Glucose affects the reaction [Fusaric Acid results in increased expression of PDK1 protein] Glucose affects the expression of PDK1 mRNA |
CTD |
PMID:14711829 PMID:24349266 PMID:31654802 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
affects expression |
EXP |
Glucose affects the expression of PDK2 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of PDK4 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PDK4 mRNA |
CTD |
PMID:17178593 PMID:37567420 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp1 |
pyruvate dehydrogenase phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
[Dexamethasone results in decreased oxidation of Glucose] which results in increased phosphorylation of and results in decreased activity of PDP1 protein |
CTD |
PMID:20181797 |
|
NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
multiple interactions affects localization decreases expression affects expression increases expression increases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose affects the localization of PDX1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein]; [Glucose co-treated with INS protein] affects the localization of PDX1 protein; [Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein; [SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; [wortmannin co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; calyculin A inhibits the reaction [Glucose affects the localization of PDX1 protein]; Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein; Okadaic Acid inhibits the reaction [Glucose affects the localization of PDX1 protein]; Palmitic Acid inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [[Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein]; wortmannin inhibits the reaction [Glucose affects the localization of PDX1 protein]; wortmannin inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein] Glucose results in decreased expression of PDX1 protein Glucose affects the expression of PDX1 mRNA lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of PDX1 mRNA] Glucose results in increased activity of PDX1 promoter [copper bis(3,5-diisopropylsalicylate) co-treated with Glucose] results in increased expression of PDX1 protein; [ebselen co-treated with Glucose] results in increased expression of PDX1 protein; [Glucose co-treated with INS1 protein] affects the localization of PDX1 protein; [Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein; [Metformin co-treated with Glucose] affects the localization of PDX1 protein; calyculin A inhibits the reaction [Glucose affects the localization of PDX1 protein]; Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein; IL1B protein inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]; lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]; Okadaic Acid inhibits the reaction [Glucose affects the localization of PDX1 protein]; Palmitic Acid inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]; PDX1 protein affects the reaction [bisphenol A promotes the reaction [Glucose results in increased secretion of INS protein]]; rosiglitazone promotes the reaction [Glucose results in increased activity of PDX1 promoter]; SB 203580 inhibits the reaction [[Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose affects the localization of PDX1 protein]; TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]]; wortmannin inhibits the reaction [Glucose affects the localization of PDX1 protein] |
CTD |
PMID:9873045 PMID:11574405 PMID:16489446 PMID:22558381 PMID:23795780 PMID:24349266 PMID:28774890 More...
|
|
NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
increases expression increases secretion |
ISO |
Glucose deficiency results in increased expression of PEBP1 protein Glucose deficiency results in increased secretion of PEBP1 protein |
CTD |
PMID:22314686 PMID:24802182 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
ISO |
Glucose results in decreased expression of PECAM1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Peg10 |
paternally expressed 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PEG10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Penk |
proenkephalin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PENK mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PENK mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Per3 |
period circadian regulator 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of PER3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
Glucose results in increased expression of PF4 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Phb2 |
prohibitin 2 |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of PHB2 protein Inositol inhibits the reaction [Glucose results in decreased expression of PHB2 protein] |
CTD |
PMID:35243728 |
|
NCBI chr 4:157,517,662...157,522,268
Ensembl chr 4:157,517,577...157,522,272
|
|
G |
Phf11 |
PHD finger protein 11 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of PHF11 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:33,390,290...33,414,647
Ensembl chr15:33,390,292...33,413,009
|
|
G |
Phf19 |
PHD finger protein 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PHF19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PHGDH mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Glucose results in increased expression of PHLDA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pi16 |
peptidase inhibitor 16 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PI16 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:7,376,073...7,385,386
Ensembl chr20:7,376,126...7,385,383
|
|
G |
Pianp |
PILR alpha associated neural protein |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PIANP mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:157,796,425...157,804,842
Ensembl chr 4:157,798,808...157,804,842
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
ISO |
Glucose results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [PIK3R1 protein binds to IRS1 protein] |
CTD |
PMID:10430617 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in decreased expression of PIM1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in decreased expression of PIM1 protein]]; resveratrol inhibits the reaction [Glucose results in decreased expression of PIM1 mRNA]; resveratrol inhibits the reaction [Glucose results in decreased expression of PIM1 protein] Glucose results in decreased expression of PIM1 mRNA; Glucose results in decreased expression of PIM1 protein |
CTD |
PMID:27049278 |
|
NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pimreg |
PICALM interacting mitotic regulator |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PIMREG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791
|
|
G |
Pink1 |
PTEN induced kinase 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of PINK1 mRNA Glucose results in decreased expression of PINK1 protein Inositol inhibits the reaction [Glucose results in decreased expression of PINK1 protein] [Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA] |
CTD |
PMID:33962019 PMID:35243728 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
multiple interactions decreases methylation increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased methylation of PIP5K1B gene]; fucoxanthin inhibits the reaction [Glucose results in increased expression of PIP5K1B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Pitpnm3 |
PITPNM family member 3 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of PITPNM3 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of PITPNM3 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr10:56,674,697...56,766,552
Ensembl chr10:56,676,261...56,766,584
|
|
G |
Pjvk |
pejvakin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PJVK mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:61,594,644...61,605,051
Ensembl chr 3:61,596,641...61,605,045
|
|
G |
Pklr |
pyruvate kinase L/R |
increases expression increases activity multiple interactions |
ISO EXP |
Glucose results in increased expression of PKLR mRNA Glucose results in increased activity of PKLR protein 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile inhibits the reaction [Glucose results in increased expression of PKLR mRNA]; Fatty Acids affects the reaction [Glucose results in increased activity of PKLR protein]; Fatty Acids, Unsaturated inhibits the reaction [Glucose results in increased expression of PKLR mRNA]; Glucose promotes the reaction [H3F4 protein modified form binds to PKLR promoter]; Glucose promotes the reaction [H4C16 protein modified form binds to PKLR promoter]; Metformin inhibits the reaction [Glucose results in increased expression of PKLR mRNA]; pirinixic acid inhibits the reaction [Glucose results in increased activity of PKLR protein]; pirinixic acid inhibits the reaction [Glucose results in increased expression of PKLR mRNA] |
CTD |
PMID:2824512 PMID:8144600 PMID:16644726 PMID:16790840 PMID:17786952 PMID:27226639 PMID:31974165 More...
|
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions increases uptake |
ISO |
Fulvestrant inhibits the reaction [Glucose promotes the reaction [Estradiol results in increased phosphorylation of PKM protein]]; Glucose affects the reaction [Fusaric Acid results in increased expression of PKM mRNA]; Glucose affects the reaction [Fusaric Acid results in increased expression of PKM protein]; Glucose deficiency promotes the reaction [SAICAR binds to and results in increased activity of PKM protein]; Glucose promotes the reaction [Estradiol results in increased phosphorylation of PKM protein] PKM protein results in increased uptake of Glucose |
CTD |
PMID:22574221 PMID:23086999 PMID:31654802 PMID:32078667 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pla2g12b |
phospholipase A2, group XIIB |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PLA2G12B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:27,369,196...27,389,517
Ensembl chr20:27,370,266...27,388,743
|
|
G |
Plagl1 |
PLAG1 like zinc finger 1 |
decreases expression |
ISO |
Glucose results in decreased expression of PLAGL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Glucose results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Glucose results in decreased expression of PLAU mRNA |
CTD |
PMID:31655124 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions increases expression |
EXP |
acetovanillone inhibits the reaction [Glucose results in increased expression of PLCB1 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB1 protein] |
CTD |
PMID:20691780 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcb2 |
phospholipase C, beta 2 |
multiple interactions increases expression |
EXP |
acetovanillone inhibits the reaction [Glucose results in increased expression of PLCB2 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB2 protein] |
CTD |
PMID:20691780 |
|
NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302
|
|
G |
Plg |
plasminogen |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PLG mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PLIN1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression |
ISO |
Glucose results in increased expression of PLK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plod2 |
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 |
increases expression |
ISO |
Glucose results in increased expression of PLOD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
|
|
G |
Pls3 |
plastin 3 |
increases expression |
ISO |
Glucose results in increased expression of PLS3 mRNA |
CTD |
PMID:10026205 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Plxdc1 |
plexin domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PLXDC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:82,922,499...82,982,124
Ensembl chr10:82,922,508...82,982,130
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:33962019 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pnkp |
polynucleotide kinase 3'-phosphatase |
decreases expression |
ISO |
Glucose results in decreased expression of PNKP mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 1:95,341,465...95,346,921
Ensembl chr 1:95,341,620...95,346,920
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of PNPLA2 protein |
CTD |
PMID:24802182 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions decreases expression increases response to substance |
ISO EXP |
POMC inhibits the reaction [INS1 results in increased uptake of Glucose] Glucose results in decreased expression of POMC mRNA Glucose results in increased susceptibility to POMC protein |
CTD |
PMID:18310442 PMID:18627777 PMID:19489000 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pon2 |
paraoxonase 2 |
affects abundance |
ISO |
PON2 gene polymorphism affects the abundance of Glucose |
CTD |
PMID:16185677 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Popdc3 |
popeye domain containing 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of POPDC3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:48,772,397...48,800,677
Ensembl chr20:48,772,462...48,800,593
|
|
G |
Pou4f1 |
POU class 4 homeobox 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of POU4F1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:81,253,714...81,260,057
Ensembl chr15:81,257,781...81,259,728
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects localization |
ISO |
Glucose affects the localization of POU5F1 protein |
CTD |
PMID:33992720 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions affects expression affects metabolic processing affects abundance |
ISO EXP |
Glucose results in decreased expression of PPARA protein [pirinixic acid binds to and results in increased activity of PPARA protein] which affects the metabolism of Glucose; [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased susceptibility to Glucose; Allopurinol inhibits the reaction [Glucose results in decreased expression of PPARA protein]; HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein]; PPARA protein promotes the reaction [Glucose results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [Glucose results in decreased expression of PPARA protein]; TXNIP mRNA promotes the reaction [Glucose results in decreased expression of PPARA protein] Glucose results in decreased expression of PPARA mRNA; Glucose results in decreased expression of PPARA protein [Bezafibrate binds to and results in increased activity of PPARA protein] which results in decreased abundance of Glucose; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of PPARA mRNA; Allopurinol inhibits the reaction [Glucose results in decreased expression of PPARA protein]; Quercetin inhibits the reaction [Glucose results in decreased expression of PPARA protein]; TXNIP mRNA promotes the reaction [Glucose results in decreased expression of PPARA protein] Glucose affects the expression of PPARA mRNA [Acetylglucosamine co-treated with Glucose] binds to PPARA protein; [Atropine co-treated with Glucose] binds to PPARA protein; [Budesonide co-treated with Glucose] binds to PPARA protein; [Enalapril co-treated with Glucose] binds to PPARA protein; [gamma-Aminobutyric Acid co-treated with Glucose] binds to PPARA protein; [gedunin co-treated with Glucose] binds to PPARA protein; [GW 7647 binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium]; [Oleylethanolamide binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium]; [pirinixic acid binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium]; [Pyrazinamide co-treated with Glucose] binds to PPARA protein; [Saccharin co-treated with Glucose] binds to PPARA protein; [salicylamide co-treated with Glucose] binds to PPARA protein; [Tolazoline co-treated with Glucose] binds to PPARA protein; [Tolmetin co-treated with Glucose] binds to PPARA protein; Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; PPARA protein promotes the reaction [pirinixic acid results in decreased abundance of Glucose]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Resveratrol inhibits the reaction [Glucose results in decreased expression of PPARA protein]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] PPARA protein affects the metabolism of Glucose PPARA protein affects the abundance of Glucose |
CTD |
PMID:15878969 PMID:16600694 PMID:16777972 PMID:18469201 PMID:18812576 PMID:18854422 PMID:19017711 PMID:20059764 PMID:20404010 PMID:23090186 PMID:23647015 PMID:24349266 PMID:31063766 PMID:32613381 More...
|
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects expression multiple interactions decreases expression |
EXP ISO |
Glucose affects the expression of PPARD mRNA [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of PPARD mRNA HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein] |
CTD |
PMID:24349266 PMID:31063766 PMID:32613381 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased expression of PPARG protein]]; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of PPARG mRNA; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Fulvestrant inhibits the reaction [bisphenol A inhibits the reaction [INS protein results in increased uptake of Glucose]]]; Rosiglitazone inhibits the reaction [Glucose results in decreased expression of PPARG protein] Glucose results in decreased expression of PPARG mRNA; Glucose results in decreased expression of PPARG protein [ciglitazone binds to and results in increased activity of PPARG protein] which results in increased transport of Glucose; HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]; PPARG protein inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:15878969 PMID:18063688 PMID:19609456 PMID:21333731 PMID:31063766 PMID:32407875 PMID:32613381 PMID:32623698 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions increases expression affects expression increases acetylation |
ISO EXP |
Glucose deficiency results in decreased expression of PPARGC1A mRNA; Glucose results in decreased expression of PPARGC1A mRNA; Glucose results in decreased expression of PPARGC1A protein Inositol inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; SRT1720 inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein] Glucose deficiency results in increased expression of PPARGC1A mRNA; Glucose results in increased expression of PPARGC1A mRNA Glucose affects the expression of PPARGC1A mRNA 4-phenylbutyric acid inhibits the reaction [Glucose results in decreased expression of PPARGC1A mRNA]; [SIRT1 protein co-treated with Resveratrol] affects the reaction [Glucose affects the expression of PPARGC1A protein]; AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; CEBPB protein inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; DDIT3 affects the reaction [Glucose results in decreased expression of PPARGC1A mRNA]; Glucose inhibits the reaction [DDIT3 protein binds to PPARGC1A promoter]; Metformin inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; morroniside inhibits the reaction [Glucose results in decreased expression of PPARGC1A mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein] 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]]; [Pyruvic Acid co-treated with Glucose] results in decreased acetylation of PPARGC1A protein; ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]; Glucose promotes the reaction [YY1 protein binds to PPARGC1A promoter]; Nitroprusside inhibits the reaction [Glucose deficiency results in decreased expression of PPARGC1A mRNA]; YY1 promotes the reaction [Glucose results in decreased expression of PPARGC1A protein] Glucose results in increased acetylation of PPARGC1A protein |
CTD |
PMID:17855661 PMID:19071085 PMID:23090186 PMID:24349266 PMID:26811028 PMID:28482072 PMID:31639451 PMID:33957017 PMID:33962019 PMID:34485530 PMID:35243728 PMID:35445903 PMID:36156098 More...
|
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]; Y 27632 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
Glucose results in increased expression of PRDX1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
decreases expression |
ISO |
Glucose results in decreased expression of PREX1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; Apigenin inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; Glucose inhibits the reaction [SGA 360 results in increased phosphorylation of PRKAA1 protein]; Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein; Metformin inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; PRKAA1 protein affects the reaction [Metformin inhibits the reaction [Glucose deficiency results in increased chemical synthesis of Reactive Oxygen Species]]; PRKAA1 protein affects the reaction [Ribonucleosides inhibits the reaction [Glucose deficiency results in increased chemical synthesis of Reactive Oxygen Species]]; PRKAA1 protein affects the reaction [Rosiglitazone inhibits the reaction [Glucose affects the localization of NCF1 protein]]; PRKAA1 protein affects the reaction [Rosiglitazone inhibits the reaction [Glucose affects the localization of RAC1 protein]]; PRKAA1 protein affects the reaction [Rosiglitazone inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein] [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]; Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein; PRKAA1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]] |
CTD |
PMID:16380484 PMID:16873680 PMID:17916771 PMID:18482975 PMID:19052259 PMID:23090186 PMID:31225620 PMID:31974165 More...
|
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions decreases expression affects response to substance |
ISO EXP |
[Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]] which results in decreased abundance of Triglycerides; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]; Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein; PRKAA2 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased abundance of Triglycerides]]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in increased abundance of Triglycerides]]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in increased expression of FASN protein]]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]; SIRT1 protein promotes the reaction [[Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]] which results in decreased abundance of Triglycerides] Glucose results in decreased expression of PRKAA2 mRNA; Glucose results in decreased expression of PRKAA2 protein PRKAA2 protein mutant form affects the susceptibility to Glucose deficiency [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]; Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; PRKAA2 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]] |
CTD |
PMID:15806154 PMID:18482975 PMID:19052259 PMID:23090186 PMID:24349266 PMID:31974165 More...
|
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of PRKAR2B mRNA 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside inhibits the reaction [[Oxygen co-treated with Glucose deficiency] results in decreased expression of PRKAR2B protein]; [Oxygen co-treated with Glucose deficiency] results in decreased expression of PRKAR2B protein; rhodioloside inhibits the reaction [[Oxygen co-treated with Glucose deficiency] results in decreased expression of PRKAR2B protein] |
CTD |
PMID:17178593 PMID:24726522 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkca |
protein kinase C, alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucose results in increased phosphorylation of PRKCA protein [Glucose co-treated with Silymarin] results in increased phosphorylation of PRKCA protein; Glucose promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of PRKCA protein] Glucose promotes the reaction [zinc chloride affects the localization of and results in increased activity of PRKCA protein] |
CTD |
PMID:20800666 PMID:22162761 PMID:29753610 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
increases phosphorylation increases expression multiple interactions increases activity |
ISO EXP |
Glucose results in increased phosphorylation of PRKCB protein Glucose results in increased expression of PRKCB protein; Glucose results in increased expression of PRKCB protein alternative form Glucose results in increased phosphorylation of and results in increased activity of PRKCB protein; PRKCB protein affects the reaction [Glucose results in increased activity of RELA protein]; PRKCB protein affects the reaction [Glucose results in increased expression of NOS2 protein]; PRKCB protein affects the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PRKCB protein affects the reaction [Glucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; ruboxistaurin inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PRKCB protein] 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of PRKCB protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of PRKCB protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of PRKCB protein]; Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein]; resveratrol inhibits the reaction [Glucose results in increased activity of PRKCB protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of PRKCB protein] |
CTD |
PMID:16285992 PMID:19587355 PMID:20578705 PMID:22162761 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases expression |
EXP ISO |
diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of PRKCD protein] 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of PRKCD protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of PRKCD protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of PRKCD protein]; Mannitol inhibits the reaction [Glucose results in increased expression of PRKCD protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of PRKCD protein] |
CTD |
PMID:12821678 PMID:16285992 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkch |
protein kinase C, eta |
decreases expression |
ISO |
Glucose results in decreased expression of PRKCH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:92,292,000...92,490,663
Ensembl chr 6:92,292,000...92,490,654
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
EXP |
PRKCZ protein promotes the reaction [NRG1 protein results in increased transport of Glucose] |
CTD |
PMID:14711829 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions decreases expression |
EXP |
acetovanillone inhibits the reaction [Glucose results in decreased expression of PRKG1 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in decreased expression of PRKG1 protein]; Glucose results in decreased expression of and results in decreased activity of PRKG1 protein; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased expression of PRKG1 protein]; Reactive Oxygen Species promotes the reaction [Glucose results in decreased expression of PRKG1 protein]; tempol inhibits the reaction [Glucose results in decreased expression of PRKG1 protein] Glucose results in decreased expression of PRKG1 mRNA |
CTD |
PMID:17320767 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prkg2 |
protein kinase cGMP-dependent 2 |
increases expression |
ISO |
Glucose results in increased expression of PRKG2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:10,559,882...10,668,479
Ensembl chr14:10,559,882...10,666,888
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of PRKN protein Inositol inhibits the reaction [Glucose results in decreased expression of PRKN protein] |
CTD |
PMID:35243728 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Prlr |
prolactin receptor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of PRLR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Prnp |
prion protein |
multiple interactions |
ISO |
[PRNP protein results in increased expression of SLC2A1 protein] which results in increased uptake of Glucose |
CTD |
PMID:21265952 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Prok1 |
prokineticin 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PROK1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PROK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250
|
|
G |
Prpf40a |
pre-mRNA processing factor 40 homolog A |
decreases expression |
ISO |
Glucose results in decreased expression of PRPF40A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:37,625,585...37,689,859
Ensembl chr 3:37,627,690...37,690,886
|
|
G |
Prr11 |
proline rich 11 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PRR11 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
|
|
G |
Prr32 |
proline rich 32 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PRR32 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:123,978,010...123,979,928
Ensembl chr X:123,977,985...123,979,942
|
|
G |
Prr33 |
proline rich 33 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of PRR33 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:197,644,903...197,650,774
Ensembl chr 1:197,644,902...197,650,714
|
|
G |
Prrg4 |
proline rich and Gla domain 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PRRG4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:91,214,646...91,243,347
Ensembl chr 3:91,214,653...91,243,273
|
|
G |
Prrt3 |
proline-rich transmembrane protein 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of PRRT3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:146,641,173...146,650,487
Ensembl chr 4:146,641,173...146,650,317
|
|
G |
Prtn3 |
proteinase 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of PRTN3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:9,822,123...9,831,300
Ensembl chr 7:9,822,122...9,831,944
|
|
G |
Psd2 |
pleckstrin and Sec7 domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of PSD2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:27,564,912...27,616,674
Ensembl chr18:27,565,587...27,616,672
|
|
G |
Psen2 |
presenilin 2 |
increases methylation decreases expression multiple interactions |
ISO |
Glucose results in increased methylation of PSEN2 gene Glucose results in decreased expression of PSEN2 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of PSEN2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of PSMA1 protein |
CTD |
PMID:22314686 |
|
NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PSMB10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:33,830,958...33,833,442
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of PSMB5 protein |
CTD |
PMID:24802182 |
|
NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440
|
|
G |
Psmb8 |
proteasome 20S subunit beta 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PSMB8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,652,159...4,655,122
Ensembl chr20:4,652,159...4,655,283
|
|
G |
Psors1c2 |
psoriasis susceptibility 1 candidate 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of PSORS1C2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:3,202,178...3,203,599
Ensembl chr20:3,202,174...3,203,599
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PTAFR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTCH1 protein; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTCH1 protein]; SHH protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTCH1 protein] |
CTD |
PMID:27481074 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Ptgds |
prostaglandin D2 synthase |
decreases secretion |
ISO |
Glucose deficiency results in decreased secretion of PTGDS protein |
CTD |
PMID:24802182 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
increases expression |
EXP |
Glucose results in increased expression of PTGER1 mRNA |
CTD |
PMID:12888618 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
increases expression |
EXP |
Glucose results in increased expression of PTGER4 mRNA; Glucose results in increased expression of PTGER4 protein |
CTD |
PMID:12888618 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
EXP ISO |
Glucose results in increased expression of PTGS1 protein Glucose results in increased expression of PTGS1 mRNA |
CTD |
PMID:12888618 PMID:32942007 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased expression of PTGS2 protein]]; [Oxygen deficiency co-treated with Glucose deficiency] inhibits the reaction [Vehicle Emissions results in increased expression of PTGS2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Catechin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Catechin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased expression of PTGS2 protein]; Rutin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Rutin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of PTGS2 protein] IL1RN protein inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; IL1RN protein inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of PTGS2 protein] Glucose results in increased expression of PTGS2 mRNA; Glucose results in increased expression of PTGS2 protein [Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of PTGS2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein; NFKB1 protein inhibits the reaction [SOD1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein]]; SOD1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein] Glucose results in decreased expression of PTGS2 mRNA; Glucose results in decreased expression of PTGS2 protein |
CTD |
PMID:12888618 PMID:14514642 PMID:16395278 PMID:17178593 PMID:19225232 PMID:19557821 PMID:19861503 PMID:20578705 PMID:21333731 PMID:23770986 PMID:28400208 PMID:29753610 PMID:31655124 PMID:36462176 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptgs2os |
prostaglandin-endoperoxide synthase 2, opposite strand |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of PTGS2OS mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of PTGS2OS mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr13:62,160,002...62,163,710
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions decreases expression |
ISO |
Eucalyptol inhibits the reaction [Glucose results in decreased expression of PTK2 protein]; Glucose inhibits the reaction [IL1B protein results in increased phosphorylation of PTK2 protein] Glucose results in decreased expression of PTK2 mRNA |
CTD |
PMID:30098273 PMID:31483951 PMID:31655124 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptpn7 |
protein tyrosine phosphatase, non-receptor type 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of PTPN7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:46,570,904...46,584,048
Ensembl chr13:46,571,712...46,583,308
|
|
G |
Ptprh |
protein tyrosine phosphatase, receptor type, H |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of PTPRH mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:69,243,704...69,276,294
Ensembl chr 1:69,242,321...69,285,077
|
|
G |
Pvr |
PVR cell adhesion molecule |
increases expression |
ISO |
Glucose results in increased expression of PVR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715
|
|
G |
Pxn |
paxillin |
multiple interactions decreases expression increases expression |
ISO |
Eucalyptol inhibits the reaction [Glucose results in decreased expression of PXN protein]; Eucalyptol inhibits the reaction [Glucose results in increased expression of PXN protein modified form]; RHOA protein inhibits the reaction [Glucose results in decreased expression of PXN protein]; RHOA protein promotes the reaction [Eucalyptol inhibits the reaction [Glucose results in decreased expression of PXN protein]] |
CTD |
PMID:31483951 |
|
NCBI chr12:41,060,791...41,107,952
Ensembl chr12:41,060,791...41,107,931
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions increases expression |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of PYCARD protein]; Quercetin inhibits the reaction [Glucose results in increased expression of PYCARD protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PYCARD protein; Allopurinol inhibits the reaction [Glucose results in increased expression of PYCARD protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PYCARD protein]; Quercetin inhibits the reaction [Glucose results in increased expression of PYCARD protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of PYCARD protein] |
CTD |
PMID:23647015 PMID:29031534 PMID:35191607 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Pygl |
glycogen phosphorylase L |
multiple interactions |
EXP |
Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] |
CTD |
PMID:747652 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Pyy |
peptide YY |
affects expression |
EXP |
Glucose affects the expression of PYY protein |
CTD |
PMID:18627777 |
|
NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,061,161...87,061,815
|
|
G |
R3hdml |
R3H domain containing-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of R3HDML mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:152,171,382...152,182,151
Ensembl chr 3:152,171,382...152,182,151
|
|
G |
Rab40b |
Rab40b, member RAS oncogene family |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of RAB40B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090
|
|
G |
Rab42 |
RAB42, member RAS oncogene family |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of RAB42 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:144,497,159...144,498,829
Ensembl chr 5:144,496,215...144,498,848
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions increases expression increases activity affects localization increases localization |
ISO EXP |
Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]; bisindolylmaleimide I inhibits the reaction [Glucose affects the localization of RAC1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]]; PRKAA1 protein affects the reaction [Rosiglitazone inhibits the reaction [Glucose affects the localization of RAC1 protein]]; Rosiglitazone inhibits the reaction [Glucose affects the localization of RAC1 protein] Glucose results in increased expression of RAC1 protein Glucose results in increased activity of RAC1 protein dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased activity of RAC1 protein]]; Resveratrol inhibits the reaction [Glucose results in increased activity of RAC1 protein] [Resveratrol co-treated with Glucose] results in decreased expression of RAC1 mRNA; Eucalyptol inhibits the reaction [Glucose results in increased expression of RAC1 protein] |
CTD |
PMID:17279352 PMID:17916771 PMID:24659233 PMID:26054749 PMID:31483951 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rad51b |
RAD51 paralog B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of RAD51B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:98,096,525...98,640,988
Ensembl chr 6:98,098,868...98,640,979
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
increases expression |
ISO |
Glucose results in increased expression of RAMP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
increases expression |
ISO |
Glucose results in increased expression of RAMP3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902
|
|
G |
Ranbp17 |
RAN binding protein 17 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of RANBP17 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:17,800,406...18,102,947
Ensembl chr10:17,800,999...18,102,831
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of RARRES2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rasl12 |
RAS-like, family 12 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of RASL12 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of RASL12 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:65,917,840...65,931,885
Ensembl chr 8:65,917,840...65,932,741
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases expression |
ISO |
Fluorometholone inhibits the reaction [Glucose results in increased expression of RB1 protein] |
CTD |
PMID:35264022 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbm3 |
RNA binding motif protein 3 |
increases expression |
ISO |
Glucose results in increased expression of RBM3 mRNA |
CTD |
PMID:10026205 |
|
NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580
|
|
G |
Rbp4 |
retinol binding protein 4 |
increases abundance |
ISO |
RBP4 protein results in increased abundance of Glucose |
CTD |
PMID:31228551 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rbpjl |
recombination signal binding protein for immunoglobulin kappa J region-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of RBPJL mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:153,134,044...153,147,421
Ensembl chr 3:153,134,140...153,146,513
|
|
G |
Rd3 |
RD3 regulator of GUCY2D |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of RD3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:103,551,823...103,562,925
Ensembl chr13:103,552,857...103,562,622
|
|
G |
Rdh10 |
retinol dehydrogenase 10 |
decreases expression |
ISO |
Glucose results in decreased expression of RDH10 mRNA |
CTD |
PMID:25627686 |
|
NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572
|
|
G |
Recql4 |
RecQ like helicase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of RECQL4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization increases expression multiple interactions increases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
Glucose affects the localization of RELA protein Glucose results in increased expression of RELA mRNA; Glucose results in increased expression of RELA protein; Glucose results in increased expression of RELA protein modified form [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of RELA mRNA; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 protein]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of TNF mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of TNF protein]; [Resveratrol affects the localization of RELA protein] which results in decreased susceptibility to Glucose; aspalathin inhibits the reaction [Glucose affects the localization of RELA protein]; Aspirin inhibits the reaction [Glucose results in increased expression of RELA protein]; Bosentan inhibits the reaction [Glucose results in increased activity of RELA protein]; Catechin inhibits the reaction [Glucose affects the localization of RELA protein]; chelerythrine inhibits the reaction [Glucose results in increased activity of RELA protein]; Clofibrate inhibits the reaction [Glucose results in increased expression of RELA protein]; Curcumin inhibits the reaction [Glucose results in increased activity of RELA protein]; epigallocatechin gallate inhibits the reaction [Glucose affects the localization of RELA protein]; Fenofibrate inhibits the reaction [Glucose results in increased expression of RELA protein]; GLO1 inhibits the reaction [Glucose promotes the reaction [RELA protein binds to AGER promoter]]; Glucose promotes the reaction [RELA protein binds to AGER promoter]; Glucose promotes the reaction [RELA protein binds to MMP9 promoter]; Glucose promotes the reaction [RELA protein binds to SRI promoter]; isoangustone A inhibits the reaction [Glucose affects the localization of RELA protein]; Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of RELA protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of RELA protein]; Luteolin inhibits the reaction [Glucose affects the localization of RELA protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose promotes the reaction [RELA protein binds to MMP9 promoter]]; nothofagin inhibits the reaction [Glucose affects the localization of RELA protein]; PARP1 protein affects the reaction [Glucose promotes the reaction [RELA protein binds to MMP9 promoter]]; Phytic Acid inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; Polyphenols inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose affects the localization of RELA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased activity of RELA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of RELA protein]; pyrrolidine dithiocarbamic acid promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of RELA protein]]; Quercetin inhibits the reaction [Glucose affects the localization of RELA protein]; RELA promotes the reaction [Glucose results in increased expression of AGER mRNA]; RELA protein affects the reaction [Glucose affects the localization of MLXIP protein]; RELA protein affects the reaction [Glucose results in decreased expression of SRI protein]; Rutin inhibits the reaction [Glucose affects the localization of RELA protein]; sitaxsentan inhibits the reaction [Glucose results in increased activity of RELA protein]; SN50 peptide inhibits the reaction [Glucose results in increased activity of RELA protein]; swietenine inhibits the reaction [Glucose results in increased expression of RELA protein] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in increased expression of and affects the localization of RELA protein]; ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; Artesunate inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; Gallic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Glucose results in increased expression of and affects the localization of RELA protein; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]]; PRKCB protein affects the reaction [Glucose results in increased activity of RELA protein]; prolinedithiocarbamate inhibits the reaction [Glucose affects the localization of RELA protein]; Quercetin inhibits the reaction [Glucose affects the localization of RELA protein]; Quercetin inhibits the reaction [Glucose results in increased expression of RELA mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of RELA protein]; ruboxistaurin inhibits the reaction [Glucose results in increased activity of RELA protein]; Y 27632 inhibits the reaction [Glucose affects the localization of RELA protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of and affects the localization of RELA protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of RELA protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of RELA protein; [Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Glucose results in increased phosphorylation of and affects the localization of RELA protein; Prodigiosin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of RELA protein]; prolinedithiocarbamate inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of RELA protein]; RELA protein modified form promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 mRNA alternative form]; RELA protein promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 mRNA alternative form]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein] Glucose results in decreased phosphorylation of RELA protein |
CTD |
PMID:12388107 PMID:16395278 PMID:16600694 PMID:19557821 PMID:19587355 PMID:19833897 PMID:19861503 PMID:20200188 PMID:20542118 PMID:21367880 PMID:21682256 PMID:21925195 PMID:22666436 PMID:23376009 PMID:23770986 PMID:24436987 PMID:24513509 PMID:24877639 PMID:25338943 PMID:26341651 PMID:27415824 PMID:28478229 PMID:30031708 PMID:30101366 PMID:31323227 PMID:32613381 PMID:33930463 PMID:36066211 PMID:36462176 PMID:38000455 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
increases expression |
EXP |
Glucose results in increased expression of REN mRNA; Glucose results in increased expression of REN protein |
CTD |
PMID:19861503 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ret |
ret proto-oncogene |
increases expression |
EXP |
Glucose results in increased expression of RET mRNA |
CTD |
PMID:21818840 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Retn |
resistin |
decreases uptake multiple interactions |
ISO |
RETN protein results in decreased uptake of Glucose [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of RETN mRNA |
CTD |
PMID:14671216 PMID:37567420 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Retreg1 |
reticulophagy regulator 1 |
multiple interactions decreases expression |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of RETREG1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:76,335,609...76,474,817
Ensembl chr 2:76,335,609...76,493,898
|
|
G |
Rhd |
Rh blood group, D antigen |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of RHD mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:147,087,479...147,121,716
Ensembl chr 5:147,087,518...147,121,715
|
|
G |
Rhoa |
ras homolog family member A |
increases activity increases expression multiple interactions |
EXP ISO |
Glucose results in increased activity of RHOA protein Glucose results in increased expression of RHOA protein Eucalyptol inhibits the reaction [Glucose results in increased expression of RHOA protein]; RHOA protein inhibits the reaction [Eucalyptol inhibits the reaction [Glucose results in increased expression of GSK3B protein]]; RHOA protein inhibits the reaction [Glucose results in decreased expression of PXN protein]; RHOA protein inhibits the reaction [Glucose results in decreased expression of VCL protein]; RHOA protein promotes the reaction [Eucalyptol inhibits the reaction [Glucose results in decreased expression of PXN protein]]; RHOA protein promotes the reaction [Eucalyptol inhibits the reaction [Glucose results in decreased expression of VCL protein]]; RHOA protein promotes the reaction [Glucose results in increased expression of GSK3B protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased activity of RHOA protein] |
CTD |
PMID:22031849 PMID:23376009 PMID:31483951 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Glucose results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoxf2b |
Rhox homeobox family member 2B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of RHOX6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:116,507,488...116,514,240
Ensembl chr X:116,507,488...116,513,870
|
|
G |
Ribc2 |
RIB43A domain with coiled-coils 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of RIBC2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:116,242,863...116,257,868
Ensembl chr 7:116,242,863...116,257,863
|
|
G |
Rimbp3 |
RIMS binding protein 3 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of RIMBP3 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of RIMBP3 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr11:83,783,816...83,789,391
Ensembl chr11:83,784,244...83,789,082
|
|
G |
Rmi2 |
RecQ mediated genome instability 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of RMI2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:4,829,333...4,837,264
Ensembl chr10:4,830,553...4,837,235
|
|
G |
Rnasel |
ribonuclease L |
multiple interactions |
ISO |
[2',5'-oligoadenylate binds to and results in increased activity of RNASEL protein] which results in increased uptake of Glucose |
CTD |
PMID:24651439 |
|
NCBI chr13:65,894,990...65,910,354
Ensembl chr13:65,901,459...65,908,704
|
|
G |
Rnf180 |
ring finger protein 180 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of RNF180 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:36,330,285...36,511,168
Ensembl chr 2:36,330,292...36,512,614
|
|
G |
Rnf24 |
ring finger protein 24 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of RNF24 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:118,520,459...118,575,213
Ensembl chr 3:118,525,349...118,541,080
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions increases expression |
EXP ISO |
[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein] Glucose results in increased expression of ROCK1 protein Eucalyptol inhibits the reaction [Glucose results in increased expression of ROCK1 protein] |
CTD |
PMID:25305180 PMID:31483951 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rpl13a |
ribosomal protein L13A |
multiple interactions |
EXP |
RPL13A protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 1:95,609,374...95,612,557
Ensembl chr 1:95,609,370...95,620,463
|
|
G |
Rps12 |
ribosomal protein S12 |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of RPS12 protein |
CTD |
PMID:22314686 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
EXP |
resveratrol inhibits the reaction [Glucose results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:20332614 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO |
Glucose results in increased phosphorylation of RPS6KB1 protein HU 308 inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30459625 PMID:35445903 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rpsa |
ribosomal protein SA |
decreases expression multiple interactions |
ISO EXP |
Glucose deficiency results in decreased expression of RPSA protein RPSA protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 PMID:22314686 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Rptn |
repetin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of RPTN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:179,061,768...179,066,056
Ensembl chr 2:179,060,017...179,065,910
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of H2-AB1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-DMa |
RT1 class II, locus DMa |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of H2-DMA mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of H2-DMB1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of H2-M3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Rtn3 |
reticulon 3 |
multiple interactions increases expression |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of RTN3 protein]; Metformin inhibits the reaction [Glucose results in increased expression of RTN3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275
|
|
G |
Rtn4rl2 |
reticulon 4 receptor-like 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of RTN4RL2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:69,954,557...69,971,108
Ensembl chr 3:69,955,169...69,971,488
|
|
G |
Rtp4 |
receptor (chemosensory) transporter protein 4 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of RTP4 mRNA [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of RTP4 mRNA; fucoxanthin inhibits the reaction [Glucose results in increased expression of RTP4 mRNA] |
CTD |
PMID:33448797 PMID:37567420 |
|
NCBI chr11:77,237,341...77,249,194
Ensembl chr11:77,238,216...77,335,437
|
|
G |
Rubcnl |
rubicon like autophagy enhancer |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of RUBCNL mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:50,332,458...50,377,494
Ensembl chr15:50,332,418...50,400,849
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions decreases expression |
ISO EXP |
Glucose results in increased expression of RUNX2 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]]; [EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA; [EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein; Melatonin inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]; Melatonin inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of RUNX2 protein] Glucose results in decreased expression of RUNX2 mRNA; Glucose results in decreased expression of RUNX2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]]; Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]; Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]] morroniside inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of RUNX2 protein] |
CTD |
PMID:17178593 PMID:30894315 PMID:32643284 PMID:33450223 PMID:38000455 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of RUNX3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of S100A14 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100A14 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions increases expression |
ISO |
GLO1 inhibits the reaction [Glucose promotes the reaction [JUN protein binds to S100A8 promoter]]; GLO1 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of S100A8 protein]; Glucose promotes the reaction [JUN protein binds to S100A8 promoter]; JUN promotes the reaction [Glucose results in increased expression of S100A8 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of S100A8 protein]; UCP1 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of S100A8 protein] Glucose results in increased expression of S100A8 mRNA; Glucose results in increased expression of S100A8 protein |
CTD |
PMID:19833897 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of S100A9 protein |
CTD |
PMID:24802182 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100B mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
decreases expression |
EXP |
Glucose results in decreased expression of S1PR1 mRNA |
CTD |
PMID:22406263 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
multiple interactions increases expression |
EXP |
[JTE 013 binds to and results in decreased activity of S1PR2 protein] inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; [JTE 013 binds to and results in decreased activity of S1PR2 protein] results in decreased susceptibility to [sphingosine 1-phosphate co-treated with Glucose] Glucose results in increased expression of S1PR2 mRNA |
CTD |
PMID:22406263 |
|
NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
decreases expression |
EXP |
Glucose results in decreased expression of S1PR3 mRNA |
CTD |
PMID:22406263 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
S1pr4 |
sphingosine-1-phosphate receptor 4 |
decreases expression |
EXP |
Glucose results in decreased expression of S1PR4 mRNA |
CTD |
PMID:22406263 |
|
NCBI chr 7:8,207,767...8,210,043
Ensembl chr 7:8,208,098...8,211,893
|
|
G |
S1pr5 |
sphingosine-1-phosphate receptor 5 |
increases expression |
EXP |
Glucose results in increased expression of S1PR5 mRNA |
CTD |
PMID:22406263 |
|
NCBI chr 8:19,786,676...19,791,862
Ensembl chr 8:19,786,663...19,791,795
|
|
G |
Saa4 |
serum amyloid A4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SAA4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:97,247,580...97,251,882
|
|
G |
Samd15 |
sterile alpha motif domain containing 15 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SAMD15 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:106,841,405...106,856,197
Ensembl chr 6:106,840,781...106,860,423
|
|
G |
Sash3 |
SAM and SH3 domain containing 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of SASH3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:127,326,815...127,341,521
Ensembl chr X:127,326,859...127,341,519
|
|
G |
Sbsn |
suprabasin |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of SBSN mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:85,978,970...86,006,034
Ensembl chr 1:86,001,567...86,006,034
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of SCAMP4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967
|
|
G |
Scarna17 |
small Cajal body-specific RNA 17 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of SCARNA17 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:68,344,475...68,344,553
Ensembl chr18:68,344,475...68,344,553
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of SCD1 mRNA (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA] Glucose results in increased expression of SCD mRNA; Glucose results in increased expression of SCD1 mRNA |
CTD |
PMID:15066988 PMID:16790840 PMID:22413010 PMID:32613381 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scn1a |
sodium voltage-gated channel alpha subunit 1 |
increases expression |
ISO |
Glucose results in increased expression of SCN1A mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 3:50,952,790...51,071,804
Ensembl chr 3:50,952,791...51,071,699
|
|
G |
Scn4a |
sodium voltage-gated channel alpha subunit 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SCN4A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:91,246,936...91,296,670
Ensembl chr10:91,246,936...91,296,545
|
|
G |
Sec11c |
SEC11 homolog C, signal peptidase complex subunit |
decreases expression |
ISO |
Glucose results in decreased expression of SEC11C mRNA |
CTD |
PMID:17178593 |
|
NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364
|
|
G |
Sec13 |
SEC13 homolog, nuclear pore and COPII coat complex component |
decreases expression |
ISO |
Glucose deficiency results in decreased expression of SEC13 protein |
CTD |
PMID:22314686 |
|
NCBI chr 4:146,877,739...146,891,130
Ensembl chr 4:146,875,524...146,891,173
|
|
G |
Sec14l3 |
SEC14-like lipid binding 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SEC14L3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:78,944,568...78,955,608
Ensembl chr14:78,912,750...78,956,099
|
|
G |
Sec14l4 |
SEC14-like lipid binding 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SEC14L4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:78,912,750...78,928,799
Ensembl chr14:78,912,750...78,956,099
|
|
G |
Sec62 |
SEC62 homolog, preprotein translocation factor |
multiple interactions increases expression |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of SEC62 protein]; Metformin inhibits the reaction [Glucose results in increased expression of SEC62 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:112,570,810...112,598,198
Ensembl chr 2:112,570,819...112,601,814
|
|
G |
Sele |
selectin E |
multiple interactions increases secretion increases expression |
ISO |
5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of SELE mRNA]; 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of SELE protein]; aspalathin inhibits the reaction [Glucose results in increased expression of SELE protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of SELE mRNA]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of SELE protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of SELE mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of SELE protein]; Mannitol inhibits the reaction [Glucose results in increased expression of SELE mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of SELE protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased expression of SELE mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased secretion of SELE protein]; nothofagin inhibits the reaction [Glucose results in increased expression of SELE protein]; Polyphenols inhibits the reaction [Glucose results in increased expression of SELE mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of SELE mRNA]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of SELE mRNA]]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of SELE mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of SELE protein] Glucose results in increased expression of SELE; Glucose results in increased expression of SELE mRNA; Glucose results in increased expression of SELE protein |
CTD |
PMID:15304054 PMID:16285992 PMID:20960276 PMID:21682256 PMID:22074828 PMID:25338943 More...
|
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selenop |
selenoprotein P |
increases expression multiple interactions increases secretion |
EXP |
Glucose results in increased expression of SELENOP mRNA Metformin inhibits the reaction [Glucose results in increased expression of SELENOP mRNA]; Metformin inhibits the reaction [Glucose results in increased secretion of SELENOP protein] |
CTD |
PMID:19576170 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Selenos |
selenoprotein S |
affects expression |
ISO |
Glucose affects the expression of SELENOS mRNA |
CTD |
PMID:18498015 |
|
NCBI chr 1:119,659,779...119,669,546
Ensembl chr 1:119,659,751...119,669,833
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
[Glucose results in increased susceptibility to sodium arsenite] which results in increased expression of SELP protein; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]] |
CTD |
PMID:18413191 PMID:28264687 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sema3a |
semaphorin 3A |
decreases expression |
ISO |
Glucose results in decreased expression of SEMA3A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SERPINA3N mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpinc1 |
serpin family C member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of SERPINC1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SERPINC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion decreases expression increases expression multiple interactions |
ISO EXP |
Glucose results in increased secretion of SERPINE1 protein Glucose results in decreased expression of SERPINE1 mRNA Glucose results in increased expression of SERPINE1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA]; [Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA; [Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein; [eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; [eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; UCP1 protein inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA] Indomethacin inhibits the reaction [Glucose results in increased secretion of SERPINE1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:11050244 PMID:12409145 PMID:16320596 PMID:18682491 PMID:31655124 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinf1 |
serpin family F member 1 |
decreases secretion multiple interactions |
ISO |
Glucose deficiency results in decreased secretion of SERPINF1 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SERPINF1 mRNA |
CTD |
PMID:24802182 PMID:37567420 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
multiple interactions |
EXP |
Glucose promotes the reaction [SETD7 protein binds to CDKN1A promoter]; TGFB1 protein promotes the reaction [Glucose promotes the reaction [SETD7 protein binds to CDKN1A promoter]] |
CTD |
PMID:27652271 |
|
NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SFRP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sftpd |
surfactant protein D |
decreases expression |
ISO |
Glucose results in decreased expression of SFTPD mRNA |
CTD |
PMID:32942007 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression decreases expression |
ISO EXP |
Glucose results in increased expression of SGK1 mRNA Glucose results in decreased expression of SGK1 mRNA; Glucose results in decreased expression of SGK1 protein |
CTD |
PMID:17178593 PMID:31729781 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose] |
CTD |
PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Sh3bgr |
SH3 domain binding glutamate-rich protein |
decreases expression |
ISO |
Glucose results in decreased expression of SH3BGR mRNA |
CTD |
PMID:31525975 |
|
NCBI chr11:35,503,663...35,527,853
Ensembl chr11:35,503,725...35,527,853
|
|
G |
Sh3bp2 |
SH3-domain binding protein 2 |
increases expression |
ISO |
Glucose results in increased expression of SH3BP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:76,176,097...76,213,300
Ensembl chr14:76,176,101...76,213,251
|
|
G |
Shbg |
sex hormone binding globulin |
multiple interactions decreases expression |
ISO |
Cerulenin inhibits the reaction [Glucose results in decreased expression of SHBG protein]; Glucose affects the reaction [HNF4A protein binds to SHBG promoter]; Glucose affects the reaction [NR2F1 protein binds to SHBG promoter] |
CTD |
PMID:17992261 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Shc1 |
SHC adaptor protein 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of SHC1; Glucose results in increased expression of SHC1 mRNA; Glucose results in increased expression of SHC1 protein SIRT1 inhibits the reaction [Glucose results in increased expression of SHC1]; SIRT1 mutant form promotes the reaction [Glucose results in increased expression of SHC1 mRNA]; SIRT1 mutant form promotes the reaction [Glucose results in increased expression of SHC1 protein]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of SHC1 mRNA]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of SHC1 protein] |
CTD |
PMID:21778425 PMID:23993977 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Shc3 |
SHC adaptor protein 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of SHC3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SHC3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,651,202...13,772,710
|
|
G |
Shc4 |
SHC adaptor protein 4 |
multiple interactions increases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in increased expression of SHC4 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 3:112,880,598...112,974,216
Ensembl chr 3:112,880,600...112,974,366
|
|
G |
Shcbp1l |
SHC binding and spindle associated 1 like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SHCBP1L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:65,568,863...65,599,155
Ensembl chr13:65,568,863...65,599,154
|
|
G |
Shfl |
shiftless antiviral inhibitor of ribosomal frameshifting |
decreases expression |
ISO |
Glucose results in decreased expression of SHFL mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 8:19,408,298...19,414,084
Ensembl chr 8:19,408,333...19,413,971
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SHH mRNA; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein]; SHH protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTCH1 protein]; SHH protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMO protein] |
CTD |
PMID:27481074 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Shisal1 |
shisa like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SHISAL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:115,506,947...115,611,518
Ensembl chr 7:115,509,035...115,575,449
|
|
G |
Si |
sucrase-isomaltase |
increases expression |
ISO |
Glucose results in increased expression of SI mRNA |
CTD |
PMID:17786952 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Siglec1 |
sialic acid binding Ig like lectin 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SIGLEC1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:118,287,988...118,307,125
Ensembl chr 3:118,287,988...118,306,850
|
|
G |
Sik1 |
salt-inducible kinase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of SIK1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Sim2 |
SIM bHLH transcription factor 2 |
multiple interactions increases response to substance increases expression |
EXP |
Curcumin inhibits the reaction [Glucose results in increased expression of SIM2 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of SIM2 protein] SIM2 protein results in increased susceptibility to Glucose Glucose results in increased expression of SIM2 mRNA; Glucose results in increased expression of SIM2 protein |
CTD |
PMID:23333261 |
|
NCBI chr11:33,414,218...33,453,663
Ensembl chr11:33,414,218...33,453,663
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases phosphorylation decreases expression increases expression affects expression increases response to substance decreases response to substance affects abundance |
ISO EXP |
[6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Glucose; [[Resveratrol results in increased activity of SIRT1 protein] which results in increased phosphorylation of and results in decreased activity of FOXO3 protein] which results in decreased susceptibility to Glucose; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 protein; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of BAD protein]; [Resveratrol results in increased localization of and results in increased activity of SIRT1 protein] which results in decreased susceptibility to Glucose; [SIRT1 protein co-treated with Resveratrol] affects the reaction [Glucose affects the expression of PPARGC1A protein]; [sirtinol results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Glucose; AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 mRNA]; icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 protein]; Metformin inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; PRKAA1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]]; PRKAA2 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 mRNA]]; SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 protein]] Glucose deficiency results in increased phosphorylation of SIRT1 protein Glucose results in decreased expression of SIRT1 mRNA; Glucose results in decreased expression of SIRT1 protein Glucose deficiency results in increased expression of SIRT1 mRNA; Glucose deficiency results in increased expression of SIRT1 protein [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; [SRT1720 results in increased activity of SIRT1 protein] which results in increased abundance of Glucose; Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Inositol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; MIR217 mRNA affects the reaction [Glucose results in decreased expression of SIRT1 mRNA]; MIR217 mRNA affects the reaction [Glucose results in decreased expression of SIRT1 protein]; NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Sirolimus inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of EDN1 protein]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of FN1 protein]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of HIF1A protein]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of TGFB1 protein]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of VEGFA protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [Glucose results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; SRT1720 inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; UCP2 protein inhibits the reaction [SIRT1 protein promotes the reaction [Glucose results in increased expression of INS1 protein]] 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [[Glucose co-treated with Resveratrol] results in increased expression of SIRT1 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [SIRT1 protein inhibits the reaction [Resveratrol promotes the reaction [Glucose results in increased secretion of INS protein]]]; [Glucose co-treated with Resveratrol] results in increased expression of SIRT1 protein; [Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; [Palmitic Acid co-treated with Glucose] promotes the reaction [Glutathione binds to SIRT1 protein]; [Palmitic Acid co-treated with Glucose] results in increased oxidation of and results in decreased activity of SIRT1 protein; [Pyruvic Acid co-treated with Glucose] results in increased expression of and results in increased activity of SIRT1 protein; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [[Glucose results in increased expression of FASN protein] which results in increased abundance of Triglycerides]; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]; ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]; Acetylcysteine inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; GLRX protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] promotes the reaction [Glutathione binds to SIRT1 protein]]; GLRX protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased oxidation of and results in decreased activity of SIRT1 protein]; Glucose results in decreased expression of and results in decreased activity of SIRT1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of SIRT1 protein]; PARP1 protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in increased abundance of Triglycerides]]; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in increased expression of FASN protein]]; Resveratrol inhibits the reaction [Glucose results in decreased expression of SIRT1 mRNA]; salvianolic acid inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 inhibits the reaction [Glucose results in increased expression of SHC1]; SIRT1 mutant form promotes the reaction [Glucose results in increased expression of SHC1 mRNA]; SIRT1 mutant form promotes the reaction [Glucose results in increased expression of SHC1 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of NOS3 mRNA]]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of SELE mRNA]]; SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein]; SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [Glucose promotes the reaction [PARP1 protein binds to MMP9 promoter]]; SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]; SIRT1 protein inhibits the reaction [Glucose results in increased abundance of Triglycerides]; SIRT1 protein inhibits the reaction [Glucose results in increased acetylation of PARP1 protein]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of FASN protein]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of SHC1 mRNA]; SIRT1 protein inhibits the reaction [Glucose results in increased expression of SHC1 protein]; SIRT1 protein inhibits the reaction [Resveratrol promotes the reaction [Glucose results in increased secretion of INS protein]]; SIRT1 protein mutant form inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased expression of BBC3 mRNA]; SIRT1 protein mutant form inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased expression of CDKN1A mRNA]; SIRT1 protein promotes the reaction [[Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of PRKAA2 protein]] which results in decreased abundance of Triglycerides]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein]] Glucose affects the expression of SIRT1 protein SIRT1 protein results in increased susceptibility to Glucose SIRT1 protein results in decreased susceptibility to Glucose SIRT1 protein affects the abundance of Glucose |
CTD |
PMID:16366736 PMID:18482975 PMID:18849969 PMID:19071085 PMID:19303870 PMID:20068143 PMID:20195491 PMID:20370652 PMID:20960276 PMID:21031461 PMID:21163946 PMID:21212096 PMID:21778425 PMID:22561310 PMID:23090186 PMID:23993977 PMID:24064760 PMID:24349266 PMID:24451382 PMID:24802182 PMID:25162824 PMID:26811028 PMID:26891083 PMID:27049278 PMID:27358235 PMID:28478229 PMID:30431688 PMID:31639451 PMID:33957017 PMID:35243728 More...
|
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression decreases expression multiple interactions |
ISO |
Glucose deficiency results in increased expression of SIRT3 protein Glucose results in decreased expression of SIRT3 protein SIRT3 protein inhibits the reaction [sodium arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]] polyethylene glycol loxenatide inhibits the reaction [Glucose results in decreased expression of SIRT3 protein]; SIRT3 protein inhibits the reaction [Glucose results in increased acetylation of FOXO1 protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of CAT protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of CDKN2A protein alternative form]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of SOD2 protein] |
CTD |
PMID:23494737 PMID:25979314 PMID:37417536 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sirt4 |
sirtuin 4 |
affects expression decreases expression |
EXP |
Glucose affects the expression of SIRT4 protein Glucose results in decreased expression of SIRT4 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr12:41,125,533...41,139,440
Ensembl chr12:41,131,262...41,139,439
|
|
G |
Sirt7 |
sirtuin 7 |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT7 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT7 protein; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BBC3 protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein modified form]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein] |
CTD |
PMID:28675767 |
|
NCBI chr10:105,896,476...105,903,301
Ensembl chr10:105,896,476...105,903,172
|
|
G |
Sit1 |
signaling threshold regulating transmembrane adaptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SIT1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:57,740,212...57,741,838
Ensembl chr 5:57,740,218...57,741,838
|
|
G |
Skil |
SKI-like proto-oncogene |
increases expression |
ISO |
Glucose results in increased expression of SKIL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:112,247,047...112,275,176
Ensembl chr 2:112,247,051...112,275,080
|
|
G |
Slamf1 |
signaling lymphocytic activation molecule family member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLAMF1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:84,270,316...84,305,497
Ensembl chr13:84,270,316...84,305,497
|
|
G |
Slamf8 |
SLAM family member 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of SLAMF8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:85,047,729...85,057,571
Ensembl chr13:85,047,727...85,057,211
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 mRNA alternative form; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 protein alternative form RELA protein modified form promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 mRNA alternative form]; RELA protein promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC11A2 mRNA alternative form] |
CTD |
PMID:22666436 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
increases activity multiple interactions |
EXP |
Glucose results in increased activity of SLC12A1 protein [Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water |
CTD |
PMID:12433675 |
|
NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions |
ISO |
Bumetanide inhibits the reaction [SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]]; SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:22872759 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc16a14 |
solute carrier family 16, member 14 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC16A14 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318
|
|
G |
Slc16a5 |
solute carrier family 16 member 5 |
decreases expression multiple interactions increases methylation |
ISO |
Glucose results in decreased expression of SLC16A5 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of SLC16A5 mRNA] Glucose results in increased methylation of SLC16A5 gene |
CTD |
PMID:33448797 |
|
NCBI chr10:100,707,434...100,721,338
Ensembl chr10:100,707,434...100,721,338
|
|
G |
Slc17a2 |
solute carrier family 17, member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC17A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:41,318,312...41,339,012
Ensembl chr17:41,319,701...41,336,325
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of SLC17A8 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC17A8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
decreases expression multiple interactions |
EXP |
Glucose results in decreased expression of SLC1A3 mRNA; Glucose results in decreased expression of SLC1A3 protein resveratrol inhibits the reaction [Glucose results in decreased expression of SLC1A3 mRNA]; resveratrol inhibits the reaction [Glucose results in decreased expression of SLC1A3 protein] |
CTD |
PMID:26677078 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC22A19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of SLC22A3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc25a1 |
solute carrier family 25 member 1 |
increases expression |
EXP |
Glucose results in increased expression of SLC25A1 protein |
CTD |
PMID:24349266 |
|
NCBI chr11:83,055,764...83,058,781
Ensembl chr11:83,055,748...83,058,781
|
|
G |
Slc25a10 |
solute carrier family 25 member 10 |
increases expression |
EXP |
Glucose results in increased expression of SLC25A10 mRNA; Glucose results in increased expression of SLC25A10 protein |
CTD |
PMID:24349266 |
|
NCBI chr10:105,765,598...105,775,159
Ensembl chr10:105,765,372...105,773,556
|
|
G |
Slc25a12 |
solute carrier family 25 member 12 |
decreases expression |
EXP |
Glucose results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100
|
|
G |
Slc25a14 |
solute carrier family 25 member 14 |
increases expression |
EXP |
Glucose results in increased expression of SLC25A14 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr X:127,807,630...127,845,823
Ensembl chr X:127,807,449...127,845,823
|
|
G |
Slc25a22 |
solute carrier family 25 member 22 |
affects expression |
EXP |
Glucose affects the expression of SLC25A22 protein |
CTD |
PMID:24349266 |
|
NCBI chr 1:196,528,471...196,536,398
Ensembl chr 1:196,528,472...196,536,331
|
|
G |
Slc25a27 |
solute carrier family 25, member 27 |
increases expression |
EXP |
Glucose results in increased expression of SLC25A27 mRNA |
CTD |
PMID:24349266 |
|
NCBI chr 9:17,306,898...17,333,942
Ensembl chr 9:17,307,023...17,332,731
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of SLC26A3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC26A6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases uptake decreases expression increases activity increases transport increases stability increases expression |
ISO EXP |
7-hydroxyflavone inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; [bisphenol A results in increased activity of and affects the localization of SLC2A1 protein] which results in increased uptake of Glucose; [Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein; [PRNP protein results in increased expression of SLC2A1 protein] which results in increased uptake of Glucose; [sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [[Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein]; Barbiturates inhibits the reaction [SLC2A1 protein results in increased transport of Glucose]; Chloral Hydrate inhibits the reaction [SLC2A1 protein results in increased transport of Glucose]; Cyclofenil inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Cytochalasin B inhibits the reaction [SLC2A1 protein results in increased transport of Glucose]; daidzein inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Diazepam inhibits the reaction [SLC2A1 protein results in increased transport of Glucose]; Diethylstilbestrol inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Genistein inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; isoliquiritigenin inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; kaempferol inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; myricetin inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; naringenin inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Phloretin inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Quercetin inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Resveratrol inhibits the reaction [SLC2A1 protein results in increased uptake of Glucose]; Tamoxifen inhibits the reaction [SLC2A1 protein affects the transport of Glucose]; Valproic Acid inhibits the reaction [SLC2A1 protein results in increased transport of Glucose] [troglitazone results in increased expression of SLC2A1 mRNA] which results in increased uptake of Glucose Glucose results in decreased expression of SLC2A1 mRNA [2-butenal co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [3-phenylpropanol-1 co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [benzaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [bromopyruvate results in decreased expression of SLC2A1 protein] which results in decreased uptake of Glucose; [cinnamaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [cinnamyl alcohol co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [Progesterone results in increased expression of SLC2A1 protein] which results in increased uptake of Glucose; [propionaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein; [Troglitazone results in increased expression of SLC2A1 mRNA] which results in increased uptake of Glucose; [Troglitazone results in increased expression of SLC2A1 protein] which results in increased uptake of Glucose; Cysteine inhibits the reaction [[cinnamaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein]; Mercaptoethanol inhibits the reaction [[cinnamaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein]; oxophenylarsine inhibits the reaction [Glucose deficiency results in increased activity of SLC2A1 protein] Glucose results in increased stability of SLC2A1 protein Glucose results in increased expression of SLC2A1 mRNA |
CTD |
PMID:1727734 PMID:8457197 PMID:8895337 PMID:10726906 PMID:11420438 PMID:14642735 PMID:15864539 PMID:18455367 PMID:18948400 PMID:19686715 PMID:20955755 PMID:21265952 PMID:23615963 PMID:28433571 PMID:31398423 PMID:32403449 More...
|
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions increases expression decreases expression increases transport |
ISO EXP |
Catechin inhibits the reaction [Glucose results in decreased expression of SLC2A2 protein]; Glucose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A2 protein results in increased transport of Fructose]; Plant Extracts inhibits the reaction [Glucose results in decreased expression of SLC2A2 protein] Glucose results in increased expression of SLC2A2 mRNA Dactinomycin inhibits the reaction [Glucose results in increased expression of SLC2A2 mRNA]; ML 7 inhibits the reaction [SLC2A2 protein results in increased uptake of Glucose]; Phloretin inhibits the reaction [SLC2A2 protein results in increased uptake of Glucose] [copper bis(3,5-diisopropylsalicylate) co-treated with Glucose] results in increased expression of SLC2A2 protein; [ebselen co-treated with Glucose] results in increased expression of SLC2A2 protein; [Sodium Selenite co-treated with Glucose] results in increased expression of SLC2A2 protein; Glucose inhibits the reaction [Alloxan results in decreased expression of SLC2A2 mRNA]; Glucose results in increased expression of and affects the localization of SLC2A2 protein SLC2A2 protein results in increased transport of Glucose |
CTD |
PMID:1727734 PMID:8457197 PMID:12137914 PMID:12787936 PMID:12937289 PMID:17272349 PMID:17710649 PMID:17786952 PMID:23795780 PMID:24262486 PMID:36156098 More...
|
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP ISO |
[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased expression of SLC2A3 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased expression of SLC2A3 protein] [INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein] |
CTD |
PMID:8457197 PMID:24726522 PMID:28951307 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases uptake increases expression decreases expression |
ISO EXP |
[3,3',4,5'-tetrahydroxystilbene results in increased localization of SLC2A4 protein] which results in increased uptake of Glucose; [Glucose co-treated with picolinic acid] affects the localization of SLC2A4 protein; Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine]; mangiferin promotes the reaction [SLC2A4 protein results in increased uptake of Glucose]; MYH2 protein affects the reaction [SLC2A4 protein results in increased uptake of Glucose]; Plant Extracts promotes the reaction [SLC2A4 protein results in increased uptake of Glucose] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Chloroquine affects the localization of SLC2A4 protein] which results in increased uptake of Glucose]; [[Chloroquine results in increased abundance of Calcium] which affects the localization of SLC2A4 protein] which results in increased uptake of Glucose; [Chloroquine affects the localization of SLC2A4 protein] which results in increased uptake of Glucose; [Resveratrol results in increased localization of SLC2A4 protein] which results in increased uptake of Glucose; ESR1 protein promotes the reaction [[Resveratrol results in increased localization of SLC2A4 protein] which results in increased uptake of Glucose]; Fulvestrant inhibits the reaction [[Resveratrol results in increased localization of SLC2A4 protein] which results in increased uptake of Glucose] Glucose results in increased expression of SLC2A4 mRNA Glucose results in decreased expression of SLC2A4 mRNA ACACB protein affects the reaction [Glucose results in decreased expression of SLC2A4 protein] |
CTD |
PMID:1727734 PMID:15111496 PMID:16870493 PMID:18426865 PMID:18773891 PMID:19373748 PMID:19477051 PMID:22579688 PMID:27160165 PMID:33957017 More...
|
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions increases expression increases transport |
ISO EXP |
Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA]; Glucose promotes the reaction [PAIP2 protein binds to SLC2A5 3' UTR] Glucose results in increased expression of SLC2A5 protein SLC2A5 protein results in increased transport of Glucose Glucose results in increased expression of SLC2A5 mRNA; Glucose results in increased expression of SLC2A5 protein |
CTD |
PMID:8048533 PMID:8554516 PMID:12820898 PMID:12937289 PMID:17710649 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
decreases expression |
ISO |
Glucose results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc2a7 |
solute carrier family 2 member 7 |
increases transport |
ISO |
SLC2A7 protein results in increased transport of Glucose |
CTD |
PMID:15033637 PMID:17710649 |
|
NCBI chr 5:160,624,793...160,643,994
Ensembl chr 5:160,624,793...160,643,514
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions increases transport |
ISO |
Glucose promotes the reaction [SLC2A9 protein alternative form results in increased transport of Uric Acid] SLC2A9 protein results in increased transport of Glucose |
CTD |
PMID:17710649 PMID:18842065 |
|
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of SLC30A1 mRNA N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Glucose results in increased expression of SLC30A1 mRNA]; zinc chloride promotes the reaction [Glucose results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:23056475 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Slc30a3 |
solute carrier family 30 member 3 |
increases expression affects expression multiple interactions |
ISO EXP |
Glucose results in increased expression of SLC30A3 Glucose affects the expression of SLC30A3 [Glucose co-treated with dihydroxyethyldithiocarbamate] results in increased expression of SLC30A3 mRNA SLC30A3 results in increased susceptibility to [Glucose co-treated with INS1 protein] |
CTD |
PMID:18545258 PMID:19492079 |
|
NCBI chr 6:25,264,310...25,284,720
Ensembl chr 6:25,275,528...25,284,720
|
|
G |
Slc30a5 |
solute carrier family 30 member 5 |
affects expression |
EXP |
Glucose affects the expression of SLC30A5 |
CTD |
PMID:19492079 |
|
NCBI chr 2:31,945,745...31,975,969
Ensembl chr 2:31,945,729...31,975,934
|
|
G |
Slc30a7 |
solute carrier family 30 member 7 |
multiple interactions |
ISO |
SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of GSDMD protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL18 protein]]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased secretion of IL1B protein]] |
CTD |
PMID:35607288 |
|
NCBI chr 2:203,855,484...203,922,155
Ensembl chr 2:203,859,175...203,922,132
|
|
G |
Slc30a8 |
solute carrier family 30 member 8 |
multiple interactions decreases expression |
ISO EXP |
SLC30A8 protein promotes the reaction [Glucose results in increased secretion of INS protein] [Glucose co-treated with dihydroxyethyldithiocarbamate] results in decreased expression of SLC30A8; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Glucose results in decreased expression of SLC30A8 mRNA]; SLC30A8 protein affects the reaction [Glucose results in increased secretion of INS1 protein] Glucose results in decreased expression of SLC30A8; Glucose results in decreased expression of SLC30A8 mRNA SLC30A8 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:16984975 PMID:19450229 PMID:19479076 PMID:19492079 PMID:23056475 |
|
NCBI chr 7:83,591,993...83,627,786
Ensembl chr 7:83,591,993...83,626,305
|
|
G |
Slc38a11 |
solute carrier family 38, member 11 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of SLC38A11 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:49,987,119...50,033,615
Ensembl chr 3:49,987,124...50,033,615
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC38A4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC47A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions increases expression |
ISO |
Furans analog inhibits the reaction [Glucose results in increased expression of SLC4A1 protein] |
CTD |
PMID:28911973 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Slc4a5 |
solute carrier family 4 member 5 |
decreases expression |
ISO |
Glucose results in decreased expression of SLC4A5 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 4:115,710,101...115,810,330
Ensembl chr 4:115,725,592...115,810,323
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions affects uptake increases expression affects transport |
ISO EXP |
Glucose inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside] SLC5A1 protein affects the uptake of Glucose Glucose results in increased expression of SLC5A1 protein [Cisplatin results in decreased expression of SLC5A1 mRNA] which affects the transport of Glucose; [Gentamicins results in decreased expression of SLC5A1 mRNA] which affects the transport of Glucose Glucose results in increased expression of SLC5A1 mRNA [gentamicin C results in decreased expression of SLC5A1 protein] which results in decreased uptake of Glucose; [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of Glucose SLC5A1 protein affects the transport of Glucose |
CTD |
PMID:8048533 PMID:12927799 PMID:12937289 PMID:16300400 PMID:17288452 PMID:18656965 PMID:23927891 More...
|
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc5a10 |
solute carrier family 5 member 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC5A10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:46,352,060...46,400,795
Ensembl chr10:46,352,061...46,399,811
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
multiple interactions |
EXP |
[Cisplatin results in decreased expression of SLC5A2 mRNA] which affects the transport of Glucose; [Gentamicins results in decreased expression of SLC5A2 mRNA] which affects the transport of Glucose; EDN3 protein inhibits the reaction [SLC5A2 protein results in increased uptake of Glucose]; NPPA protein inhibits the reaction [SLC5A2 protein results in increased uptake of Glucose] |
CTD |
PMID:15127950 PMID:18656965 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Slc5a4 |
solute carrier family 5 member 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLC5A4A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:12,475,644...12,518,738
Ensembl chr20:12,475,644...12,518,738
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC5A7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slc6a18 |
solute carrier family 6 member 18 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of SLC6A18 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of SLC6A18 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:29,607,288...29,621,925
Ensembl chr 1:29,608,077...29,621,925
|
|
G |
Slc6a7 |
solute carrier family 6 member 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC6A7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:54,448,464...54,467,319
Ensembl chr18:54,448,464...54,467,319
|
|
G |
Slc7a10 |
solute carrier family 7 member 10 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC7A10 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:87,829,084...87,845,073
Ensembl chr 1:87,829,175...87,845,071
|
|
G |
Slc7a12 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 12 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SLC7A12 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:87,079,724...87,146,875
Ensembl chr 2:87,079,749...87,146,875
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
[[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of HIF1A protein] which results in increased expression of SLC8A1 mRNA; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC8A1 mRNA; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of SLC8A1 protein |
CTD |
PMID:21293012 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Slfnl1 |
schlafen-like 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLFNL1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:134,117,634...134,122,105
Ensembl chr 5:133,990,520...134,122,105
|
|
G |
Slitrk6 |
SLIT and NTRK-like family, member 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SLITRK6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr15:87,563,506...87,570,125
Ensembl chr15:87,563,322...87,570,393
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation multiple interactions |
ISO EXP |
Glucose results in increased phosphorylation of SMAD2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]; farrerol inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]; LY2109761 inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein] Glucose results in increased phosphorylation of and affects the localization of SMAD2 protein; isoangustone A inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]; protocatechualdehyde inhibits the reaction [Glucose results in increased phosphorylation of and affects the localization of SMAD2 protein] |
CTD |
PMID:17597607 PMID:21367880 PMID:31838053 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation |
ISO |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in increased phosphorylation of SMAD3 protein]; Glucose results in increased phosphorylation of and affects the localization of SMAD3 protein; protocatechualdehyde inhibits the reaction [Glucose results in increased phosphorylation of and affects the localization of SMAD3 protein] |
CTD |
PMID:17597607 PMID:26045780 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad4 |
SMAD family member 4 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of SMAD4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of SMAD4 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of SMAD4 protein]; farrerol inhibits the reaction [Glucose results in increased expression of SMAD4 protein]; LY2109761 inhibits the reaction [Glucose results in increased expression of SMAD4 protein] isoangustone A inhibits the reaction [Glucose results in increased expression of SMAD4 protein] |
CTD |
PMID:21367880 PMID:31838053 |
|
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
multiple interactions |
ISO |
[MIR144 mRNA results in decreased expression of SMARCA4 protein] affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 protein; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 mRNA]; MIR144 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMARCA4 protein] |
CTD |
PMID:29457851 |
|
NCBI chr 8:20,167,717...20,258,975
Ensembl chr 8:20,167,717...20,258,975
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
increases expression |
ISO |
Glucose results in increased expression of SMC4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMO protein; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMO protein]; SHH protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SMO protein] |
CTD |
PMID:27481074 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Smox |
spermine oxidase |
increases expression |
ISO |
Glucose results in increased expression of SMOX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:118,731,900...118,765,710
|
|
G |
Smyd1 |
SET and MYND domain containing 1 |
decreases expression |
ISO |
Glucose results in decreased expression of SMYD1 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 4:103,195,330...103,252,989
Ensembl chr 4:103,200,322...103,311,766
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of SNAI1 mRNA; Glucose results in increased expression of SNAI1 protein [Glucose co-treated with TGFB1 protein] results in increased expression of SNAI1 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of SNAI1 protein]; gingerol inhibits the reaction [Glucose results in increased expression of SNAI1 mRNA]; MAPK14 protein promotes the reaction [Glucose results in increased expression of SNAI1 mRNA] |
CTD |
PMID:21829520 PMID:35445903 PMID:35961541 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai3 |
snail family transcriptional repressor 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SNAI3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr19:50,516,771...50,529,295
Ensembl chr19:50,516,771...50,523,486
|
|
G |
Snap25 |
synaptosome associated protein 25 |
decreases expression |
EXP |
Glucose results in decreased expression of SNAP25 protein |
CTD |
PMID:23776493 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Snora5c |
small nucleolar RNA, H/ACA box 5C |
increases expression |
ISO |
Glucose results in increased expression of SNORA5C mRNA |
CTD |
PMID:31525975 |
|
NCBI chr14:81,487,218...81,487,354
Ensembl chr14:81,487,218...81,487,354
|
|
G |
Snord49a |
small nucleolar RNA, C/D box 49A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of SNORD49A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:47,297,488...47,297,559
Ensembl chr10:47,297,488...47,297,559
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Glucose results in increased expression of SOCS3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects binding decreases metabolic processing decreases expression increases expression multiple interactions |
ISO EXP |
Glucose binds to SOD1 protein mutant form SOD1 protein mutant form results in decreased metabolism of Glucose Glucose results in decreased expression of SOD1 mRNA Glucose results in increased expression of SOD1 mRNA [Glucose co-treated with Palmitic Acid] results in decreased expression of SOD1 protein; [Oxygen co-treated with Glucose] promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SOD1 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SOD1 protein; naringenin inhibits the reaction [Glucose results in increased expression of SOD1 mRNA]; SOD1 protein inhibits the reaction [[INS1 protein co-treated with Glucose] results in increased activity of PARP1 protein] copper bis(3,5-diisopropylsalicylate) inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; ebselen inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; NFKB1 protein inhibits the reaction [SOD1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Glucose results in decreased expression of SOD1 protein]; SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased activity of NFKB1 protein]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK1 protein]; SOD1 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of MAPK3 protein]; SOD1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [SOD1 gene mutant form inhibits the reaction [Glucose results in increased secretion of INS1 protein]] Glucose results in increased expression of SOD1 protein [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of SOD1 protein; Acetylcysteine inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; CAT inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; Glucose deficiency results in decreased expression of and results in increased degradation of SOD1 protein; Glucose promotes the reaction [SOD1 protein mutant form results in increased chemical synthesis of Hydrogen Peroxide]; lactacystin inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; SOD1 protein inhibits the reaction [Glucose results in increased expression of NOS2 mRNA]; SOD1 protein inhibits the reaction [Glucose results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Glucose deficiency results in decreased expression of and results in increased degradation of SOD1 protein]; U 0126 inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein] |
CTD |
PMID:12626432 PMID:16395278 PMID:17309078 PMID:18545258 PMID:19228841 PMID:21818840 PMID:22425406 PMID:23061969 PMID:23090186 PMID:23192364 PMID:23795780 PMID:28027979 PMID:28400208 PMID:29419416 PMID:31655124 PMID:32942007 More...
|
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects folding affects expression decreases secretion decreases expression multiple interactions decreases activity increases expression decreases response to substance |
ISO EXP |
Glucose deficiency affects the folding of SOD2 protein Glucose affects the expression of SOD2 mRNA Glucose deficiency results in decreased secretion of SOD2 protein Glucose results in decreased expression of SOD2 mRNA; Glucose results in decreased expression of SOD2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; Acetylcysteine inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; KU-32 compound inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; naringenin inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA]; SRT1720 inhibits the reaction [Glucose results in decreased expression of SOD2 protein] [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased expression of SOD2 protein; [Glucose co-treated with SOD2 gene mutant form] results in decreased expression of HIF1A protein; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased expression of SOD2 protein]; pimagedine inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; resveratrol inhibits the reaction [Glucose results in decreased expression of SOD2 protein]; SOD2 protein inhibits the reaction [sodium arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]] 2,3-bis(4-hydroxyphenyl)-propionitrile inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in decreased expression of SOD2 protein]]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of SOD2 protein]; Acetylcysteine inhibits the reaction [Glucose deficiency affects the folding of SOD2 protein]; CAT inhibits the reaction [Glucose deficiency affects the folding of SOD2 protein]; Fulvestrant inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of SOD2 protein]]; Glucose results in decreased expression of and results in decreased activity of SOD2 protein; manganese chloride inhibits the reaction [Glucose results in decreased activity of SOD2 protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of SOD2 protein]; SOD2 inhibits the reaction [Glucose results in decreased expression of GLO1 protein]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER protein]; SOD2 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; SOD2 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of S100A12 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of S100A8 protein]; SOD2 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein]; SOD2 protein inhibits the reaction [Glucose results in decreased activity of and results in increased ADP-ribosylation of GAPDH protein]; SOD2 protein inhibits the reaction [Glucose results in decreased phosphorylation of SP1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased activity of PARP1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone]; SOD2 protein inhibits the reaction [Glucose results in increased chemical synthesis of Reactive Oxygen Species]; SOD2 protein inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA]; SOD2 protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; SOD2 protein inhibits the reaction [Glucose results in increased O-linked glycosylation of SP1 protein] Glucose deficiency results in increased expression of SOD2 protein; Glucose results in increased expression of SOD2 protein Glucose results in increased expression of SOD2 mRNA SOD2 protein results in decreased susceptibility to Glucose Glucose deficiency results in decreased expression of SOD2 protein |
CTD |
PMID:11050244 PMID:14514642 PMID:14523042 PMID:17309078 PMID:18483403 PMID:19429140 PMID:19833897 PMID:20962025 PMID:21818840 PMID:21940958 PMID:22314686 PMID:22413817 PMID:23090186 PMID:23159718 PMID:23192364 PMID:23329836 PMID:23494737 PMID:24349266 PMID:24802182 PMID:25162824 PMID:25979314 PMID:28027979 PMID:31639451 PMID:32942007 More...
|
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
EXP |
Glucose results in decreased expression of SOD3 mRNA |
CTD |
PMID:21818840 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sorcs1 |
sortilin-related VPS10 domain containing receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of SORCS1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of SORCS1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:249,080,662...249,594,520
Ensembl chr 1:249,081,355...249,594,507
|
|
G |
Sord |
sorbitol dehydrogenase |
increases expression |
ISO |
Glucose results in increased expression of SORD mRNA |
CTD |
PMID:16805838 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Glucose results in decreased expression of SOX2 protein |
CTD |
PMID:33992720 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox6 |
SRY-box transcription factor 6 |
increases expression |
ISO |
Glucose results in increased expression of SOX6 mRNA; Glucose results in increased expression of SOX6 protein |
CTD |
PMID:36073553 |
|
NCBI chr 1:169,723,306...170,334,846
Ensembl chr 1:169,729,194...170,277,386
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SOX9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO EXP |
SOD2 protein inhibits the reaction [Glucose results in decreased phosphorylation of SP1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased O-linked glycosylation of SP1 protein] UCP1 protein inhibits the reaction [Glucose results in decreased phosphorylation of SP1 protein]; UCP1 protein inhibits the reaction [Glucose results in increased O-linked glycosylation of SP1 protein] |
CTD |
PMID:11050244 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
[EPO protein co-treated with Glucose] results in increased expression of SP7 mRNA; [EPO protein co-treated with Glucose] results in increased expression of SP7 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of SP7 mRNA |
CTD |
PMID:30894315 PMID:37567420 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spaca9 |
sperm acrosome associated 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of SPACA9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:12,019,376...12,028,801
Ensembl chr 3:12,019,363...12,029,119
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
multiple interactions decreases expression |
ISO |
cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] |
CTD |
PMID:19924377 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spata20 |
spermatogenesis associated 20 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of SPATA20 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SPATA20 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:79,427,525...79,435,472
Ensembl chr10:79,427,528...79,434,368
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Glucose results in increased expression of and results in increased activity of SPHK1 protein]; Glucose results in increased expression of and results in increased activity of SPHK1 protein; N,N-dimethylsphingosine inhibits the reaction [Glucose results in increased activity of SPHK1 protein]; Pyridoxamine inhibits the reaction [Glucose results in increased expression of and results in increased activity of SPHK1 protein]; SPHK1 mRNA affects the reaction [Glucose results in increased expression of FN1 protein]; SPHK1 protein inhibits the reaction [Glucose results in increased expression of FN1 protein] Glucose results in increased expression of SPHK1 mRNA |
CTD |
PMID:21998146 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Spib |
Spi-B transcription factor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SPIB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:95,018,939...95,024,804
Ensembl chr 1:95,018,947...95,024,780
|
|
G |
Spmip7 |
sperm microtubule inner protein 7 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of SPMIP7 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr14:86,030,427...86,085,644
Ensembl chr14:86,030,655...86,085,644
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression decreases expression multiple interactions increases secretion |
ISO EXP |
Glucose results in increased expression of SPP1 mRNA Glucose results in decreased expression of SPP1 mRNA; Glucose results in decreased expression of SPP1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in decreased expression of SPP1 mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in decreased expression of SPP1 protein]]; Melatonin inhibits the reaction [Glucose results in decreased expression of SPP1 mRNA]; Melatonin inhibits the reaction [Glucose results in decreased expression of SPP1 protein]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of SPP1 mRNA]; Phytic Acid inhibits the reaction [Glucose results in decreased expression of SPP1 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of SPP1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SPP1 mRNA Glucose results in increased secretion of SPP1 protein Glucose results in increased expression of SPP1; Glucose results in increased expression of SPP1 mRNA 1-Methyl-3-isobutylxanthine inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; 8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; Dinitrochlorobenzene inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; Dinitrochlorobenzene inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; Dipyridamole inhibits the reaction [Glucose results in increased expression of SPP1 mRNA]; Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; KT 5823 inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; morroniside inhibits the reaction [Glucose results in decreased expression of SPP1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] |
CTD |
PMID:12505755 PMID:17178593 PMID:20453393 PMID:32643284 PMID:37567420 PMID:38000455 More...
|
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
increases expression |
ISO |
Glucose results in increased expression of SPRY2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009
|
|
G |
Spsb1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
increases expression |
ISO |
Glucose results in increased expression of SPSB1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:160,358,292...160,418,541
Ensembl chr 5:160,358,308...160,418,468
|
|
G |
Spta1 |
spectrin, alpha, erythrocytic 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of SPTA1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:86,203,504...86,279,371
Ensembl chr13:86,203,504...86,279,371
|
|
G |
Sptlc3 |
serine palmitoyltransferase, long chain base subunit 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of SPTLC3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:126,847,878...126,978,010
Ensembl chr 3:126,847,878...126,978,010
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions decreases expression |
EXP ISO |
Glucose results in increased expression of SQSTM1 protein Glucose deficiency results in increased expression of SQSTM1 protein HU 308 inhibits the reaction [Glucose results in increased expression of SQSTM1 protein] Glucose deficiency results in decreased expression of SQSTM1 protein 3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]]; Chloroquine promotes the reaction [Glucose results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [Resveratrol promotes the reaction [Glucose results in increased expression of SQSTM1 protein]]; Inositol inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]; N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]; Resveratrol promotes the reaction [Glucose results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]]; ULK1 protein affects the reaction [Glucose results in increased expression of SQSTM1 protein]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]] |
CTD |
PMID:28713934 PMID:29128638 PMID:29649567 PMID:30459625 PMID:34580807 PMID:35243728 More...
|
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions decreases expression |
ISO EXP |
[Resveratrol co-treated with Glucose] results in decreased expression of SRC mRNA; [Resveratrol co-treated with Glucose] results in decreased expression of SRC protein; [Resveratrol co-treated with Glucose] results in decreased expression of SRC protein modified form; Eucalyptol inhibits the reaction [Glucose results in decreased expression of SRC protein]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose] [Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein]; Chlorpromazine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein] |
CTD |
PMID:11990355 PMID:24659233 PMID:29702141 PMID:31483951 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of SREBF1 mRNA; Glucose results in increased expression of SREBF1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased cleavage of SREBF1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Glucose results in increased cleavage of SREBF1 protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [Glucose results in increased cleavage of SREBF1 protein]; fatostatin inhibits the reaction [Glucose promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; fatostatin inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]; Glucose promotes the reaction [SREBF1 protein binds to FASN promoter]; Glucose promotes the reaction [SREBF1 protein binds to TGFB1 promoter]; Glucose results in increased activity of and results in increased cleavage of SREBF1 protein; L 709049 analog inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; RTKI cpd inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]; SREBF1 protein affects the reaction [Glucose results in increased expression of TGFB1 mRNA]; Wortmannin inhibits the reaction [Glucose results in increased cleavage of SREBF1 protein]; Y 27632 inhibits the reaction [Glucose results in increased cleavage of SREBF1 protein] [INS protein co-treated with Glucose] results in increased expression of SREBF1 mRNA; Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]]; dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]; L 709049 analog inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]; platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]; platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of SREBF1 mRNA]; STO 609 inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]] resveratrol inhibits the reaction [Glucose results in increased expression of SREBF1 protein] |
CTD |
PMID:10913129 PMID:15066988 PMID:19724016 PMID:22031849 PMID:23090186 PMID:23319015 PMID:23647015 More...
|
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF2 protein]; L 709049 analog inhibits the reaction [Glucose results in increased expression of SREBF2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of SREBF2 protein] |
CTD |
PMID:23647015 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Sri |
sorcin |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of SRI protein Glucose promotes the reaction [NCOR1 protein binds to SRI promoter]; Glucose promotes the reaction [RELA protein binds to SRI promoter]; NCOR1 protein affects the reaction [Glucose results in decreased expression of SRI protein]; RELA protein affects the reaction [Glucose results in decreased expression of SRI protein]; SRI protein inhibits the reaction [Glucose affects the localization of MLXIP protein] |
CTD |
PMID:33930463 |
|
NCBI chr 4:25,973,493...25,997,879
Ensembl chr 4:25,966,750...25,998,077
|
|
G |
Sstr3 |
somatostatin receptor 3 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of SSTR3 protein 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased expression of SSTR3 protein]]; Dexamethasone inhibits the reaction [Glucose results in increased expression of SSTR3 protein] |
CTD |
PMID:31778773 |
|
NCBI chr 7:110,092,563...110,109,043
Ensembl chr 7:110,092,575...110,099,769
|
|
G |
St18 |
ST18 C2H2C-type zinc finger transcription factor |
increases expression |
ISO |
Glucose results in increased expression of ST18 mRNA |
CTD |
PMID:23236509 |
|
NCBI chr 5:12,582,493...12,914,221
Ensembl chr 5:12,584,110...12,671,790
|
|
G |
Stac2 |
SH3 and cysteine rich domain 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of STAC2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:83,032,418...83,048,260
Ensembl chr10:83,032,417...83,048,260
|
|
G |
Stag2 |
STAG2 cohesin complex component |
decreases expression |
ISO |
Glucose results in decreased expression of STAG2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:120,974,687...121,105,677
Ensembl chr X:120,974,857...121,105,677
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases phosphorylation multiple interactions |
EXP ISO |
Glucose results in increased phosphorylation of STAT1 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of STAT1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Glucose results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:20060012 PMID:37567420 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation increases expression |
EXP ISO |
[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of STAT3 mRNA; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of STAT3 protein; cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of STAT3 mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in increased expression of STAT3 protein]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of NPPA mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]] [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] inhibits the reaction [IL6RA protein binds to IL6ST protein]] promotes the reaction [IL6ST protein binds to and results in increased phosphorylation of STAT3 protein]; [[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased phosphorylation of STAT3 protein; IL6 protein inhibits the reaction [[[Oxygen deficiency co-treated with Glucose deficiency] co-treated with Oxygen] results in decreased phosphorylation of STAT3 protein]; STAT3 gene mutant form inhibits the reaction [IL22 protein results in decreased abundance of Glucose] 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of STAT3 protein modified form]]; resveratrol inhibits the reaction [Glucose results in increased expression of STAT3 protein modified form] Glucose results in increased expression of STAT3 protein; Glucose results in increased expression of STAT3 protein modified form |
CTD |
PMID:21940958 PMID:23421680 PMID:24064760 PMID:24810525 PMID:26064446 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stim1 |
stromal interaction molecule 1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of STIM1 mRNA; Glucose results in increased expression of STIM1 protein STIM1 protein affects the reaction [Glucose results in decreased expression of BCL2 protein]; STIM1 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; STIM1 protein affects the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:27234048 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
Glucose results in increased acetylation of and results in decreased activity of STK11 protein; resveratrol inhibits the reaction [Glucose results in increased acetylation of and results in decreased activity of STK11 protein] |
CTD |
PMID:19765649 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Stmnd1 |
stathmin domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of STMND1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:18,393,312...18,420,655
Ensembl chr17:18,394,346...18,437,412
|
|
G |
Stra6 |
signaling receptor and transporter of retinol STRA6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of STRA6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:58,548,899...58,568,861
Ensembl chr 8:58,549,736...58,568,860
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
decreases expression |
ISO |
Glucose results in decreased expression of STRBP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:21,328,310...21,467,753
Ensembl chr 3:21,337,855...21,414,949
|
|
G |
Strip2 |
striatin interacting protein 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of STRIP2 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of STRIP2 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 4:58,536,034...58,578,279
Ensembl chr 4:58,536,055...58,578,291
|
|
G |
Stum |
stum, mechanosensory transduction mediator homolog |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of STUM mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:92,172,175...92,227,205
Ensembl chr13:92,173,544...92,227,213
|
|
G |
Stx19 |
syntaxin 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of STX19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:172,855...178,053
Ensembl chr11:171,395...179,191
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of SULT4A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Syn1 |
synapsin I |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of SYN1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of SYN1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Syndig1 |
synapse differentiation inducing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of SYNDIG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:138,030,995...138,234,646
Ensembl chr 3:138,031,769...138,198,122
|
|
G |
Synpo2l |
synaptopodin 2-like |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of SYNPO2L mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr15:3,631,974...3,641,429
Ensembl chr15:3,631,834...3,641,429
|
|
G |
Syp |
synaptophysin |
decreases expression |
EXP |
Glucose results in decreased expression of SYP protein |
CTD |
PMID:23776493 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Syt1 |
synaptotagmin 1 |
increases expression |
EXP |
Glucose results in increased expression of SYT1 protein |
CTD |
PMID:23776493 |
|
NCBI chr 7:43,813,204...44,358,020
Ensembl chr 7:43,815,785...44,357,803
|
|
G |
Syvn1 |
synoviolin 1 |
decreases expression |
ISO |
Glucose results in decreased expression of SYVN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:203,339,235...203,346,137
Ensembl chr 1:203,339,619...203,346,152
|
|
G |
Tagln |
transgelin |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of TAGLN protein |
CTD |
PMID:24802182 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of TAP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tas1r1 |
taste 1 receptor member 1 |
multiple interactions |
ISO |
Glucose promotes the reaction [TAS1R3 protein binds to TAS1R1 protein]; TAS1R1 protein affects the reaction [Glucose results in decreased expression of CDKN1A protein] |
CTD |
PMID:33992720 |
|
NCBI chr 5:162,533,838...162,546,408
Ensembl chr 5:162,533,841...162,545,562
|
|
G |
Tas1r2 |
taste 1 receptor member 2 |
multiple interactions |
ISO |
Glucose promotes the reaction [TAS1R3 protein binds to TAS1R2 protein] |
CTD |
PMID:33992720 |
|
NCBI chr 5:151,909,617...151,925,760
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Tas1r3 |
taste 1 receptor member 3 |
multiple interactions |
ISO |
Glucose promotes the reaction [TAS1R3 protein binds to TAS1R1 protein]; Glucose promotes the reaction [TAS1R3 protein binds to TAS1R2 protein] |
CTD |
PMID:33992720 |
|
NCBI chr 5:166,468,703...166,472,759
Ensembl chr 5:166,469,589...166,472,742
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
multiple interactions increases phosphorylation |
ISO |
GH1 protein promotes the reaction [Glucose results in increased phosphorylation of TBC1D4 protein] |
CTD |
PMID:21559284 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tbx15 |
T-box transcription factor 15 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of TBX15 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:186,576,650...186,687,748
Ensembl chr 2:186,576,676...186,687,663
|
|
G |
Tbx2 |
T-box transcription factor 2 |
increases expression |
EXP |
Glucose results in increased expression of TBX2 mRNA |
CTD |
PMID:21818840 |
|
NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
|
|
G |
Tbx4 |
T-box transcription factor 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of TBX4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:70,730,686...70,760,829
Ensembl chr10:70,731,163...70,760,825
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of TC2N mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tcf19 |
transcription factor 19 |
affects response to substance multiple interactions affects activity |
ISO |
TCF19 protein affects the susceptibility to Glucose Glucose promotes the reaction [TCF19 protein binds to CHD2 protein] Glucose affects the activity of TCF19 protein |
CTD |
PMID:29042441 |
|
NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271
|
|
G |
Tdrd9 |
tudor domain containing 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of TDRD9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:131,029,644...131,145,076
Ensembl chr 6:131,029,652...131,144,651
|
|
G |
Tek |
TEK receptor tyrosine kinase |
decreases expression |
ISO |
Glucose results in decreased expression of TEK mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions decreases activity |
ISO |
Fluorometholone inhibits the reaction [Glucose results in decreased activity of TERT protein] |
CTD |
PMID:35264022 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tex51 |
testis expressed 51 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of TEX51 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr18:24,093,015...24,097,223
Ensembl chr18:24,093,115...24,097,007
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions decreases expression increases expression |
EXP ISO |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein; Inositol inhibits the reaction [Glucose results in decreased expression of TFAM protein] Glucose deficiency results in increased expression of TFAM mRNA |
CTD |
PMID:25997894 PMID:26811028 PMID:35243728 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
decreases expression |
ISO |
Glucose results in decreased expression of TFPI mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions increases expression |
ISO EXP |
Diazooxonorleucine inhibits the reaction [Glucose results in increased expression of TGFA mRNA]; EGF protein promotes the reaction [Glucose results in increased expression of TGFA mRNA]; Glucose promotes the reaction [EGF protein results in increased expression of TGFA mRNA] [Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 PMID:8638660 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression increases acetylation increases secretion |
ISO EXP |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; [Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein; [Glucose co-treated with TGFB1 protein] results in decreased expression of KRT20 protein; [Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of HSPA5 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of NLRP3 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of NOX4 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of SNAI1 protein; [Glucose co-treated with TGFB1 protein] results in increased expression of TXNIP protein; [Glucose co-treated with TGFB1 protein] results in increased expression of VIM protein; [Glucose co-treated with TGFB1 protein] results in increased phosphorylation of ERN1 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of HSPA5 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of NLRP3 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of NOX4 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of SNAI1 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of TXNIP protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased phosphorylation of ERN1 protein]; isoangustone A inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of CDH1 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in decreased expression of KRT20 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of VIM protein]; protocatechualdehyde inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; protocatechualdehyde inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; SOD2 protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Troglitazone inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Troglitazone inhibits the reaction [Glucose results in increased secretion of TGFB1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; CDK9 protein affects the reaction [Glucose results in increased expression of TGFB1 mRNA]; CEBPB protein inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Valsartan inhibits the reaction [Glucose results in increased expression of TGFB1 protein] Glucose results in increased expression of TGFB1 mRNA; Glucose results in increased expression of TGFB1 protein Glucose results in increased acetylation of TGFB1 promoter 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; [Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein; [Eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; [Eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; [Lipopolysaccharides co-treated with Glucose] results in increased secretion of TGFB1 protein; Acetylcysteine inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Acetylcysteine inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]; Calcitriol inhibits the reaction [[Lipopolysaccharides co-treated with Glucose] results in increased secretion of TGFB1 protein]; Curcumin analog inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Dinoprostone inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; diphenyliodonium inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; farrerol inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; fatostatin inhibits the reaction [Glucose promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; fatostatin inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Glucose promotes the reaction [SREBF1 protein binds to TGFB1 promoter]; Glycyrrhizic Acid inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of TGFB1 protein]; LY2109761 inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; manumycin inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; MIR217 mRNA affects the reaction [Glucose results in increased expression of TGFB1 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of TGFB1 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of TGFB1 protein]]; SREBF1 protein affects the reaction [Glucose results in increased expression of TGFB1 mRNA]; Superoxides affects the reaction [Glucose results in increased expression of TGFB1 mRNA]; TGFB1 protein promotes the reaction [Glucose promotes the reaction [SETD7 protein binds to CDKN1A promoter]]; TGFB1 protein promotes the reaction [Glucose results in increased expression of CDKN1A mRNA]; UCP1 protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; Y 27632 inhibits the reaction [Glucose results in increased expression of TGFB1 protein] |
CTD |
PMID:8877289 PMID:11050244 PMID:16572112 PMID:17199790 PMID:17597607 PMID:17611328 PMID:18682491 PMID:20578705 PMID:21367880 PMID:21788014 PMID:21829520 PMID:22031849 PMID:23159718 PMID:23376009 PMID:25162824 PMID:25559857 PMID:26045780 PMID:26891083 PMID:27652271 PMID:28700904 PMID:29266779 PMID:31838053 PMID:33270355 PMID:33631230 PMID:35961541 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
increases methylation decreases expression multiple interactions |
ISO |
Glucose results in increased methylation of TGFB1I1 gene Glucose results in decreased expression of TGFB1I1 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of TGFB1I1 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of TGFBR1 protein isoangustone A inhibits the reaction [Glucose results in increased expression of TGFBR1 protein] |
CTD |
PMID:21367880 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of TGFBR2 protein isoangustone A inhibits the reaction [Glucose results in increased expression of TGFBR2 protein] |
CTD |
PMID:21367880 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tgm4 |
transglutaminase 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of TGM4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:122,689,429...122,726,463
Ensembl chr 8:122,689,429...122,726,463
|
|
G |
Tgm5 |
transglutaminase 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of TGM5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:108,008,087...108,044,013
Ensembl chr 3:108,008,143...108,043,976
|
|
G |
Thbd |
thrombomodulin |
decreases expression |
ISO |
Glucose results in decreased expression of THBD mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions decreases expression |
EXP ISO |
Glucose inhibits the reaction [Dietary Fats results in increased expression of THBS1 protein] Glucose results in decreased expression of THBS1 mRNA |
CTD |
PMID:21394550 PMID:31655124 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thbs2 |
thrombospondin 2 |
increases expression |
ISO |
Glucose results in increased expression of THBS2 protein |
CTD |
PMID:23723366 |
|
NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789
|
|
G |
Them5 |
thioesterase superfamily member 5 |
increases expression |
ISO |
Glucose results in increased expression of THEM5 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 2:181,980,783...181,986,002
Ensembl chr 2:181,980,783...181,986,002
|
|
G |
Themis |
thymocyte selection associated |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of THEMIS mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:16,433,906...16,623,889
Ensembl chr 1:16,432,631...16,664,329
|
|
G |
Themis2 |
thymocyte selection associated family member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of THEMIS2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:144,991,110...145,006,362
Ensembl chr 5:144,991,112...145,006,400
|
|
G |
Thg1l |
tRNA-histidine guanylyltransferase 1-like |
increases expression |
ISO |
Glucose results in increased expression of THG1L mRNA |
CTD |
PMID:10026205 |
|
NCBI chr10:30,387,929...30,396,579
Ensembl chr10:30,387,940...30,396,687
|
|
G |
Thsd7a |
thrombospondin type 1 domain containing 7A |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of THSD7A mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of THSD7A mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 4:40,461,124...40,899,345
Ensembl chr 4:40,460,814...40,899,583
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases secretion multiple interactions |
ISO |
Glucose deficiency results in increased secretion of TIMP1 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TIMP1 mRNA |
CTD |
PMID:24802182 PMID:37567420 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of TIMP2 protein [Glucose co-treated with Air Pollutants] results in decreased expression of TIMP2 mRNA; [Glucose co-treated with Particulate Matter] results in decreased expression of TIMP2 mRNA; isoangustone A inhibits the reaction [Glucose results in increased expression of TIMP2 protein] |
CTD |
PMID:21367880 PMID:26179980 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
ISO |
2-methoxyestradiol inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Glucose results in decreased expression of TJP1 protein] Acetylcysteine inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; NLRP3 protein promotes the reaction [Glucose results in decreased expression of TJP1 protein] |
CTD |
PMID:21617913 PMID:27783111 PMID:35445903 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tjp2 |
tight junction protein 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of TJP2 protein Acetylcysteine inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; NLRP3 protein promotes the reaction [Glucose results in decreased expression of TJP2 protein] |
CTD |
PMID:27783111 |
|
NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295
|
|
G |
Tlcd2 |
TLC domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of TLCD2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:60,310,577...60,314,263
Ensembl chr10:60,311,099...60,313,622
|
|
G |
Tlk1 |
tousled-like kinase 1 |
decreases expression |
ISO |
Glucose results in decreased expression of TLK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:55,520,559...55,627,580
Ensembl chr 3:55,503,358...55,691,968
|
|
G |
Tln1 |
talin 1 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of TLN1 protein Eucalyptol inhibits the reaction [Glucose results in decreased expression of TLN1 protein] |
CTD |
PMID:31483951 |
|
NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900
|
|
G |
Tlr2 |
toll-like receptor 2 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of TLR2 protein [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TLR2 mRNA |
CTD |
PMID:20200188 PMID:37567420 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression increases expression multiple interactions |
ISO EXP |
Glucose results in decreased expression of TLR4 protein Glucose results in increased expression of TLR4 protein Phytic Acid inhibits the reaction [Glucose results in increased expression of TLR4 protein] artesunate inhibits the reaction [Glucose results in increased expression of TLR4 protein] TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of INS2 mRNA alternative form]]; TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of MAFA mRNA]]; TLR4 affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [Glucose results in increased expression of PDX1 mRNA]] |
CTD |
PMID:20200188 PMID:22558381 PMID:30031708 PMID:38000455 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tlr8 |
toll-like receptor 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TLR8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of TLR9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
decreases expression |
ISO |
Glucose results in decreased expression of TMED3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346
|
|
G |
Tmeff1 |
transmembrane protein with EGF-like and two follistatin-like domains 1 |
decreases expression increases methylation multiple interactions |
ISO |
Glucose results in decreased expression of TMEFF1 mRNA Glucose results in increased methylation of TMEFF1 gene fucoxanthin inhibits the reaction [Glucose results in decreased expression of TMEFF1 mRNA]; fucoxanthin inhibits the reaction [Glucose results in increased methylation of TMEFF1 gene] |
CTD |
PMID:33448797 |
|
NCBI chr 5:62,910,740...62,996,494
Ensembl chr 5:62,910,740...62,996,493
|
|
G |
Tmem123 |
transmembrane protein 123 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Glucose deficiency] affects the expression of TMEM123 mRNA |
CTD |
PMID:23637816 |
|
NCBI chr 8:4,922,077...4,952,228
Ensembl chr 8:4,922,098...4,952,224
|
|
G |
Tmem145 |
transmembrane protein 145 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TMEM145 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:80,891,888...80,901,615
Ensembl chr 1:80,891,927...80,901,611
|
|
G |
Tmem229b |
transmembrane protein 229B |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of TMEM229B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 6:97,771,645...97,819,582
Ensembl chr 6:97,775,332...97,819,489
|
|
G |
Tmem232 |
transmembrane protein 232 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of TMEM232 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:104,887,669...105,115,737
Ensembl chr 9:104,887,669...105,143,027
|
|
G |
Tmem45a2 |
transmembrane protein 45A2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of TMEM45A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:43,483,509...43,527,025
Ensembl chr11:43,483,519...43,526,916
|
|
G |
Tmem52 |
transmembrane protein 52 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of TMEM52 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TMEM52 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:166,048,669...166,050,423
Ensembl chr 5:166,046,565...166,050,433
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
increases expression |
ISO |
Glucose results in increased expression of TMSB4X mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion decreases uptake increases expression increases oxidation |
ISO EXP |
2-chloro-4'-methoxychalcone inhibits the reaction [Glucose results in increased expression of TNF mRNA]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased expression of TNF mRNA]; 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide inhibits the reaction [Glucose results in increased secretion of TNF protein]; [Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; CDK9 protein affects the reaction [Glucose results in increased expression of TNF mRNA]; CDK9 protein affects the reaction [Glucose results in increased secretion of TNF protein]; MIR27B mRNA affects the reaction [Glucose results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [TNF protein results in decreased uptake of Glucose]; Silymarin inhibits the reaction [[Glucose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; SNHG1 affects the reaction [Glucose results in increased expression of TNF mRNA]; SNHG1 affects the reaction [Glucose results in increased expression of TNF protein]; SNHG1 affects the reaction [MIR27B mRNA affects the reaction [Glucose results in increased expression of TNF protein]] Glucose results in increased expression of TNF mRNA; Glucose results in increased expression of TNF protein TNF protein results in increased oxidation of Glucose (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; [Glucose co-treated with Lipopolysaccharides] results in decreased expression of TNF protein; [Glucose co-treated with Pam(3)CSK(4) peptide] results in decreased expression of TNF protein; [Glucose co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of PPARG mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of PPARA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CXCL5 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NFKB1 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of PPARD mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of RELA mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of TNF mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of TNF protein]; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] inhibits the reaction [Glucose results in increased secretion of INS protein alternative form]; Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of TNF protein]]; asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Bezafibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Catechin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Catechin inhibits the reaction [Glucose results in increased expression of TNF protein]; chromic acid inhibits the reaction [[Glucose co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF protein]; Fenofibrate affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Fluorometholone inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Fluorometholone inhibits the reaction [Glucose results in increased secretion of TNF protein]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; lanifibranor affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF protein]; MIR217 mRNA inhibits the reaction [Glucose results in increased secretion of TNF protein]; Phytic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Quercetin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of TNF protein]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; rutecarpine inhibits the reaction [Glucose results in increased expression of TNF mRNA]; rutecarpine inhibits the reaction [Glucose results in increased expression of TNF protein]; Rutin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Rutin inhibits the reaction [Glucose results in increased expression of TNF protein]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; TNF protein inhibits the reaction [INS protein results in increased uptake of Glucose]; Troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Glucose]] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in increased expression of TNF mRNA]; [Glucose co-treated with IGF2R protein modified form] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Glucose] results in increased secretion of TNF protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein; [TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Artesunate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in increased oxidation of Glucose]; Calcitriol inhibits the reaction [[Lipopolysaccharides co-treated with Glucose] results in increased secretion of TNF protein]; Curcumin analog inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Glucose results in increased secretion of TNF protein]; farrerol inhibits the reaction [Glucose results in increased expression of TNF mRNA]; farrerol inhibits the reaction [Glucose results in increased secretion of TNF protein]; Gallic Acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; morroniside inhibits the reaction [Glucose results in increased secretion of TNF protein]; prolinedithiocarbamate inhibits the reaction [Glucose results in increased secretion of TNF protein]; Quercetin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of TNF protein]; quercitrin inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; S-4-bromobenzylglutathione cyclopentyl diester inhibits the reaction [morroniside inhibits the reaction [Glucose results in increased secretion of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein] |
CTD |
PMID:7956951 PMID:11726202 PMID:19557821 PMID:20200188 PMID:21788014 PMID:21818840 PMID:21988173 PMID:22343369 PMID:23138875 PMID:23770986 PMID:24436987 PMID:24513509 PMID:24877639 PMID:26341651 PMID:28572933 PMID:28700904 PMID:29753610 PMID:30031708 PMID:30802477 PMID:31323227 PMID:31776611 PMID:31838053 PMID:31935362 PMID:32613381 PMID:32643284 PMID:33283391 PMID:33631230 PMID:35264022 PMID:36243327 PMID:36462176 PMID:36928891 PMID:38000455 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Glucose results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfaip8l3 |
TNF alpha induced protein 8 like 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of TNFAIP8L3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:54,413,503...54,455,512
Ensembl chr 8:54,414,457...54,500,079
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
decreases secretion multiple interactions |
ISO |
Glucose results in decreased secretion of TNFRSF11B protein cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased secretion of TNFRSF11B protein] |
CTD |
PMID:19924377 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
decreases expression |
ISO |
Glucose results in decreased expression of TNFRSF25 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases expression |
ISO |
Glucose results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf13 |
TNF superfamily member 13 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of TNFSF13 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of TNFSF13 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr10:54,400,054...54,403,723
Ensembl chr10:54,400,065...54,403,042
|
|
G |
Tnfsf14 |
TNF superfamily member 14 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of TNFSF14 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:2,068,295...2,073,128
Ensembl chr 9:2,069,104...2,073,216
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TNFSF8 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
ISO |
Glucose results in increased expression of TNNT2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tomm20l |
translocase of outer mitochondrial membrane 20 like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of TOMM20L mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:89,594,016...89,612,070
Ensembl chr 6:89,599,873...89,610,147
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of TOP2A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases acetylation multiple interactions increases expression affects localization |
ISO EXP |
Glucose results in increased acetylation of TP53 protein [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein modified form; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein modified form]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TRP53 protein] Glucose results in increased expression of TP53 mRNA; Glucose results in increased expression of TP53 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased expression of TP53 mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytic Acid inhibits the reaction [Glucose results in increased expression of TP53 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Fluorometholone inhibits the reaction [Glucose results in increased expression of TP53 protein]]; [Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA; [Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein; [Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein]; [Tretinoin results in increased uptake of Glucose] inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein]; Fluorometholone inhibits the reaction [Glucose results in increased expression of TP53 protein]; Glucose inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; Melatonin inhibits the reaction [Glucose results in increased expression of TP53 protein]; Phytic Acid inhibits the reaction [Glucose results in increased expression of TP53 mRNA]; Phytic Acid inhibits the reaction [Glucose results in increased expression of TP53 protein]; Resveratrol inhibits the reaction [Glucose affects the localization of TP53 protein]; Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 protein]; SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein]] [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TP53 protein; TP53 protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2]; TP53 protein affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:20068143 PMID:21548882 PMID:23451161 PMID:24218232 PMID:24451382 PMID:25997894 PMID:26188290 PMID:27049278 PMID:28675767 PMID:33962019 PMID:35264022 PMID:38000455 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of TRP63 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of TRP73 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
TPH1 protein affects the reaction [Glucose results in increased secretion of INS protein]; TPH1 protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]]; TPH1 protein affects the reaction [UGT1A6A protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]]] |
CTD |
PMID:30562058 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
G |
Tph2 |
tryptophan hydroxylase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TPH2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424
|
|
G |
Tpsb2 |
tryptase beta 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of TPSB2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions increases expression |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of TRAF2 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
multiple interactions increases expression |
ISO |
tempol inhibits the reaction [Glucose results in increased expression of TRAF3 protein]; TRAF3 affects the reaction [Glucose results in increased cleavage of CASP3 protein] |
CTD |
PMID:25516495 |
|
NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481
|
|
G |
Trcg1 |
taste receptor cell gene 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TRCG1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:57,633,748...57,643,007
Ensembl chr 8:57,633,840...57,642,860
|
|
G |
Trem2 |
triggering receptor expressed on myeloid cells 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TREM2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
EXP |
TRIB3 protein affects the reaction [INS1 protein results in increased uptake of Glucose] |
CTD |
PMID:21190014 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim66 |
tripartite motif-containing 66 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of TRIM66 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:163,468,944...163,539,633
Ensembl chr 1:163,470,350...163,537,185
|
|
G |
Trim69 |
tripartite motif-containing 69 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TRIM69 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:109,111,468...109,135,255
Ensembl chr 3:109,111,468...109,132,037
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of TRPM2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Trpm7 |
transient receptor potential cation channel, subfamily M, member 7 |
multiple interactions increases expression |
ISO |
Glucose results in increased expression of and results in increased activity of TRPM7 protein; TRPM7 affects the reaction [Glucose results in decreased expression of NOS3 protein]; U 0126 inhibits the reaction [TRPM7 affects the reaction [Glucose results in decreased expression of NOS3 protein]] Glucose results in increased expression of TRPM7 mRNA Glucose results in increased expression of and results in increased activity of TRPM7 protein; TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP12 protein]; TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; TRPM7 protein affects the reaction [Glucose results in increased expression of DDIT3 protein] |
CTD |
PMID:24223965 PMID:30076216 |
|
NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190
|
|
G |
Tsbp1 |
testis expressed basic protein 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of TSBP1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:4,410,002...4,467,284
Ensembl chr20:4,410,004...4,457,053
|
|
G |
Tsc22d1 |
TSC22 domain family, member 1 |
increases expression |
ISO |
Glucose results in increased expression of TSC22D1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of TSHB mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TSHR mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Tsku |
tsukushi, small leucine rich proteoglycan |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of TSKU mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588
|
|
G |
Tspan7 |
tetraspanin 7 |
multiple interactions |
EXP |
TSPAN7 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr X:12,208,783...12,306,092
Ensembl chr X:12,208,783...12,306,131
|
|
G |
Tssk2 |
testis-specific serine kinase 2 |
decreases expression |
ISO |
Glucose results in decreased expression of TSSK2 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr11:83,086,578...83,087,933
|
|
G |
Ttc21a |
tetratricopeptide repeat domain 21A |
increases methylation decreases expression multiple interactions |
ISO |
Glucose results in increased methylation of TTC21A gene Glucose results in decreased expression of TTC21A mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of TTC21A mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 8:119,667,044...119,702,028
Ensembl chr 8:119,666,933...119,702,456
|
|
G |
Ttc6 |
tetratricopeptide repeat domain 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of TTC6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:75,136,827...75,368,176
Ensembl chr 6:75,136,792...75,368,178
|
|
G |
Ttk |
Ttk protein kinase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of TTK mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Tuba1a |
tubulin, alpha 1A |
multiple interactions |
EXP |
TUBA1A protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
increases expression |
ISO |
Glucose results in increased expression of TUBB2A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714
|
|
G |
Tubb6 |
tubulin, beta 6 class V |
increases expression |
ISO |
Glucose results in increased expression of TUBB6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418
|
|
G |
Tug1 |
taurine up-regulated 1 |
multiple interactions decreases expression |
ISO |
Glucose promotes the reaction [HDAC1 protein binds to TUG1 promoter]; Glucose promotes the reaction [MLX protein binds to TUG1 promoter]; Glucose promotes the reaction [MLXIP protein binds to TUG1 promoter]; Glucose promotes the reaction [MLXIPL protein binds to TUG1 promoter]; Glucose promotes the reaction [MXD1 protein binds to TUG1 promoter] Glucose results in decreased expression of TUG1 mRNA |
CTD |
PMID:32467232 |
|
NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927
|
|
G |
Tvp23a |
trans-golgi network vesicle protein 23 homolog A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of TVP23A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:5,227,198...5,263,185
Ensembl chr10:5,227,220...5,263,180
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
decreases expression increases expression |
ISO |
Glucose deficiency results in decreased expression of TWIST1 mRNA Glucose results in increased expression of TWIST1 protein |
CTD |
PMID:35427737 PMID:35445903 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions increases secretion decreases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in decreased expression of TXN1 protein]; 8-bromocyclic GMP inhibits the reaction [Glucose results in decreased expression of TXN1 protein]; Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]] Glucose deficiency results in increased secretion of TXN protein [[[[Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA] which results in increased expression of TXNIP protein] promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; [Glucose promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; Glucose promotes the reaction [TXNIP protein binds to TXN1 protein] |
CTD |
PMID:17178593 PMID:20453393 PMID:24802182 PMID:26660634 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression increases response to substance increases expression multiple interactions increases activity |
ISO EXP |
Glucose deficiency results in decreased expression of TXNIP mRNA; Glucose deficiency results in decreased expression of TXNIP protein TXNIP mRNA results in increased susceptibility to Glucose Glucose results in increased expression of TXNIP protein Allopurinol inhibits the reaction [Glucose results in increased expression of TXNIP protein]; Quercetin inhibits the reaction [Glucose results in increased expression of TXNIP protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of TXNIP protein]; TXNIP mRNA promotes the reaction [Glucose results in decreased expression of PPARA protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of TXNIP protein]; TXNIP protein affects the reaction [Glucose results in increased expression of CERT1 mRNA]; TXNIP protein affects the reaction [Glucose results in increased expression of FN1 mRNA]; TXNIP protein affects the reaction [Glucose results in increased expression of FN1 protein] [Glucose co-treated with TGFB1 protein] results in increased expression of TXNIP protein; Allopurinol inhibits the reaction [Glucose results in increased expression of TXNIP protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of TXNIP protein]; Quercetin inhibits the reaction [Glucose results in increased expression of TXNIP protein]; TXNIP mRNA promotes the reaction [Glucose results in decreased expression of PPARA protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of TXNIP protein] [[[[Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA] which results in increased expression of TXNIP protein] promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; [Glucose promotes the reaction [TXNIP protein binds to TXN1 protein]] which results in increased activity of MAP3K5 protein; [Glucose results in decreased expression of MIR17 mRNA] which results in increased expression of TXNIP mRNA; [Glucose results in decreased expression of MIR17 mRNA] which results in increased stability of TXNIP protein; [NFE2L2 protein binds to TXNIP promoter] inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; Glucose promotes the reaction [TXNIP protein binds to TXN1 protein]; Glucose promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; GPD2 protein inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; Metformin inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; NFE2L2 protein inhibits the reaction [Glucose results in increased expression of TXNIP mRNA]; TXNIP promotes the reaction [Glucose results in increased expression of FN1 mRNA]; TXNIP promotes the reaction [Glucose results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucose results in increased expression of LAMB2 mRNA]; TXNIP promotes the reaction [Glucose results in increased expression of LAMB3 mRNA]; TXNIP promotes the reaction [Glucose results in increased expression of LAMC1 mRNA] Glucose results in increased expression of TXNIP mRNA; Glucose results in increased expression of TXNIP protein Glucose results in increased activity of TXNIP mRNA |
CTD |
PMID:17178593 PMID:20195491 PMID:21832250 PMID:22869588 PMID:23647015 PMID:26660634 PMID:29031534 PMID:31974165 PMID:35961541 More...
|
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
Glucose results in increased expression of TXNRD1 mRNA |
CTD |
PMID:32942007 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ubd |
ubiquitin D |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UBD mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639 Ensembl chr20:1,385,864...1,408,639
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of UBE2C mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ube2l6 |
ubiquitin-conjugating enzyme E2L 6 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of UBE2L6 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048
|
|
G |
Uchl3 |
ubiquitin C-terminal hydrolase L3 |
increases secretion |
ISO |
Glucose deficiency results in increased secretion of UCHL3 protein |
CTD |
PMID:24802182 |
|
NCBI chr15:78,485,304...78,527,355
Ensembl chr15:78,485,315...78,527,355 Ensembl chr 3:78,485,315...78,527,355
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions decreases response to substance |
EXP ISO |
UCP1 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein]; UCP1 protein inhibits the reaction [Glucose results in decreased activity of and results in increased ADP-ribosylation of GAPDH protein]; UCP1 protein inhibits the reaction [Glucose results in decreased phosphorylation of SP1 protein]; UCP1 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone]; UCP1 protein inhibits the reaction [Glucose results in increased chemical synthesis of Reactive Oxygen Species]; UCP1 protein inhibits the reaction [Glucose results in increased expression of SERPINE1 mRNA]; UCP1 protein inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]; UCP1 protein inhibits the reaction [Glucose results in increased O-linked glycosylation of SP1 protein] UCP1 inhibits the reaction [Glucose results in decreased expression of GLO1 protein]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER protein]; UCP1 inhibits the reaction [Glucose results in increased expression of and results in increased secretion of HMGB1 protein]; UCP1 inhibits the reaction [Glucose results in increased expression of HMGB1 mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of S100A12 mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of S100A8 mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of S100A8 protein] UCP1 protein results in decreased susceptibility to Glucose |
CTD |
PMID:11050244 PMID:14514642 PMID:14523042 PMID:19833897 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression multiple interactions |
ISO EXP |
Glucose results in increased expression of UCP2 protein Glucose results in increased expression of UCP2 mRNA [copper bis(3,5-diisopropylsalicylate) co-treated with Glucose] results in increased expression of UCP2 protein; [ebselen co-treated with Glucose] results in decreased expression of UCP2 protein; [Sodium Selenite co-treated with Glucose] results in decreased expression of UCP2 protein [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; UCP2 protein inhibits the reaction [SIRT1 protein promotes the reaction [Glucose results in increased expression of INS1 protein]] |
CTD |
PMID:16366736 PMID:18167556 PMID:23795780 PMID:28027979 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ucp3 |
uncoupling protein 3 |
decreases expression multiple interactions |
ISO |
Glucose results in decreased expression of UCP3 protein UCP3 protein promotes the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:18167556 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of UGT1A1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UGT1A1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of UGT1A2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UGT1A2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
TPH1 protein affects the reaction [UGT1A6A protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]]]; UGT1A6A protein affects the reaction [sodium arsenite inhibits the reaction [Glucose results in increased secretion of INS protein]] |
CTD |
PMID:30562058 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UGT1A8 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UGT1A9 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of UHRF1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
affects phosphorylation multiple interactions |
EXP |
Glucose affects the phosphorylation of ULK1 protein 3-methyladenine affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]; Sirolimus affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; ULK1 protein affects the reaction [Glucose affects the phosphorylation of ULK1 protein]; ULK1 protein affects the reaction [Glucose results in decreased expression of ATG5 protein]; ULK1 protein affects the reaction [Glucose results in decreased expression of MAP1LC3B protein]; ULK1 protein affects the reaction [Glucose results in increased expression of SQSTM1 protein]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Unc13c |
unc-13 homolog C |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of UNC13C mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:74,247,026...74,697,629
Ensembl chr 8:74,247,899...74,673,223
|
|
G |
Unc79 |
unc-79 homolog, NALCN channel complex subunit |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of UNC79 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 6:122,082,369...122,327,641
Ensembl chr 6:122,080,308...122,327,591
|
|
G |
Unc80 |
unc-80 homolog, NALCN channel complex subunit |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of UNC80 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:68,011,940...68,190,135
Ensembl chr 9:68,011,728...68,187,659
|
|
G |
Upp2 |
uridine phosphorylase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of UPP2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417
|
|
G |
Usf2 |
upstream transcription factor 2, c-fos interacting |
increases activity |
ISO |
Glucose results in increased activity of USF2 protein |
CTD |
PMID:15767253 |
|
NCBI chr 1:86,174,703...86,185,942
Ensembl chr 1:86,174,703...86,185,617
|
|
G |
Vash2 |
vasohibin 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of VASH2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions increases secretion increases expression |
ISO EXP |
5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; [Glucose co-treated with Serotonin] results in increased expression of VCAM1 protein; aspalathin inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased secretion of VCAM1 protein]; nothofagin inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; Polyphenols inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Rimonabant inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; sarpogrelate inhibits the reaction [[Glucose co-treated with Serotonin] results in increased expression of VCAM1 protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of VCAM1 protein] [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of VCAM1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of VCAM1 mRNA Curcumin analog inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA] Glucose results in increased expression of VCAM1 mRNA; Glucose results in increased expression of VCAM1 protein |
CTD |
PMID:15304054 PMID:16285992 PMID:21373835 PMID:21682256 PMID:22785018 PMID:25338943 PMID:28700904 PMID:31655124 PMID:37567420 More...
|
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vcl |
vinculin |
multiple interactions decreases expression increases expression |
ISO |
Eucalyptol inhibits the reaction [Glucose results in decreased expression of VCL protein]; Eucalyptol inhibits the reaction [Glucose results in increased expression of VCL protein modified form]; RHOA protein inhibits the reaction [Glucose results in decreased expression of VCL protein]; RHOA protein promotes the reaction [Eucalyptol inhibits the reaction [Glucose results in decreased expression of VCL protein]] |
CTD |
PMID:31483951 |
|
NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of VDAC1 protein; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of VDAC1 protein]; VDAC1 protein inhibits the reaction [Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; VDAC1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; VDAC1 protein results in increased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:25488258 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Glucose] results in decreased expression of VDR mRNA; [Lipopolysaccharides co-treated with Glucose] results in decreased expression of VDR protein; Calcitriol inhibits the reaction [[Lipopolysaccharides co-treated with Glucose] results in decreased expression of VDR mRNA]; Calcitriol inhibits the reaction [[Lipopolysaccharides co-treated with Glucose] results in decreased expression of VDR protein] |
CTD |
PMID:21788014 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion decreases expression multiple interactions increases expression |
ISO EXP |
Glucose deficiency results in increased secretion of VEGFA protein Glucose results in decreased expression of VEGFA mRNA [cobaltous chloride co-treated with Glucose] results in increased expression of VEGFA mRNA; [cobaltous chloride co-treated with Glucose] results in increased expression of VEGFA protein; [Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA; [Glucose co-treated with Resveratrol] results in decreased expression of VEGFA mRNA; Fluorometholone inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Fluorometholone inhibits the reaction [Glucose results in increased expression of VEGFA protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of VEGFA protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of VEGFA mRNA]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of VEGFA protein] [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of VEGFA protein]; HIF1A protein affects the reaction [Glucose results in increased expression of VEGFA protein]; manumycin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; MIR217 mRNA affects the reaction [Glucose results in increased expression of VEGFA protein]; resveratrol inhibits the reaction [Glucose results in increased expression of VEGFA protein]; rosiglitazone inhibits the reaction [Glucose results in decreased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of VEGFA protein]] Glucose results in increased expression of VEGFA mRNA; Glucose results in increased expression of VEGFA protein 2-methoxyestradiol inhibits the reaction [Glucose results in increased expression of VEGFA protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Glucose results in increased expression of VEGFA protein]; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of VEGFA protein Glucose deficiency results in increased expression of VEGFA mRNA; Glucose results in increased expression of VEGFA mRNA; Glucose results in increased expression of VEGFA protein |
CTD |
PMID:12147617 PMID:18569938 PMID:19228841 PMID:19609456 PMID:19759273 PMID:20578705 PMID:21617913 PMID:22467055 PMID:24064760 PMID:25192544 PMID:26891083 PMID:31655124 PMID:33962019 PMID:35264022 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Glucose results in increased expression of VEGFD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vim |
vimentin |
multiple interactions increases secretion increases expression |
ISO |
[Glucose co-treated with TGFB1 protein] results in increased expression of VIM protein; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of VIM protein]; MAPK14 protein promotes the reaction [Glucose results in increased expression of VIM mRNA] Glucose deficiency results in increased secretion of VIM protein Glucose results in increased expression of VIM mRNA; Glucose results in increased expression of VIM protein |
CTD |
PMID:21829520 PMID:24802182 PMID:33992720 PMID:35445903 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vpreb3 |
V-set pre-B cell surrogate light chain 3 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of VPREB3 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr20:12,717,421...12,718,785
Ensembl chr20:12,716,779...12,719,520
|
|
G |
Vwa1 |
von Willebrand factor A domain containing 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of VWA1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:166,377,451...166,382,784
Ensembl chr 5:166,377,455...166,382,637
|
|
G |
Vwf |
von Willebrand factor |
decreases expression |
ISO |
Glucose results in decreased expression of VWF mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wdr17 |
WD repeat domain 17 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of WDR17 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:37,059,923...37,191,125
Ensembl chr16:37,059,895...37,191,122
|
|
G |
Wdr35 |
WD repeat domain 35 |
multiple interactions increases expression |
EXP |
WDR35 protein affects the reaction [Glucose results in increased activity of CASP3 protein] Glucose results in increased expression of WDR35 mRNA |
CTD |
PMID:20224876 |
|
NCBI chr 6:31,771,315...31,831,450
Ensembl chr 6:31,771,360...31,831,029
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:79,185,563...79,191,657
Ensembl chr10:79,186,647...79,191,657
|
|
G |
Wnk2 |
WNK lysine deficient protein kinase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of WNK2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr17:15,503,672...15,612,479
Ensembl chr17:15,504,261...15,612,479
|
|
G |
Wnt1 |
Wnt family member 1 |
increases expression |
ISO |
Glucose results in increased expression of WNT1 mRNA |
CTD |
PMID:29163160 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
G |
Wnt3a |
Wnt family member 3A |
decreases expression |
EXP |
Glucose results in decreased expression of WNT3A mRNA |
CTD |
PMID:21818840 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA] |
CTD |
PMID:18004065 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions increases expression decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA] Glucose results in increased expression of WNT5A mRNA |
CTD |
PMID:18004065 PMID:29163160 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wnt7a |
Wnt family member 7A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of WNT7A mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:123,863,108...123,908,981
Ensembl chr 4:123,863,108...123,908,981
|
|
G |
Wnt7b |
Wnt family member 7B |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of WNT7B mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 7:116,634,817...116,679,459
Ensembl chr 7:116,634,814...116,679,581
|
|
G |
Wwp1 |
WW domain containing E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
Glucose results in decreased expression of WWP1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:33,092,379...33,185,887
Ensembl chr 5:33,098,494...33,186,046
|
|
G |
Xaf1 |
XIAP associated factor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of XAF1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression multiple interactions increases splicing increases expression |
ISO EXP |
Glucose results in decreased expression of XBP1 mRNA Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of XBP1 mRNA]; Metformin inhibits the reaction [Glucose results in increased expression of XBP1 mRNA] Glucose deficiency results in increased splicing of XBP1 mRNA 4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased splicing of XBP1 mRNA]; XBP1 mRNA alternative form promotes the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]] Glucose deficiency results in increased expression of XBP1 protein; Glucose results in increased expression of XBP1 mRNA |
CTD |
PMID:17178593 PMID:21337367 PMID:24349266 PMID:31022492 PMID:34801538 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xcr1 |
X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of XCR1 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:123,479,454...123,516,168
Ensembl chr 8:123,479,590...123,487,226
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xkr5 |
XK related 5 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of XKR5 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr16:70,874,983...70,892,972
Ensembl chr16:70,875,093...70,892,967
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
multiple interactions |
ISO |
[2-hydroxyethyl disulfide co-treated with Glucose deficiency] results in decreased activity of [XRCC5 protein binds to XRCC6 protein] |
CTD |
PMID:22926048 |
|
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
|
|
G |
Xrcc6 |
X-ray repair cross complementing 6 |
multiple interactions |
ISO |
[2-hydroxyethyl disulfide co-treated with Glucose deficiency] results in decreased activity of [XRCC5 protein binds to XRCC6 protein] 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one inhibits the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein]; [Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein; Glucose inhibits the reaction [Bupivacaine results in increased expression of XRCC6 protein] |
CTD |
PMID:22926048 PMID:31672611 |
|
NCBI chr 7:113,542,992...113,563,762
Ensembl chr 7:113,543,057...113,563,762
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
multiple interactions |
ISO |
YWHAZ protein affects the reaction [G3BP1 protein results in increased uptake of Glucose] |
CTD |
PMID:35945655 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
G |
Yy1 |
YY1 transcription factor |
multiple interactions |
ISO |
[Glucose promotes the reaction [MTOR protein binds to YY1 protein]] which results in increased expression of YY1 protein; Glucose promotes the reaction [YY1 protein binds to PPARGC1A promoter]; Glucose results in increased expression of and affects the localization of YY1 protein; YY1 promotes the reaction [Glucose results in decreased expression of PPARGC1A protein] Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of YY1 protein] |
CTD |
PMID:35445903 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ZAP70 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ZBTB16 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zdhhc19 |
zinc finger DHHC-type palmitoyltransferase 19 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of ZDHHC19 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr11:68,277,847...68,289,110
Ensembl chr11:68,277,848...68,288,954
|
|
G |
Zfand4 |
zinc finger AN1-type containing 4 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ZFAND4 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 4:149,327,339...149,399,495
Ensembl chr 4:149,327,412...149,399,487
|
|
G |
Zfp386 |
zinc finger protein 386 (Kruppel-like) |
decreases expression |
ISO |
Glucose results in decreased expression of ZFP386 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:136,966,547...136,984,013
Ensembl chr 6:136,966,586...136,983,441
|
|
G |
Zfp521 |
zinc finger protein 521 |
increases expression multiple interactions decreases expression |
ISO |
Glucose results in increased expression of ZFP521 mRNA fucoxanthin inhibits the reaction [Glucose results in decreased expression of ZFP521 mRNA] |
CTD |
PMID:16805838 PMID:33448797 |
|
NCBI chr18:4,775,952...5,068,592
Ensembl chr18:4,787,295...5,068,458
|
|
G |
Zfp566 |
zinc finger protein 566 |
increases expression multiple interactions |
ISO |
Glucose results in increased expression of ZFP566 mRNA fucoxanthin inhibits the reaction [Glucose results in increased expression of ZFP566 mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr 1:85,318,449...85,342,186
Ensembl chr 1:85,318,452...85,333,161
|
|
G |
Zfp647 |
zinc finger protein 647 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of ZFP647 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 7:108,632,248...108,649,264
Ensembl chr 7:108,632,250...108,637,433
|
|
G |
Zfp68 |
zinc finger protein 68 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ZFP300 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr12:16,026,058...16,040,995
Ensembl chr12:16,026,079...16,040,995
|
|
G |
Zfp683 |
zinc finger protein 683 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ZFP683 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ZFP683 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 5:146,277,972...146,285,856
Ensembl chr 5:146,278,978...146,285,000
|
|
G |
Zic2 |
Zic family member 2 |
decreases expression |
ISO |
Glucose results in decreased expression of ZIC2 mRNA |
CTD |
PMID:31525975 |
|
NCBI chr15:99,576,697...99,581,522
Ensembl chr15:99,576,697...99,581,522
|
|
G |
Zkscan2 |
zinc finger with KRAB and SCAN domains 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of ZKSCAN2 mRNA |
CTD |
PMID:37567420 |
|
NCBI chr 1:178,006,003...178,028,239
Ensembl chr 1:178,009,238...178,028,131
|
|
G |
Zwint |
ZW10 interacting kinetochore protein |
multiple interactions |
EXP |
ZWINT protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] |
CTD |
PMID:21124846 |
|
NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957
|
|
G |
Zxdb |
zinc finger, X-linked, duplicated B |
multiple interactions decreases expression |
ISO |
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ZXDA mRNA] |
CTD |
PMID:33448797 |
|
NCBI chr X:59,700,765...59,706,737
Ensembl chr X:59,701,178...59,703,871 Ensembl chr X:59,701,178...59,703,871
|
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases transport increases uptake |
EXP |
Manganese deficiency inhibits the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of 3-O-Methylglucose]; pervanadate promotes the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]; Quercetin inhibits the reaction [pervanadate promotes the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]] |
CTD |
PMID:2185640 PMID:2204694 PMID:8404595 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases uptake decreases transport |
ISO |
Pentobarbital inhibits the reaction [SLC2A1 protein results in increased uptake of 3-O-Methylglucose]; Pentobarbital promotes the reaction [SLC2A1 gene polymorphism results in decreased uptake of 3-O-Methylglucose]; Phenobarbital inhibits the reaction [SLC2A1 protein results in increased uptake of 3-O-Methylglucose]; Phenobarbital promotes the reaction [SLC2A1 gene polymorphism results in decreased uptake of 3-O-Methylglucose] SLC2A1 protein mutant form results in decreased transport of 3-O-Methylglucose |
CTD |
PMID:10590023 PMID:11603379 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions increases uptake |
ISO EXP |
Fluorouracil promotes the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]; Phloretin inhibits the reaction [Fluorouracil promotes the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]]; Phloretin inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose] Cytochalasin B inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]; Mercuric Chloride inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose] |
CTD |
PMID:10825458 PMID:15986457 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression multiple interactions |
ISO EXP |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO EXP |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions |
ISO |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO EXP |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in increased expression of ATF6 protein ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
ISO |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd28 |
Cd28 molecule |
increases expression |
EXP |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc23 |
cell division cycle 23 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP ISO |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
EXP |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions affects expression increases expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
EXP |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased expression of EIF2AK3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] Glucosamine results in increased expression of ERN1 mRNA NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
EXP |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta |
increases expression |
ISO |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933
|
|
G |
Gpd1l1 |
glycerol-3-phosphate dehydrogenase 1 like 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation multiple interactions |
ISO |
Glucosamine results in decreased phosphorylation of GSK3B protein Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
EXP |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases expression |
EXP |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
ISO EXP |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
ISO |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
EXP |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5k |
inositol polyphosphate-5-phosphatase K |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of INPP5K mRNA NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
ISO |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:95,990,009...96,021,356
Ensembl chr10:95,960,725...96,021,702
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
ISO |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Lama4 |
laminin subunit alpha 4 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
EXP |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
ISO |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202
|
|
G |
Mfap3l |
microfibril associated protein 3 like |
increases expression |
ISO |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO EXP |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
EXP |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
EXP |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
EXP |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
ISO |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
EXP |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
ISO |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Ostn |
osteocrin |
multiple interactions increases expression |
ISO |
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Psme3 |
proteasome activator subunit 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
EXP |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
ISO |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc37a4 |
solute carrier family 37 member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
St6gal1 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Testin |
testin gene |
decreases expression |
EXP |
Glucosamine results in decreased expression of TESTIN mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression multiple interactions |
ISO |
Glucosamine analog results in increased expression of TGFBR1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions increases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
ISO |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
EXP |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
ISO |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO EXP |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in increased expression of XBP1 protein alternative form 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
ISO |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
|
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of CEBPA protein |
CTD |
PMID:19427183 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of DLK1 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FABP4 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FAS mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LEP mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
glucosamine 6-phosphate results in increased expression of LIPE mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LPL mRNA |
CTD |
PMID:19427183 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of PPARG protein |
CTD |
PMID:19427183 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of SREBF1 protein |
CTD |
PMID:19427183 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of TNF mRNA |
CTD |
PMID:19427183 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|